[
  {
    "brandName": "mRNA-1273",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 13 Jan 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 04 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 11 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "mRNA-based vaccine",
    "numSites": "2",
    "otherPartners": "CEPI",
    "phase": "1",
    "preferredName": "mRNA-1273",
    "productId": 1,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Seattle",
        "country": "US",
        "lat": 47.6169397,
        "lng": -122.329572,
        "locationId": "a6018262eeb2425434539c72bd2bc1cf527bca54",
        "name": "1730 Minor Ave, Seattle, WA 98101, USA",
        "state": "WA"
      },
      {
        "city": "Atlanta",
        "country": "US",
        "lat": 33.7934917,
        "lng": -84.3195325,
        "locationId": "a20a7fbfc641e0fed17496f7f38d14ea4ba6c6a3",
        "name": "1405 E Clifton Rd NE, Atlanta, GA 30322, USA",
        "state": "GA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "375ad6c4b12a03acefcf5e9b052423279351910a",
        "sponsorName": "Moderna"
      },
      {
        "sponsorId": "69301ed353817a1eb80b77b32f82e5809965a871",
        "sponsorName": "National Institute of Allergy and Infectious Diseases"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT04283461"
  },
  {
    "brandName": "Novavax Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "not totally clear that it is prophylactic vaccine. P1 expected late spring",
    "numSites": "",
    "otherPartners": "CEPI",
    "phase": "",
    "preferredName": "Novavax Vaccine",
    "productId": 2,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "605f6647f1bdd3849bac0626225a6effc774a373",
        "sponsorName": "Novavax Inc"
      },
      {
        "sponsorId": "f4d20a236175ba7e1926d1e68974b9e499bd94ed",
        "sponsorName": "Emergent BioSolutions Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "BNT-162",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Expect clinical testing in late april. Note this drug is also being developed in china with fosun pharma. Assumed this is in discovery as no explicit statements aboit preclinical found",
    "numSites": "",
    "otherPartners": "Polymun",
    "phase": "",
    "preferredName": "BNT162",
    "productId": 3,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7c4d34cd18acefd9b97f8b918fe356fec61f94d6",
        "sponsorName": "Pfizer Inc"
      },
      {
        "sponsorId": "633c14412c5bdb1e419eeef95aef4fe8eb93e2a1",
        "sponsorName": "BioNTech SE"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Imperial College London Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdon"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Expect clinical testing in summer",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Imperial College London Vaccine",
    "productId": 4,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      },
      {
        "sponsorId": "13ce668e4068319caf9e24c63ccccd2cbbe5263b",
        "sponsorName": "Maravai Lifesciences Inc"
      },
      {
        "sponsorId": "2b2a27cb9860bfb5b55a21484b211666498341e8",
        "sponsorName": "Trilink Biotechnologies Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "CELLECTRA\u00ae",
    "chemicalName": "INO-4800",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 23 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "US DoD,Bill and Melinda Gates Foundation,Coalition for Epidemic Prepardness Innovations Funding",
    "phase": "1",
    "preferredName": "INO-4800",
    "productId": 5,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "US",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "4fbd6454566c6f303ca18ea84340ce056b96f257",
        "name": "United States",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a28cb988e230163b5e185750856269de4f3cd2eb",
        "sponsorName": "Inovio Pharmaceuticals Inc"
      },
      {
        "sponsorId": "2534fc505ec4a7e9f4871746ebd7fe5a84b18af8",
        "sponsorName": "Beijing Advaccine Biotechnology"
      },
      {
        "sponsorId": "09820e27323251c097da890722d6b1060e453555",
        "sponsorName": "US Department of Defense"
      },
      {
        "sponsorId": "8b02e4cb59e0603882788f6b09eece49a6f530e2",
        "sponsorName": "Ology Bioservices Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Ad26 SARS-CoV-2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Gene therapies",
    "notes": "Expect clinical testing no later than fall 2020",
    "numSites": "",
    "otherPartners": "BARDA",
    "phase": "",
    "preferredName": "Ad26 SARS-CoV-2",
    "productId": 6,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      },
      {
        "sponsorId": "75dac04b368bcbb069fe03277a3ace5533a8d1cb",
        "sponsorName": "Jansssen Pharmaceutical"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Sanofi Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "they are repurposing vaccines that have been preclinically tested for SARS - hence I have put the current status as preclinical",
    "numSites": "",
    "otherPartners": "BARDA",
    "phase": "",
    "preferredName": "Sanofi Vaccine",
    "productId": 7,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      },
      {
        "sponsorId": "e0bdadccf43d8757f432e13f07484a9d84e509c7",
        "sponsorName": "BARDA"
      },
      {
        "sponsorId": "b0667c7bd3f77f09b501f5439a15d5af327ec17f",
        "sponsorName": "GSK"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Regeneron Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Plan to start human trials in summer 2020. Technique was previously used to develop successful REGN-EB3 ebola treatment.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Regeneron Therapeutic",
    "productId": 8,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      },
      {
        "sponsorId": "fc75c1a3f384fb950104d48eeee9665cc126614f",
        "sponsorName": "HHS"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Vaxart Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Oral tablet. Recombinant vaccine. Plan to initiate Phase I trial in second half of 2020.",
    "numSites": "",
    "otherPartners": "Emergent",
    "phase": "",
    "preferredName": "Vaxart Vaccine",
    "productId": 9,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "80a6767f041a7aef5269023e2f54d91aa27066da",
        "sponsorName": "Vaxart"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "University of Queensland Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Plans for clinical trials in July in Queensland.",
    "numSites": "",
    "otherPartners": "CEPI,The Queensland Government,Paul Ramsay Foundation,a2 Milk Company",
    "phase": "",
    "preferredName": "University of Queensland Vaccine",
    "productId": 10,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "83489a1277ddc5cf37050ab7342ac914748abdc2",
        "sponsorName": "University of Queensland"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VIDO-InterVac Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Federal Government",
    "phase": "",
    "preferredName": "VIDO-InterVac Vaccine Candidate",
    "productId": 11,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "52a54b2f0746508531714d16ee2993cb5ff764a5",
        "sponsorName": "International Vaccine Centre"
      },
      {
        "sponsorId": "7ffe768f0f9cf49a08e526fad894319b1b874d64",
        "sponsorName": "University of Saskatchewan"
      },
      {
        "sponsorId": "00779c5db9466de70c91f79cb8ce78836132058d",
        "sponsorName": "VIDOInterVac"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "ChAdOx1 nCoV-19",
    "chemicalName": "",
    "conditionOrDisease": "Coronavirus",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Oxford",
    "phase": "1/2",
    "preferredName": "ChAdOx1 nCoV-19",
    "productId": 12,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b91bf90d7d04e343ba36d6ff216e09bcbdf60f8f",
        "sponsorName": "Jenner Institute"
      },
      {
        "sponsorId": "d1cf38e4f7d70b602814433c015565b664ba5fa5",
        "sponsorName": "Oxford Vaccine Group"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "NIV Pune Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NIV Pune Vaccine Candidate",
    "productId": 13,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "db62a75311d8473967f358928e8460e901771f76",
        "sponsorName": "National Institute of VirologyPune"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Animal Testing",
    "numSites": "",
    "otherPartners": "Stermirna Therapeutics Co. Ltd",
    "phase": "",
    "preferredName": "Chinese_Center_for_Disease_Control_and_Prevention_Tongji_University_School_of_Medicine_Stermirna_Therapeutics_Co_Ltd-14",
    "productId": 14,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "52d02c14b6240aabfbdc4ded5640e554e55e2ca1",
        "sponsorName": "Chinese Center for Disease Control and Prevention"
      },
      {
        "sponsorId": "5f73dfa644e6480f6632298372551fe30f6bfc70",
        "sponsorName": "Tongji University School of Medicine"
      },
      {
        "sponsorId": "3020404bf63cebc77d8c10a2cc920657b5249ee2",
        "sponsorName": "Stermirna Therapeutics Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "DelNS1-SARS-CoV2-RBD LAIV",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Live-attenuated vaccine. Plans for clinical trials in July. Proof of concept testing done using MeRS-CoV and various animal models.",
    "numSites": "",
    "otherPartners": "CEPI,Xiamen University,Changchun-Baike,Hualan-Bio,Beijing Wantai,Sinovac,CNBG",
    "phase": "",
    "preferredName": "DelNS1-SARS-CoV2-RBD LAIV",
    "productId": 15,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6b014b07406a291e8e325b2a212ac65562a16644",
        "sponsorName": "University of Hong Kong"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Not named yet,2 products currently undergoing animal studies,plan to start a clinical trial in early summer",
    "numSites": "",
    "otherPartners": "CEPI",
    "phase": "",
    "preferredName": "CureVac_AG-16",
    "productId": 16,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "40795cb229b892237d8be44830cd652481d40676",
        "sponsorName": "CureVac AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "Ad5-nCoV",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Gene therapies",
    "notes": "Vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein,Immunogenic action,Current study is assessing evaluate the safety reactogenicity and immunogenicity,Active but not recruiting",
    "numSites": "1",
    "otherPartners": "Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China,Jiangsu Province Centers for Disease Control and Prevention,Hubei Provincial Center for Disease Control and Prevention,Tongji Hospital",
    "phase": "1",
    "preferredName": "Ad5-nCoV",
    "productId": 17,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "55e07a379cb17727226339407a902ef5bc142106",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ae6d6a42f1f04b04f866b7d03b344389efca16ee",
        "sponsorName": "CanSino Biologics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04313127"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Using existing vaccine platform called GV-MVA-VLP,3 candidates have been identified,animal trials soon to begin",
    "numSites": "",
    "otherPartners": "BravoVax",
    "phase": "",
    "preferredName": "GeoVax_Labs_Inc-18",
    "productId": 18,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f5413cebc2f1a8871f47600364147dc47dbb9ad1",
        "sponsorName": "GeoVax Labs Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "Medicago Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Medicago Vaccine",
    "productId": 19,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e59212c9eed9f476dcb441a9645267e5e6b915c2",
        "sponsorName": "Medicago"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "AdCOVID (based on NasoVax)",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Gene therapies",
    "notes": "This is a repurposing of the NasoVax technology (recombinant intranasal) for a COVID-19 vaccine,It should be noted that the provided source on Atimmune's Nasovax-based COVID-19 vaccine was published on February 28. Since then there has been no news on the vaccine until March 30 which is when a new article was published stating that Altimmune will collaborate with UAB to develop AdCOVID. Because AdCOVID possesses the same characteristics as the NasoVax analog (recombinant vaccine - single-dose - and intranasal) I believe that this entry should be reclassified as AdCOVID. NasoVax is still currently in a Phase 2a trial so I have opted to classify AdCOVID as a repurposed-not approved product. Currently working on preclinical animal studies and characterization of vaccine immunogenicity,aims to receive IND approval and enable phase 1 by Q3 2020",
    "numSites": "",
    "otherPartners": "University of Alabama at Birmingham (UAB)",
    "phase": "",
    "preferredName": "NasoVax Analog (Not Currently Specified)",
    "productId": 20,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e97fb449c577795bfb9ae1692146c17455a06ef8",
        "sponsorName": "Altimmune"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "IBV,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Adaption of Avian CoronaVirus Infectious Bronchitis Virus Vaccine for Human Use. This is an adaptation of the IBV vaccine (against poultry coronavirus) for use in humans against COVID-19,IBV vaccine was based on a protein expression vector and the COVID vaccine will likely work in a similar manner,the Israeli ministries plan to accelerate the approval process to bring the vaccine to the market ASAP,MIGAL believes the vaccine could enter Phase 1 by June 1,it is still in the final stages of development due to delays in receiving the genetic construct,MIGAL has begun trials in mice",
    "numSites": "",
    "otherPartners": "Israel Innovation Authority,Health Ministry and the Headquarters of the National Digital Israel Initiative",
    "phase": "",
    "preferredName": "Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine",
    "productId": 21,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "83dd887c3fd8789867722d2edd6b259ee645f1a3",
        "sponsorName": "MIGAL Research Institute"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "TNX-1800",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Modified horsepox virus designed to express the SARS-CoV-2 spike protein,currently in the pre-clinical stage of development and Tonix expects preliminary data from animal experiments in Q3 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TNX-1800",
    "productId": 22,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "40e82256fff7abb570316aa4f46cf693fc0c6c98",
        "sponsorName": "Tonix Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Recombinant subunit vaccine,S-Trimer",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Glaxosmithkline",
    "phase": "",
    "preferredName": "Recombinant subunit vaccine",
    "productId": 23,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ad3e27aa56a9275005c084d1c2ca3c71cc945a1",
        "sponsorName": "Clover Biopharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Linear DNA Vaccine",
    "conditionOrDisease": "",
    "countries": ["United States", "Rome - Italy"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "PCR produced linear DNA vaccine",
    "numSites": "",
    "otherPartners": "Applied DNA Sciences,Takis Biotech",
    "phase": "",
    "preferredName": "Linear DNA Vaccine",
    "productId": 24,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "35a1314de34e0181bb072a8ab28865c9f1cdecc1",
        "sponsorName": "Applied DNA Sciences"
      },
      {
        "sponsorId": "3d80bed6c0a0fd89072a0112ae97d02303dc1b5e",
        "sponsorName": "Takis Biotech"
      },
      {
        "sponsorId": "ea1f0842312281e699947cd442445fd782ddde1c",
        "sponsorName": "Linearx Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "NVX-CoV2373",
    "chemicalName": "",
    "conditionOrDisease": "Seasonal Flu/Influenza",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "recombinant quadrivalent seasonal influenza vaccine using hemagglutinin (HA) protein nanoparticles",
    "numSites": "19",
    "otherPartners": "Novavax,Emergent BioSolutions Inc,CEPI",
    "phase": "3",
    "preferredName": "NanoFlu",
    "productId": 25,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b83afd40b4f01cc1236b6df8d6a2476e04cb0bac",
        "sponsorName": "Novavax"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Predictive Oncology Vaccine AI Platform",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Unknown",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "Note the platform is for drugs and vaccines",
    "numSites": "",
    "otherPartners": "Soluble Therapeutics",
    "phase": "",
    "preferredName": "Predictive Oncology Vaccine AI Platform",
    "productId": 26,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5e5fd3a94173dbc6792d6963099af3d35fffc59a",
        "sponsorName": "Predictive Oncology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "AJ Vaccines,S protein Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "the vaccine being developed is an S protein vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AJ_Vaccines_S_protein_Vaccine",
    "productId": 27,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f3d84a99a68fdd7ad327bbc8ce41458fc29dec50",
        "sponsorName": "AJ Vaccines"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccines",
    "trialId": ""
  },
  {
    "brandName": "GS-5734",
    "chemicalName": "remdesivir",
    "conditionOrDisease": "COVID 19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 15 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Other trials undertaken by NIAD-USA,INSERM-France,China Japanese friendship hospital,No of study is increasing rapidly",
    "numSites": "41",
    "otherPartners": "Gilead Sciences",
    "phase": "3",
    "preferredName": "remdesivir",
    "productId": 28,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cbb34f9aed92e21ff89501b842a385faabf9c8c6",
        "sponsorName": "Gilead Sciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Kaletra,Aluvia",
    "chemicalName": "lopinavir,ritonavir",
    "conditionOrDisease": "2019-nCoV",
    "countries": ["Multiple"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. Some studies are published: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. Note that for the highest study there were multiple phase 4 so I picked the largest one that had alrady started recruiting",
    "numSites": "1",
    "otherPartners": "AbbVie",
    "phase": "4",
    "preferredName": "lopinavir,ritonavir",
    "productId": 29,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4018bff9870d041afd8a070c4f4e507816980b66",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "69e116d4f9df799550df0e74438d37589994fb45",
        "sponsorName": "AbbVie"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Kevzara",
    "chemicalName": "Sarilumab",
    "conditionOrDisease": "Covid-19",
    "countries": ["Unites States"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "57",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Sarilumab",
    "productId": 30,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      },
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Plaquenil",
    "chemicalName": "hydroxychloroquine",
    "conditionOrDisease": "COVID 19",
    "countries": ["NA"],
    "countryCodes": ["NAM"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "Not listed",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "hydroxychloroquine",
    "productId": 31,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a5091ee00972baec20a88b0bfc29cf8df11fc10e",
        "sponsorName": "Sanofi SA"
      },
      {
        "sponsorId": "11f8e68d5ce8289f7c1254157f73a6429006ed8c",
        "sponsorName": "Amneal Pharmaceuticals INc"
      },
      {
        "sponsorId": "a951d8e8824303ff34be3adad3b714181ce40092",
        "sponsorName": "Rising Pharma Holdings Inc"
      },
      {
        "sponsorId": "d49e1350f4c21eef623eb4e22b9709b13ac08f82",
        "sponsorName": "University of Minnesota"
      },
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      },
      {
        "sponsorId": "c6596b3fee7a992d790e288b27e50edfb07b5974",
        "sponsorName": "IHUM\u00e9diterran\u00e9e Infection"
      },
      {
        "sponsorId": "de07adc682970664b17a2475d74c5691cd707ef6",
        "sponsorName": "Sandoz Inc"
      },
      {
        "sponsorId": "67da3aa3718d35ed721af558ab42d840a58dfdbe",
        "sponsorName": "Bayer AG"
      },
      {
        "sponsorId": "00a23d14d5c43daa469abd0a9c6a20c98de6e086",
        "sponsorName": "University of Washington"
      },
      {
        "sponsorId": "d0b12c5f18dc027ada9bc28c72459c2e0d798809",
        "sponsorName": "PatientCenterede Outcomes Research Institute"
      },
      {
        "sponsorId": "03fdeb1f847122b01435c2cc44a82112b2f1e5c9",
        "sponsorName": "World Health Organization"
      },
      {
        "sponsorId": "f87860860d12518378b68c8b4c2d0d61407eac5a",
        "sponsorName": "New York State Department of Health"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "TJM2",
    "chemicalName": "TJ003234",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "AntiBody against GM-CSF. Previously passed a phase 1 trial. INDs submitted for phase II clinical trials in China USA and South Korea.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TJ003234",
    "productId": 32,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4d5fc82efed329adf6897a54f395828e900a3a4d",
        "sponsorName": "IMab Biopharma"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "AT-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Recombinant surfactant protein developed to treat bronchopulmonary dysplatia. No timeline for clinical trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AT-100",
    "productId": 33,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cce5891ec7c3582e4abbb8a5a1675065288b051b",
        "sponsorName": "Airway Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "TZLS-501",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Tiziana Life Sciences,Novimmune",
    "phase": "",
    "preferredName": "TZLS-501",
    "productId": 34,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2a18b405cfddff30dc89c827294ce141e1078ed6",
        "sponsorName": "Tiziana Life Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "OYA1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "OyaGen",
    "phase": "",
    "preferredName": "OYA1",
    "productId": 35,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "09c1011fb00f7f2c97e9b4ebc1373e23f10f3703",
        "sponsorName": "OyaGen"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "BPI-002",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Also being considered as a vaccine adjuvant to stimulate long term immunity,Very little information is available on development stages - A patent has been filed for it by the company but it is not clear what that translates to,Information in column T was seen on just one website",
    "numSites": "",
    "otherPartners": "BeyondSpring Inc",
    "phase": "",
    "preferredName": "BPI-002",
    "productId": 36,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bdc58d6b3c51adacec8fd2e5f71d1d5d71046d8d",
        "sponsorName": "BeyondSpring Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "NP-120",
    "chemicalName": "Ifenprodil",
    "conditionOrDisease": "Idiopathic Pulmonary Fibrosis",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Therapeutic approach - receptor antagonist,Drug originally evaluated for treatment of Idiopathic Pulmonary Fibrosis",
    "numSites": "",
    "otherPartners": "Cascade chemistry",
    "phase": "2",
    "preferredName": "NP-120 (Ifenprodil)",
    "productId": 37,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4ec6ff9fa7840783f9d6a9a99ce82cc52a732239",
        "sponsorName": "Algernon Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "APN01",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "9",
    "otherPartners": "Austrian government",
    "phase": "2",
    "preferredName": "APN01",
    "productId": 38,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Innsbruck",
        "country": "AT",
        "lat": 47.2692124,
        "lng": 11.4041024,
        "locationId": "349a50ac4e8614dc4e04ff2d1fd414ab757d8a7a",
        "name": "Innsbruck, Austria",
        "state": "Tyrol"
      },
      {
        "city": "Vienna",
        "country": "AT",
        "lat": 48.2081743,
        "lng": 16.3738189,
        "locationId": "0b8d625882889750788aada97084c055551e9121",
        "name": "Vienna, Austria",
        "state": "Vienna"
      },
      {
        "city": "Vienna",
        "country": "AT",
        "lat": 48.2081743,
        "lng": 16.3738189,
        "locationId": "0b8d625882889750788aada97084c055551e9121",
        "name": "Vienna, Austria",
        "state": "Vienna"
      },
      {
        "city": "Copenhagen",
        "country": "DK",
        "lat": 55.6760968,
        "lng": 12.5683372,
        "locationId": "50f0180418e819621e0d414f9942577dc36634db",
        "name": "Copenhagen, Denmark",
        "state": null
      },
      {
        "city": null,
        "country": "DK",
        "lat": 55.736943,
        "lng": 12.4215514,
        "locationId": "80e09000b562e506649b5de2fb1d8eea9f437813",
        "name": "Herlev Municipality, Denmark",
        "state": null
      },
      {
        "city": "Hiller\u00f8d",
        "country": "DK",
        "lat": 55.927909,
        "lng": 12.300806,
        "locationId": "5fce627723a9a9dc0590799271c7049a493f6a8e",
        "name": "3400 Hiller\u00f8d, Denmark",
        "state": null
      },
      {
        "city": "Hvidovre",
        "country": "DK",
        "lat": 55.64252200000001,
        "lng": 12.4753859,
        "locationId": "d61afcebb8e48be956026a9e3282e5638fb8765f",
        "name": "2650 Hvidovre, Denmark",
        "state": null
      },
      {
        "city": "Hamburg",
        "country": "DE",
        "lat": 53.5510846,
        "lng": 9.9936819,
        "locationId": "56283cd9ffd16ac1845f9da8c6a5be73605a0258",
        "name": "Hamburg, Germany",
        "state": "HH"
      },
      {
        "city": "Munich",
        "country": "DE",
        "lat": 48.1351253,
        "lng": 11.5819805,
        "locationId": "c61c4d03fbb24be1065ecc56523f31f98757fe6a",
        "name": "Munich, Germany",
        "state": "BY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6f60b15593583caa5a157b68e379e898ed540bfe",
        "sponsorName": "University of British Columbia"
      },
      {
        "sponsorId": "135275cdf7dd39808bf7b9ddb4115db4750d3cdc",
        "sponsorName": "APEIRON Biologics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04335136"
  },
  {
    "brandName": "Brilacidin",
    "chemicalName": "Brilacidin Tetrahydrochloride",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Innovation Pharamaceuticals",
    "phase": "",
    "preferredName": "Brilacidin Tetrahydrochloride",
    "productId": 39,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d74b3bc88aff79062ddc7572f048d10a2f1b7254",
        "sponsorName": "Innovation Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "PRO-140",
    "chemicalName": "leronlimab",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Patient treatment underway via Emergency IND,Phase 2 trial protocol filed",
    "numSites": "",
    "otherPartners": "RedChip companies",
    "phase": "",
    "preferredName": "leronlimab",
    "productId": 40,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a5c509d28e5944d0d7121691e82a49f47e20f7ef",
        "sponsorName": "CytoDyn"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "BTX-025",
    "chemicalName": "Novel Viral Inhibitor",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Novel galectin inhibitor for use in COVID-19. Currently pre-clinical.",
    "numSites": "",
    "otherPartners": "Bioxytran",
    "phase": "",
    "preferredName": "Novel Viral Inhibitor",
    "productId": 41,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6e5983b2fe019c343dfaeb0ad2e7419f3dfaa118",
        "sponsorName": "BIOXYTRAN"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Actemra",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "severe COVID-19 pneumonia",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).",
    "numSites": "Not disclosed",
    "otherPartners": "Roche",
    "phase": "3",
    "preferredName": "tocilizumab",
    "productId": 42,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Tulsa",
        "country": "US",
        "lat": 36.1481393,
        "lng": -95.9629478,
        "locationId": "2d450fbc1d5fac98fb5c2f76802a2413550f0b95",
        "name": "2015 E 11th St, Tulsa, OK 74104, USA",
        "state": "OK"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Galidesivir",
    "chemicalName": "BCX4430",
    "conditionOrDisease": "Yellow Fever",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Neucleoside analogue for Yellow Fever broad spectrum.",
    "numSites": "Not disclosed",
    "otherPartners": "NIAID,BARDA-NIH",
    "phase": "1",
    "preferredName": "BCX4430",
    "productId": 43,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ec79288164e657a6770558c7e361bf039abbc3c1",
        "sponsorName": "Biocryst Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "REGN3048-3051",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "There is conflicting information. I found a trial that used these drugs for MERS suggesting it is reporpused-not approved but here it says they are starting a first in human trial: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/",
    "numSites": "",
    "otherPartners": "National Institute of Allergy and Infectious Diseases (NIAID)",
    "phase": "1",
    "preferredName": "REGN3048-3051",
    "productId": 44,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7cbf979a98fdc448b32b211e3d5e8264875995e",
        "sponsorName": "Regeneron"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "CANNOT IDENTIFY STUDY"
  },
  {
    "brandName": "SNG001",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "inhaled forumation of beta-1a interferon",
    "numSites": "20",
    "otherPartners": "Public funding through shares",
    "phase": "2",
    "preferredName": "SNG001",
    "productId": 45,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "GB",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "09e1bc40a10d6d830129563cc9dd394ee9853aa6",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "844645398c47a20691e7b88009bf4a28ca9e0a56",
        "sponsorName": "Synairgen Research"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "AmnioBoost",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Lattice Biologics",
    "phase": "1",
    "preferredName": "AmnioBoost",
    "productId": 46,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Seattle",
        "country": "US",
        "lat": 47.6062095,
        "lng": -122.3320708,
        "locationId": "875020b3e5677795da0e156d120aaf26c0d6ae83",
        "name": "Seattle, WA, USA",
        "state": "WA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3269ba5b3b1fa17511555e6336cff3ddd90b84b2",
        "sponsorName": "Lattice Biologics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "direct acting antiviral",
    "numSites": "",
    "otherPartners": "Enanta Pharmaceuticals",
    "phase": "",
    "preferredName": "Enanta_Pharmaceuticals-47",
    "productId": 47,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7bf6d2f389a2e6a86e1d696dcc1c2052ef9a9eae",
        "sponsorName": "Enanta Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "COVID-HIG",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VAAST",
    "productId": 48,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cd5be69c518689ef12547e8559a4ff1c7ebed1d1",
        "sponsorName": "Emergent BioSolutions"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "LEAPS COVID-19",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 03 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "immunotherapy",
    "numSites": "",
    "otherPartners": "CEL-SCI,University of Georgia\u2019s (UGA\u2019s) Center for Vaccines",
    "phase": "1",
    "preferredName": "LEAPS COVID-19",
    "productId": 49,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7146a8671f847f80a0c4c99c0466916089840d58",
        "sponsorName": "CELSCI"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "TAK-888",
    "chemicalName": "Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)",
    "conditionOrDisease": "COVID-19",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "a plasma-derived therapy",
    "numSites": "",
    "otherPartners": "Takeda Pharmaceutical Company",
    "phase": "1",
    "preferredName": "Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)",
    "productId": 50,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ab95e09c1c41756dc8b947ebd1fa0e087a23da6c",
        "sponsorName": "Takeda Pharmaceutical Company"
      }
    ],
    "status": "On Hold",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Azithromycin,Hydroxychloroquine",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "Pfizer",
    "phase": "",
    "preferredName": "Azithromycin-Hydroxychloroquine Combination",
    "productId": 51,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      },
      {
        "sponsorId": "fd203d1438cfd911102049306e6081fba3f89b87",
        "sponsorName": "Intermountain Healthcare"
      },
      {
        "sponsorId": "e8c2d02eac49d122b3733cdbc1e0009caae5b4c7",
        "sponsorName": "University of Utah Health"
      },
      {
        "sponsorId": "f504a9b418cd0c0f06bc0337180c16761e95b8b1",
        "sponsorName": "Fondation Mediterranee Infection"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "OT-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Appears to still be in vitro testing",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OT-101",
    "productId": 52,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "839146f1d67c1b00a841adde72a3555186ed2ee2",
        "sponsorName": "Mateon Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Southwest Research Institute Screening Platform",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Unknown",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 19 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Texas Biomedical Research Institute",
    "phase": "",
    "preferredName": "Southwest_Research_Institute_Screening_Platform",
    "productId": 53,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "24d9d6c7cef2fb07a9bf63de1e32e0d49e73466f",
        "sponsorName": "Southwest Research Institute"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "NanoViricides Therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NanoViricides_Therapeutic",
    "productId": 54,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ce9215688edb9650cbc3b3d92876af43dd53d52b",
        "sponsorName": "NanoViricides"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "VIR-7831",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "2 different modifications of one single clone of antibody originally developed against SARS-CoV-1,shown to act as both vaccine and therapeutic",
    "numSites": "",
    "otherPartners": "Wuxi Biologics,Biogen",
    "phase": "",
    "preferredName": "modified anti-SARS-CoV-2 antibodies",
    "productId": 55,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c32fa743ed510db10e7c97fd975d2a2a5700a4a",
        "sponsorName": "Vir Biotechnology Inc"
      },
      {
        "sponsorId": "b0667c7bd3f77f09b501f5439a15d5af327ec17f",
        "sponsorName": "GSK"
      },
      {
        "sponsorId": "7b6f419a075a9d4cfc1742367fdc3d11cc35f994",
        "sponsorName": "Biogen Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "VIR-2703,ALN-COV",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "350 candidates undergoing in vitro test",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "siRNA against  SARS-CoV-1/2",
    "productId": 56,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165",
        "sponsorName": "Alnylam"
      },
      {
        "sponsorId": "ec6e5f3e381b52ffa801d3826f90ffc80615c431",
        "sponsorName": "Vir Biotechnology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "siRNA against  SARS-CoV-2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "150 candidates under in vitro test",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "siRNA against  SARS-CoV-2",
    "productId": 57,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4d4713f1054b2bc9d367a86155cb363519d5ad5",
        "sponsorName": "Sirnaomics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies,500 antibody sequences isolated 03/12/2020",
    "numSites": "",
    "otherPartners": "Vaccine Research Centre - NIAID",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 58,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3e548eb19a8c76ea5f8eeabdbc8086a91e469af",
        "sponsorName": "AbCellera Biologics"
      },
      {
        "sponsorId": "3415f73b4bae4701d6612a2aa318423dc3c571b2",
        "sponsorName": "Eli Lilly and Company"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "BDB-001",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Anti-C5a Antibody,Phase 2 trial number 2020L0003",
    "numSites": "",
    "otherPartners": "Staidson (Beijing) Biopharmaceuticals Co. Ltd,InflaRx",
    "phase": "2",
    "preferredName": "BDB-001",
    "productId": 59,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ff5ce7f46efeff43870c4a88459cedf1e13cc9c1",
        "sponsorName": "Beijing Defengrei Biotechnology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Sylvant",
    "chemicalName": "siltuximab",
    "conditionOrDisease": "COVID-19",
    "countries": ["England"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Clinical trial NCT04322188 started but phase UNKNOWN",
    "numSites": "1",
    "otherPartners": "Ergomed",
    "phase": "UNKNOWN",
    "preferredName": "siltuximab",
    "productId": 60,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Bergamo",
        "country": "IT",
        "lat": 45.68707329999999,
        "lng": 9.639130699999999,
        "locationId": "57fbf653730a1f3297118a2c1d52437351eee7bb",
        "name": "Piazza OMS, 1, 24127 Bergamo BG, Italy",
        "state": "Lombardia"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "887084fb166ace787dba446286c132705fbea1b3",
        "sponsorName": "EUSA Pharma"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "47D11",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies",
    "numSites": "",
    "otherPartners": "Mount Sinai,Utrecht University,Eurasmus MC",
    "phase": "",
    "preferredName": "47D11",
    "productId": 61,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4e2f58ce0e723737336ad8f95d829829f4eca5cd",
        "sponsorName": "Harbour Biomed"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "PolyTope mAb Therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PolyTope mAb Therapy",
    "productId": 62,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7670240cc18d7cdc6c4cdc1e43d130218caa45c4",
        "sponsorName": "ImmunoPrecise Antibodies Ltd"
      },
      {
        "sponsorId": "6eab2ef2c61e3007604b07fb544709610e671afa",
        "sponsorName": "EVQLV"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "IFX-1",
    "chemicalName": "",
    "conditionOrDisease": "COVID19",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Monoclonal antibodies",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "IFX-1",
    "productId": 63,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "8ab005757848f68c4be9b3f7354f0ae1b49418f3",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8b37254ccb340a35bc492a85125002e78f979b1e",
        "sponsorName": "InflaRx"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Aplidin",
    "chemicalName": "Plitidepsin",
    "conditionOrDisease": "COVID 19",
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Anti-melanoma agent",
    "numSites": "",
    "otherPartners": "CSIC",
    "phase": "2",
    "preferredName": "Plitidepsin",
    "productId": 64,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Spanish Fork",
        "country": "US",
        "lat": 40.1335888,
        "lng": -111.6381703,
        "locationId": "7e97b056d296d630175bedc02f30b6ca64a1839a",
        "name": "E Market Pl Dr, Spanish Fork, UT 84660, USA",
        "state": "UT"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ec5f02cd738afe63b04534d0cc394af54573dc39",
        "sponsorName": "Pharmamar"
      },
      {
        "sponsorId": "880c99550c8a42deeaff83ad0902af0b020c8848",
        "sponsorName": "Centro Nacional Biotecnologia"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-immunosupressive",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Ganovo,Ritonavir",
    "conditionOrDisease": "COVID19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Sat, 25 Jan 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Study patients discharged",
    "numSites": "",
    "otherPartners": "Shaoxing Government",
    "phase": "2",
    "preferredName": "Ganovo,Ritonavir",
    "productId": 65,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3799735fca71d687b33e157b0589e09999052c4f",
        "sponsorName": "Ascletis Pharma"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Protease Inhibitor",
    "trialId": ""
  },
  {
    "brandName": "LUNAR-COV19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 27 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "mRNA vaccine. They color code where in the pipeline their drugs are. Someone who can tell shades of blue apart better than me should double check their current status.",
    "numSites": "",
    "otherPartners": "Duke-National University of Singapore",
    "phase": "",
    "preferredName": "LUNAR-COV19",
    "productId": 66,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "20dfe597bbef86e0b9719260a7c300a5b0df15ae",
        "sponsorName": "Arcturus"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Avigan,favilavir,T-705",
    "chemicalName": "Favipiravir",
    "conditionOrDisease": "Covid-19",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Japan has stockpile of 2 million.",
    "numSites": "11",
    "otherPartners": "",
    "phase": "Not Applicable",
    "preferredName": "Favipiravir",
    "productId": 67,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "fc031aa317078fca15980f229a50755d121cb4ce",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Beijing",
        "country": "CN",
        "lat": 39.90419989999999,
        "lng": 116.4073963,
        "locationId": "4bed0d8e630e451ca7f1f0f81f925b1f9c6c0194",
        "name": "Beijing, China",
        "state": "Beijing"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "a8e3792c4f9f1ad8167c967d34f1c309e6377b9b",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "ca31c0141e42d7e92d07a3fa76f4c567bc224bbb",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou",
        "country": "CN",
        "lat": 30.39194,
        "lng": 114.894843,
        "locationId": "8d20a51a5707e385b5dc44146e3c00ce29986ece",
        "name": "Ezhou, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "71314ce9c1ec6216a9371500cba8f838b4f571f0",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "e6b736310add4a0d09a7abe4a125f78335283812",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "fe1aeda3b87a6f35f9bfa1d449579eb0785d51b6",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.4917469,
        "lng": 114.1732702,
        "locationId": "90520b647f0cec9dcfea5821730c40c9bd488ae8",
        "name": "58 Shenlong Ave, Caidian Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "4c9e016b9c05309cccab0807ca7d795b9e63a87a",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.552985,
        "lng": 114.353743,
        "locationId": "14966298e0e199c59ab938b0a23cefef9f4215ca",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d3f2295022832956ff09046194ed9b4ab9077636",
        "sponsorName": "Fujifilm"
      },
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "DNA plasmid Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 05 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Uses a measles vector. They also are working on a DNA vaccine.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_plasmid_Vaccine",
    "productId": 68,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Inactivated + Alum Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Inactivated vaccine. Based on a SARS platform. Very little direct information.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated__Alum_Vaccine",
    "productId": 69,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8cc7224f8b0bf621aabeff6011656a8d75f8d1ef",
        "sponsorName": "Sinovac Biotech Ltd"
      },
      {
        "sponsorId": "665f231ea402a8737df181571627bda782b741e9",
        "sponsorName": "Dynavax Technologies"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated_Vaccine",
    "productId": 70,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e1992462e6978a6ef1bdee8a86f7d513222c1ad6",
        "sponsorName": "Beijing Institute of Biological Products"
      },
      {
        "sponsorId": "ad6a16130480e1a77d5ffb88a5752fdae6685597",
        "sponsorName": "Wuhan Institute of Biological Products"
      },
      {
        "sponsorId": "3bd129a36a22b99edf40b395c2fad7b78193bda9",
        "sponsorName": "Sinopharm"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Codagenix Live-Attenuated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 13 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "Live-Attenuated vaccine. Country might need to be switched to India later. Targeting September for human trials and 2022 for release.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Codagenix_LiveAttenuated_Vaccine",
    "productId": 71,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4f658739e6abe56363d5f2d9559538ae578e3aad",
        "sponsorName": "Codagenix"
      },
      {
        "sponsorId": "adee3b214297c2f83d459d75e4e295cde4fd187c",
        "sponsorName": "Serum Institute of India"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "MVA-S encoded",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MVAS_encoded",
    "productId": 72,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "42dc4894fcc96aa20e701b0f9bbb2fb79c1f0279",
        "sponsorName": "DZIF  German Center for Infection Research"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Greffex Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 11 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "They lack funding to start animal trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Greffex_Vaccine",
    "productId": 73,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c01129b833a3f153fc0408879e5a2bb4bf21b9b",
        "sponsorName": "Greffex"
      }
    ],
    "status": "On Hold",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "AdaptVac Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 09 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Consortium of Danish companies and universities. One of the universities will likely be the sponsor when they go to clinical trials.",
    "numSites": "",
    "otherPartners": "PREVENT-nCOV Consortium",
    "phase": "",
    "preferredName": "AdaptVac_Vaccine",
    "productId": 74,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b3dd9ec1147ddf57383d3eda6cd2d861e37911df",
        "sponsorName": "AdaptVac"
      },
      {
        "sponsorId": "af0e9043938d3ffd18d4aa4f263c303abe7a87c1",
        "sponsorName": "PREVENTnCoV consortium"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 75,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "433f99ff8c5ca5efa43e610e5d05b69e4f37d5ef",
        "sponsorName": "ExpreS2ion Biotechnologies ApS"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "USAMRIID Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "USAMRIID_Vaccine",
    "productId": 76,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "455288f646569f2165f9af95d690d300bbd182a8",
        "sponsorName": "WRAIR"
      },
      {
        "sponsorId": "301d4da21e654a4dac3ab28cf3feba940a10bc5f",
        "sponsorName": "USAMRIID"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "VaxHit",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Utilized single peptide technology,",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VaxHit",
    "productId": 77,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6326cfa8bba7bb5f22c4c0c558835079ac7fc122",
        "sponsorName": "Vaxil Bio Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "FlowVax COVID 19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Approach - Biodegradable microsphere peptide vaccine targeting SARS-CoV-2 nucleocapsid,T-cell vaccine,Expected to be used for pre- and post-exposure prophylaxis,Currently being tested on nonhuman primates",
    "numSites": "",
    "otherPartners": "University of Texas Medical Branch at Galveston",
    "phase": "",
    "preferredName": "FlowVax_COVID_19",
    "productId": 78,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "306b4a5ca7bafa2c8cb1637d2068fec4dcf4c872",
        "sponsorName": "Flow Pharma"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "EPV-CoV19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Peptide-based epitope driven vaccine candidate,Expected to stimulate protective T-cell response,Expected to protect against severe disease rather than protect against infection,Specifically targeted at healthcare workers,Availability of no-cost licenses for the vaccine recipe for developing world countries who have GMP facilities for production of the vaccine,Phase 1 trial expected to begin in 3 months",
    "numSites": "",
    "otherPartners": "Generex Biotechnology,GAIA Vaccine Foundation",
    "phase": "",
    "preferredName": "EPVCoV19",
    "productId": 79,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bd27e9eeb1bca08ea29864fa4bd2121d5abb6345",
        "sponsorName": "EpiVax Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "This seems to be separate from the partnership between Epivax and Generex,Also seems to be in pre-discovery phase as no specific mechanism has been identified",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "EpiVax_University_of_Georgia-80",
    "productId": 80,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2b2068ecd13962f5098c0b0cd04aaf01f7c38c14",
        "sponsorName": "EpiVax"
      },
      {
        "sponsorId": "e4bf2c53813e4971a809acf75b015ef7d10cbebc",
        "sponsorName": "University of Georgia"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "COVID 19 Vaccine",
    "chemicalName": "gp96-mediated vaccine",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Mechanism of action - gp96 + Viral Antigens",
    "numSites": "",
    "otherPartners": "University of Miami",
    "phase": "",
    "preferredName": "gp96mediated_vaccine",
    "productId": 81,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "69a6b23cf97fddaef2d35262b69a690f029417f4",
        "sponsorName": "Heat Biologics Inc"
      },
      {
        "sponsorId": "0fc2d17219cc99046bce21a2c41bc8215617c73d",
        "sponsorName": "University of Miami"
      },
      {
        "sponsorId": "9166254a6d2692220fda9b8f507259e0813000b3",
        "sponsorName": "Zolovax Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "bacTRL-Spike",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "bacTRLSpike",
    "productId": 451,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Vancouver",
        "country": "CA",
        "lat": 49.2456824,
        "lng": -123.1257129,
        "locationId": "4217c98cf949ae6ea990cdff46f41d3cabbf9303",
        "name": "938 W 28th Ave, Vancouver, BC V5Z 4H4, Canada",
        "state": "BC"
      },
      {
        "city": "Halifax",
        "country": "CA",
        "lat": 44.6381829,
        "lng": -63.5832045,
        "locationId": "08b0241e5ff04181d190b29e9cd8d6f22cbb73e1",
        "name": "5850/5980 University Ave, Halifax, NS B3K 6R8, Canada",
        "state": "NS"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e67cd6e6e2d90ce2d60b99c1798176c943a02d7e",
        "sponsorName": "Symvivo Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT04334980"
  },
  {
    "brandName": "T-cell therapies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "T-cell therapy,Baylor college of medicine is also pushing for testing of a vaccine developed against SARS-Cov-1 in 2016 - not much information about this",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Tcell_therapies",
    "productId": 82,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "41801411fe7d66b24eae2e0411ee409f9ad29507",
        "sponsorName": "Baylor College of Medicine"
      },
      {
        "sponsorId": "e6c4cbd24fa49f8c604388e030a0790d277ad9a6",
        "sponsorName": "AlloVir"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "IBIO-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Virus-like particle,Developed using FastPharming technology,Patent filed in March 2020",
    "numSites": "",
    "otherPartners": "Texas A&M University System Laboratories",
    "phase": "",
    "preferredName": "IBIO200",
    "productId": 83,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "505b07d6981f93ee187513e197589f4c16f04b35",
        "sponsorName": "iBio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OncoGen-84",
    "productId": 84,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "102fe9bb3724bbad454162ce2f31318baff6facb",
        "sponsorName": "OncoGen"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Measles Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Molecule type - DNA based vaccine,Based on the use of measles vaccine as a vector",
    "numSites": "",
    "otherPartners": "Themis Bioscience GmbH,University of Pittsburg - Center for Vaccine Research,CEPI",
    "phase": "",
    "preferredName": "Measles_Vector_Vaccine",
    "productId": 85,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a2a15d79e1f0b774dbc631aeed3b73af7f225cfe",
        "sponsorName": "Institute Pasteur"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "RNACure 2019-nCoV Vaccine Candidate VLP",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "RNACure Biopharma",
    "phase": "",
    "preferredName": "RNACure_2019nCoV_Vaccine_Candidate_VLP",
    "productId": 86,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      },
      {
        "sponsorId": "aa6799f660cd49b264d3e155560878bb15e8b804",
        "sponsorName": "Shanghai JiatTong University"
      },
      {
        "sponsorId": "f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0",
        "sponsorName": "RNACure Biopharma"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Stermina 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Stermina Therapeutics",
    "phase": "",
    "preferredName": "Stermina_2019nCoV_Vaccine_Candidate",
    "productId": 87,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "20e19a20e9874c07beba2c307650020c6a63535b",
        "sponsorName": "China CDC"
      },
      {
        "sponsorId": "0a82122244646304c943aa942a96ad3ace268562",
        "sponsorName": "Tongji University"
      },
      {
        "sponsorId": "30508a3774a3fd8aeb4cf75885e2ee9011d8514f",
        "sponsorName": "Stermina"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "OpenCorona 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Horizon 2020",
    "phase": "",
    "preferredName": "OpenCorona_2019nCoV_Vaccine_Candidate",
    "productId": 88,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a26c2ef25366b153b9c8bb0d553426bbab80d427",
        "sponsorName": "Karolinska Institute"
      },
      {
        "sponsorId": "4b38f0c3421f6f67e79a27c6fd64a3930c0c2627",
        "sponsorName": "CobraBiologics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "ReiThera 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ReiThera_2019nCoV_Vaccine_Candidate",
    "productId": 89,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6887e6de5a46033245e0bcb4f49450dcbadd7441",
        "sponsorName": "ReiThera"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "BioNet 2019-nCoV Vaccine Candidate",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Thaialnd"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BioNet_2019nCoV_Vaccine_Candidate",
    "productId": 90,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a4be0a2fbeb04dd3db2a97fc2f68a2388bb723b",
        "sponsorName": "BioNet Asia"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "Ivomec",
    "chemicalName": "Ivermectin",
    "conditionOrDisease": "",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ivermectin",
    "productId": 91,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e8af2a52a069a3c9d2e7076dbd1450dcac577b76",
        "sponsorName": "Doherty Institute"
      },
      {
        "sponsorId": "5f1bf89bc842335651ec9768cc0377edaff0185e",
        "sponsorName": "Monash University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "NIH",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 92,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b4a99af9eec1a8f807ede0e67dd5e8d77867b245",
        "sponsorName": "Tulane University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "Vaxcelerate vaccine,Hoth Voltron 2019-nCoV Vaccine Candidate,HaloVax",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Hoth,Voltron",
    "phase": "",
    "preferredName": "Vaxcelerate_vaccine_Hoth_Voltron_2019nCoV_Vaccine_Candidate_HaloVax",
    "productId": 93,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a0e1dd25259a873fb5bbf352459b984c718be493",
        "sponsorName": "Hoth Therapeutics"
      },
      {
        "sponsorId": "465edc414eb3f341233a89dca1b03de024926e45",
        "sponsorName": "Voltron Therapeutics"
      },
      {
        "sponsorId": "d515d87719a8a1e6a5874fe40dfaa22d5f577854",
        "sponsorName": "Vaccine and Immunotherapy Center"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "STI-6991",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "STI6991",
    "productId": 94,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4f038c1fd0e4c52d93147fc334849bc67394496",
        "sponsorName": "Sorrento Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "VTP-500",
    "chemicalName": "",
    "conditionOrDisease": "MERS",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 14 Mar 2018 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "MERS",
    "numSites": "1",
    "otherPartners": "UNIVERSITY OF OXFORD,JANSSEN,CEPI",
    "phase": "1",
    "preferredName": "VTP500",
    "productId": 95,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Oxford",
        "country": "GB",
        "lat": 51.7520209,
        "lng": -1.2577263,
        "locationId": "f4afd02b264a450cb9b9726f3db2ce1267389e66",
        "name": "Oxford, UK",
        "state": "England"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3539cc93ae38ac97613e91267777269795073379",
        "sponsorName": "Vaccitech"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT03399578"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Sanofi Pasteur",
    "phase": "",
    "preferredName": "Sanofi_Translate_Bio-96",
    "productId": 96,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "551135a9f6ade78853bbd5fdbd66283c70e2f776",
        "sponsorName": "Sanofi"
      },
      {
        "sponsorId": "1ddb247542fcbc349fe829611d29e6ded2b999e7",
        "sponsorName": "Translate Bio"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "nebulized Ampion",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "In Phase 3 Trials for Osteoarthritis of the Knee",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nebulized_Ampion",
    "productId": 97,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "02881a510323f0cd43a11e035e7be1138b026116",
        "sponsorName": "Ampio Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Piclidenoson",
    "conditionOrDisease": "COVID-19",
    "countries": ["Petach Tikva-Israel"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "In Phase 3 Trials for Rhumetoid Arthritis",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Piclidenoson",
    "productId": 98,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7261135,
        "lng": -73.99561469999999,
        "locationId": "cd7f5a372e5afa518afeb79e4c4e2c0679429c07",
        "name": "636 Broadway #218, New York, NY 10012, USA",
        "state": "NY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ea7e102c17c41b12f5ea330cafbdf8e967c6742",
        "sponsorName": "CanFite BioPharma Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04333472"
  },
  {
    "brandName": "IFX-1",
    "chemicalName": "BDB-1",
    "conditionOrDisease": "COVID-19 Pneumonia",
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2/3",
    "preferredName": "BDB1",
    "productId": 99,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Amsterdam",
        "country": "NL",
        "lat": 52.35581819999999,
        "lng": 4.955726299999999,
        "locationId": "31bdf7d46ac1141c00096cbe2ba46235f2e39062",
        "name": "1012 WX Amsterdam, Netherlands",
        "state": "NH"
      },
      {
        "city": "Maastricht",
        "country": "NL",
        "lat": 50.8471422,
        "lng": 5.686401699999999,
        "locationId": "6bdeb2255b5f74c5411cccb89939a346950ce3cf",
        "name": "Minderbroedersberg 4-6, 6211 LK Maastricht, Netherlands",
        "state": "LI"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecc0feedb452374f3f35ae9224fd597c82fca6a1",
        "sponsorName": "InflaRx NV"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04333420"
  },
  {
    "brandName": "Ryoncil",
    "chemicalName": "remestemcel-L",
    "conditionOrDisease": "ARDS",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "15",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "remestemcelL",
    "productId": 100,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Los Angeles",
        "country": "US",
        "lat": 34.0223519,
        "lng": -118.285117,
        "locationId": "7a68730a1dcc791302216f7b6df1bc697fe03c2d",
        "name": "Los Angeles, CA 90007, USA",
        "state": "CA"
      },
      {
        "city": "Atlanta",
        "country": "US",
        "lat": 33.7971368,
        "lng": -84.32224,
        "locationId": "536cae7d3673a67b9d9888e82806a6f154ac3ef0",
        "name": "201 Dowman Dr, Atlanta, GA 30322, USA",
        "state": "GA"
      },
      {
        "city": "Fort Wayne",
        "country": "US",
        "lat": 41.0389032,
        "lng": -85.249408,
        "locationId": "8901bc26fb0b66af116732b7f4c522d15c1a48c9",
        "name": "7950 W Jefferson Blvd, Fort Wayne, IN 46804, USA",
        "state": "IN"
      },
      {
        "city": "New Orleans",
        "country": "US",
        "lat": 29.9631002,
        "lng": -90.1436859,
        "locationId": "71cb1aba32f422796f0c8c07e41eee650d780d36",
        "name": "1315 Jefferson Hwy, New Orleans, LA 70121, USA",
        "state": "LA"
      },
      {
        "city": "Baltimore",
        "country": "US",
        "lat": 39.2892017,
        "lng": -76.6257057,
        "locationId": "93f55711a3d5259dca07354a86a51dd94ea8dab6",
        "name": "620 W Lexington St, Baltimore, MD 21201, USA",
        "state": "MD"
      },
      {
        "city": "Boston",
        "country": "US",
        "lat": 42.3361091,
        "lng": -71.1074884,
        "locationId": "b23b063af13f7bf7098d83d1c6c9a2553a5cb6c5",
        "name": "75 Francis St, Boston, MA 02115, USA",
        "state": "MA"
      },
      {
        "city": "Ann Arbor",
        "country": "US",
        "lat": 42.2780436,
        "lng": -83.7382241,
        "locationId": "2c21d3350b83efe1f000b1c6863717dd2285b6e2",
        "name": "500 S State St, Ann Arbor, MI 48109, USA",
        "state": "MI"
      },
      {
        "city": "Lebanon",
        "country": "US",
        "lat": 43.67536399999999,
        "lng": -72.2729872,
        "locationId": "f36d0847e074837a00639a8869c19fa291546e91",
        "name": "1 Medical Center Dr, Lebanon, NH 03766, USA",
        "state": "NH"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7702407,
        "lng": -73.9906883,
        "locationId": "dd6e3d4d4106d32e81094d0b3e4f871930514fca",
        "name": "555 W 57th St, New York, NY 10019, USA",
        "state": "NY"
      },
      {
        "city": "Asheville",
        "country": "US",
        "lat": 35.5813447,
        "lng": -82.5500921,
        "locationId": "0b5176ea712d2004ab7a2fd4fe6ce63f34878b47",
        "name": "428 Biltmore Ave, Asheville, NC 28801, USA",
        "state": "NC"
      },
      {
        "city": "Durham",
        "country": "US",
        "lat": 36.0058487,
        "lng": -78.9371331,
        "locationId": "fab4f5d719be21f5cd72495eafc407c22aa4983d",
        "name": "10 Duke Medicine Cir, Durham, NC 27710, USA",
        "state": "NC"
      },
      {
        "city": "Cleveland",
        "country": "US",
        "lat": 41.4620067,
        "lng": -81.69753519999999,
        "locationId": "057fd7644c3a492024ef7b959bae193a03845157",
        "name": "2500 Metrohealth Dr, Cleveland, OH 44109, USA",
        "state": "OH"
      },
      {
        "city": "Philadelphia",
        "country": "US",
        "lat": 39.9564021,
        "lng": -75.1939526,
        "locationId": "9b0e9ac55396a9ffc6017b7380dfa5ebd2b5eac6",
        "name": "3535 Market St #100, Philadelphia, PA 19104, USA",
        "state": "PA"
      },
      {
        "city": "Waco",
        "country": "US",
        "lat": 31.5469132,
        "lng": -97.1210998,
        "locationId": "778ff3fd768bf8b64a1850e3d96ba542a6bd11b6",
        "name": "1311 S 5th St, Waco, TX 76706, USA",
        "state": "TX"
      },
      {
        "city": "Plano",
        "country": "US",
        "lat": 33.0141167,
        "lng": -96.7926581,
        "locationId": "ce419aa3bb0128c825119f4e5b68cb4df1cf464c",
        "name": "4716 Alliance Blvd, Plano, TX 75093, USA",
        "state": "TX"
      },
      {
        "city": "Charlottesville",
        "country": "US",
        "lat": 38.0335529,
        "lng": -78.5079772,
        "locationId": "ca1de73a46ab9cd9067efeb02c7455b16c78cadd",
        "name": "Charlottesville, VA, USA",
        "state": "VA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4959407d4633b3c9180469947d99a947263aeb9",
        "sponsorName": "Mesoblast Limited"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04371393"
  },
  {
    "brandName": "Actemvra",
    "chemicalName": "tocilizumab",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "tocilizumab",
    "productId": 101,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cc672ac08b0d9e540145295250d172650b81b78c",
        "sponsorName": "Rogers Corporation"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Diammonium",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Diammonium",
    "productId": 102,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "828d3ce717e4188e36142a37dde46c7150e54532",
        "sponsorName": "Sino Biopharmaceuticals"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Dantonic",
    "chemicalName": "T89",
    "conditionOrDisease": "newly diagnosed Covid-19 patients with oxygen saturation > 90%",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "T89 is an industrialized botanical drug formula developed from traditional Chinese Medicine. It is a mixture of multiple plant extracts and other excipients. It is to be tested for increasing blood O2 saturation in the ongoing clinical trial registered in US. The trial was approved but not yet recruiting.",
    "numSites": "Not specified",
    "otherPartners": "Tasly Pharmaceuticals",
    "phase": "not applicable",
    "preferredName": "T89",
    "productId": 103,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "b7ba1629417aaa0bcc9fba336509da223ffe73a3",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0dda51f9c95a47c39d878234d93d16d7902c83f1",
        "sponsorName": "Tasly Pharmaceuticals"
      },
      {
        "sponsorId": "3a0d49eb534018ed04f1ba984529ab2611135695",
        "sponsorName": "Arbor Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04285190"
  },
  {
    "brandName": "Monoclonal Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Monoclonal_Antibodies",
    "productId": 104,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "156a9d5b5c0452de6985da63b61ee8521a939741",
        "sponsorName": "AstraZeneca PLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Monoclonal Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "they have 300 candidates now will narrow down to fewer candidates",
    "numSites": "",
    "otherPartners": "Celltrion",
    "phase": "",
    "preferredName": "Monoclonal_Antibodies",
    "productId": 105,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "625c2965f7108c1ad1edf37eef366aad6b28fbd8",
        "sponsorName": "Celltrion"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Monoclonal Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "IIBR will use the manufacturing platform of Dyadic to produce their monoclonal antibody candidate",
    "numSites": "",
    "otherPartners": "IIBR,Dyadic",
    "phase": "",
    "preferredName": "Monoclonal_Antibodies",
    "productId": 106,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bc5f1b8a05634976386ebb4a0eb43f430166cf2f",
        "sponsorName": "Israel Institute for Biological Research IIBR"
      },
      {
        "sponsorId": "4aa813a58d95ae6daf00386144326869f4a7e3ee",
        "sponsorName": "Dyadic International Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "KPL-301",
    "chemicalName": "mavrilimumab",
    "conditionOrDisease": "documented Covid-19 pneumonia",
    "countries": ["Italy", "US"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The drug had up to phase-2 trial for other indications. Successfully used in Covid-19 pts in Italy (did not find the exact trial description).",
    "numSites": "1",
    "otherPartners": "Kiniksa Pharmaceuticals,Virginia Commonwealth University",
    "phase": "Phase 2",
    "preferredName": "mavrilimumab",
    "productId": 107,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Richmond",
        "country": "US",
        "lat": 37.5407246,
        "lng": -77.4360481,
        "locationId": "21c619833e0d240c60ded2b0ca3c8ce43d83cb59",
        "name": "Richmond, VA, USA",
        "state": "VA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f0b7d34b0d2bf183e3127d2f2ae6859f2e0c2303",
        "sponsorName": "Kiniksa Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Plasma-derived hyperimmune globulin therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Takeda started development as TAK-888. Several groups working on immunoglobulin strategies are now working together. They need plasma donors.",
    "numSites": "",
    "otherPartners": "Biotest,Bio Products Laboratory,Octa Pharma,LFB,CSL Behrig",
    "phase": "",
    "preferredName": "Plasmaderived_hyperimmune_globulin_therapy",
    "productId": 108,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "43916cc52a3993e63c8a49430c524b6ee70b288e",
        "sponsorName": "CoVIg19 Plasma Alliance"
      },
      {
        "sponsorId": "33b00f7cf4a1544653db151375b5993b9a65892b",
        "sponsorName": "Biotest"
      },
      {
        "sponsorId": "117e9d7e0ecaab7bb098d842d06eeb5b61264077",
        "sponsorName": "BPL"
      },
      {
        "sponsorId": "55f0aa800f25c9093f14e24ae7f37b8f48615a59",
        "sponsorName": "CSL Behring"
      },
      {
        "sponsorId": "1a10f3633823419c6252ef6740cd1775636313a8",
        "sponsorName": "LFB"
      },
      {
        "sponsorId": "0a79402e1456155833c273467179eed61b8a15b2",
        "sponsorName": "Octapharma"
      },
      {
        "sponsorId": "31759effba9dd9037b4a5b2a4e1bf87cb0e4042b",
        "sponsorName": "Takeda"
      },
      {
        "sponsorId": "33f0ad8645fb9f5cb965a79f41b7d258aeb45002",
        "sponsorName": "ADMA Biologics"
      },
      {
        "sponsorId": "8602f1675de8eabf55cab947fb769a020c61501b",
        "sponsorName": "BioPharma Plasma"
      },
      {
        "sponsorId": "fb88543fd60aa16c3c184e6208739bc678ea7909",
        "sponsorName": "GC Pharma"
      },
      {
        "sponsorId": "fdcec5fc0acc497097b5595f555306625de122b3",
        "sponsorName": "Sanquin"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 26 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma",
    "numSites": "",
    "otherPartners": "Cerus Corporation,California Department of Public Health,University of California,Irvine\u2019s Vaccine Development Research Laboratory,Vitalant Research Institute,California National Primate Research Center,Enable Biosciences",
    "phase": "Discovery",
    "preferredName": "Plasma_Immunoglobulins",
    "productId": 109,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fe619f6a989eee7d5e22b0c5a964b30deeb615db",
        "sponsorName": "CERS actually spelt Cerus Corporation"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma",
    "numSites": "",
    "otherPartners": "Grifols,BARDA,FDA",
    "phase": "Discovery",
    "preferredName": "Plasma_Immunoglobulins",
    "productId": 110,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "893c4bdb7386d6aa83dda414cb161d199a4e191f",
        "sponsorName": "Grifols"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma Program. Ongoing. No dates given.",
    "numSites": "6",
    "otherPartners": "Mayo Clinic",
    "phase": "On Market",
    "preferredName": "Plasma_Immunoglobulins",
    "productId": 111,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7899953,
        "lng": -73.9527248,
        "locationId": "cb5198b829999f502f099db32be296f99678beb3",
        "name": "1468 Madison Ave, New York, NY 10029, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7695024,
        "lng": -73.9864118,
        "locationId": "104c3684d6d0625ceca3081233c63d914f853183",
        "name": "1000 10th Ave, New York, NY 10019, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.8052591,
        "lng": -73.96117029999999,
        "locationId": "7c344265b605550d298da2b33bc830c80a093ae4",
        "name": "1111 Amsterdam Ave, New York, NY 10025, USA",
        "state": "NY"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7331965,
        "lng": -73.9820857,
        "locationId": "da1bfffd9e8979a711ec210ab0111e98fad5dcf7",
        "name": "281 1st Avenue, New York, NY 10003, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "US",
        "lat": 40.7680385,
        "lng": -73.9248154,
        "locationId": "4567819011b11eee66c32fad2d16246f97548dac",
        "name": "25-10 30th Ave, Queens, NY 11102, USA",
        "state": "NY"
      },
      {
        "city": null,
        "country": "US",
        "lat": 40.6187604,
        "lng": -73.94282380000001,
        "locationId": "59c7d024eef22e1917948609b4c5fc36061e7199",
        "name": "3201 Kings Hwy, Brooklyn, NY 11234, USA",
        "state": "NY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "67cc1b58cfec53c29d2af191d961276e32239c1b",
        "sponsorName": "Mount Sinai Health System"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Plasma Immunoglobulins",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Convalescent Plasma Program. Ongoing. No dates given.",
    "numSites": "3",
    "otherPartners": "China National Biotec Group",
    "phase": "Phase II eqvlt study completed. Randomised Control Trial recommended.",
    "preferredName": "Plasma_Immunoglobulins",
    "productId": 112,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "2fb4f1ce3d7fd1b031864a135709bf1a0d22d10a",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.375552,
        "lng": 114.320726,
        "locationId": "7fcb3ac168bc2fe0c09371275434ea6de23232e3",
        "name": "Jiangxia District, Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.3500539,
        "lng": 114.328985,
        "locationId": "6499915cf5ee22167bea5e4884945e7e3f1dc560",
        "name": "116 Jiangxia Ave, Jiangxia Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de649c1e3ec322020be03d52590a6461de6d1a6a",
        "sponsorName": "China National Biotec"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Soliris",
    "chemicalName": "Eculizumab",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "replaced by Ultomiris(ravulizumab-cwvz) for further tests.",
    "numSites": "",
    "otherPartners": "Alexion Pharmaceuticals Inc.",
    "phase": "Preclinical",
    "preferredName": "Eculizumab",
    "productId": 197,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "41794d8c7643f99fc7895546d19147d1b41daf20",
        "sponsorName": "Alexion Pharmaceuticals Inc"
      }
    ],
    "status": "On Hold",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "ARDS in Covid-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Vasoactive Intestinal Polypeptide which inhibits inflammatory cytokines causing ARDS",
    "numSites": "4",
    "otherPartners": "NeuroRx",
    "phase": "Phase III",
    "preferredName": "NeurRx_Relief_Therapeutics-113",
    "productId": 113,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Miami",
        "country": "US",
        "lat": 25.7897,
        "lng": -80.211478,
        "locationId": "64a88bfb98c895b8b0c843c2e3172fc9e9a7c100",
        "name": "1550 NW 10th Ave #118, Miami, FL 33136, USA",
        "state": "FL"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7422466,
        "lng": -73.9743033,
        "locationId": "e34a3617e4fbb6f94b05e95258d85757c19f1bee",
        "name": "560 1st Avenue, New York, NY 10016, USA",
        "state": "NY"
      },
      {
        "city": "Philadelphia",
        "country": "US",
        "lat": 39.9496698,
        "lng": -75.1579974,
        "locationId": "eff31c7e3299d1e565868bd7dd184f68232278d9",
        "name": "111 S 11th St Ste 6200, Philadelphia, PA 19107, USA",
        "state": "PA"
      },
      {
        "city": "Haifa",
        "country": "IL",
        "lat": 32.8329785,
        "lng": 34.9857062,
        "locationId": "f588b56eea347dbee03e359e28891e6b1ae39260",
        "name": "HaAliya HaShniya St 8, Haifa, 3109601, Israel",
        "state": "Haifa District"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8c18a287de447a9a8dfa13df486ebd28237a8878",
        "sponsorName": "NeurRx"
      },
      {
        "sponsorId": "a30d64bea24fb02aa2230fa1359a99643a0fc3a3",
        "sponsorName": "Relief Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04311697"
  },
  {
    "brandName": "STI-4398,COVIDTRAP",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells - which is expected to effectively interrupt the viral life cycle",
    "numSites": "",
    "otherPartners": "Sorrento Theraputics",
    "phase": "Pre-Clinical Testing",
    "preferredName": "STI4398_COVIDTRAP",
    "productId": 114,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dd736e19d9cf47b8b0d9049c8729f5f8c706b691",
        "sponsorName": "Sorrento Therapeutics inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "University_of_Life-115",
    "productId": 115,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3a828ae8c0095976a9e4da7d0e3c7bfdddeb87ac",
        "sponsorName": "University of Life"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "INOpulse",
    "chemicalName": "",
    "conditionOrDisease": "Covid-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Inhaled Nitric Oxide at Phase 2 for  for COPD - ILD - Sarcoidosis",
    "numSites": "",
    "otherPartners": "Bellerophon Therapeutics",
    "phase": "Phase 2,Currently pursuing Expanded Access Program clearance in USA,Currently applying for Phase III Trial",
    "preferredName": "INOpulse",
    "productId": 116,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e5750b2be1ef356fc53942e9fba92281f2fa8b6f",
        "sponsorName": "Bellerophon Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "CytoSorb",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 10 Apr 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Miller School of Medicine University of Miami Medical Center - Florida - United States,Robert I Grossman School of Medicine NYU Langone Medical Center New York United States,Thomas Jefferson University Hospital Philadelphia Pennsylvania United States,Rambam Health Care Campus Haifa Israel",
    "numSites": "",
    "otherPartners": "CytoSorb",
    "phase": "Emergency Use - Not under Trial",
    "preferredName": "CytoSorb",
    "productId": 117,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d550d39fbfcc114bb9424feb7ee3922ee7889355",
        "sponsorName": "CytoSorbents Corporation"
      }
    ],
    "status": "On Market",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "SNX-5542",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "SNX5542",
    "productId": 118,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "282eaef03c22bad7cc8a8fd8da311711425b1a20",
        "sponsorName": "Esanex"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Mytesi",
    "chemicalName": "crofelemer",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "antidiarrheal for those on anti-retroviral therapy - used in HIV patients - permission sought from FDA for use in COVID patients",
    "numSites": "",
    "otherPartners": "Jaguar Health",
    "phase": "",
    "preferredName": "crofelemer",
    "productId": 119,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c7563c3b7fe4829bad22fa8782140bff9d34561f",
        "sponsorName": "Jaguar Health"
      }
    ],
    "status": "Failed",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find therapeutic use,only antibody test for covid?",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Leibniz_Institute-120",
    "productId": 120,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8e15d495d6fb7018df95d75779b82dcd926be20f",
        "sponsorName": "Leibniz Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find any therapeutic drug/vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Allergan-121",
    "productId": 121,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "81ce487fc0d3a5b4c58a218b8adceb96a044468f",
        "sponsorName": "Allergan"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "CD24Fc",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "first-in-class recombinant fusion protein (biologic)",
    "numSites": "1",
    "otherPartners": "OncoImmune",
    "phase": "3",
    "preferredName": "CD24Fc",
    "productId": 122,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Baltimore",
        "country": "US",
        "lat": 39.2892017,
        "lng": -76.6257057,
        "locationId": "7abec293179327e137fb8d0440f64d1a26e521a5",
        "name": "620 W Lexington St, Baltimore, MD 21201, USA",
        "state": "MD"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "01bbc68194bde084f23cb9df2a7ae7d59d15b54f",
        "sponsorName": "OncoImmune"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "PUL-042 Inhalation Solution",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "2 Clinical Trials: one for short term immunisation,also one for reducing severity (link below for latter)",
    "numSites": "Not listed",
    "otherPartners": "Pulmotect",
    "phase": "2",
    "preferredName": "PUL042_Inhalation_Solution",
    "productId": 123,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Houston",
        "country": "US",
        "lat": 29.7106626,
        "lng": -95.399568,
        "locationId": "8117b4b828fbea858fef06ff48bafb5f9528dd5c",
        "name": "6565 Fannin St, Houston, TX 77030, USA",
        "state": "TX"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1eab813cb618e383ce0ca0e7f81c6684b50fdddc",
        "sponsorName": "Pulmotect"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "could not find therapeutic drug/vaccine",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Digestive_Disease_Research_Institute-124",
    "productId": 124,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4df36b5a59c84e2083f2bc2c1d75bda25e29f290",
        "sponsorName": "Digestive Disease Research Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Clinical Trials - stage unknown - to test 4 therapes: Remdesevir,Hydroxychloroquine,Lopinavir and Rotinavir,plus IFN-beta",
    "numSites": "",
    "otherPartners": "National Insitute for Health and Medical Research",
    "phase": "",
    "preferredName": "INSERM-125",
    "productId": 125,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0e1ea407af0902261db76719a57a5c127ea53bfe",
        "sponsorName": "INSERM"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Nitric Oxide",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "4 Current/upcoming trials - to assess use of Nitric Oxide for treating COVID patients - and also potentially preventing the disease",
    "numSites": "2",
    "otherPartners": "Massachusetts General Hospital",
    "phase": "2",
    "preferredName": "Nitric_Oxide",
    "productId": 126,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Boston",
        "country": "US",
        "lat": 42.3626109,
        "lng": -71.067566,
        "locationId": "5597b9b49eb260318e11a3397b673f2989a5ec72",
        "name": "55 Fruit St, Boston, MA 02114, USA",
        "state": "MA"
      },
      {
        "city": "Xi'an",
        "country": "CN",
        "lat": 34.2706897,
        "lng": 108.9880179,
        "locationId": "77a31cb818a4f4d29b28ad1d9857740f3777e9ff",
        "name": "Kangfu Road Shangquan, Xincheng District, Xi'an, Xi'an, Shaanxi, China",
        "state": "Shaanxi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8a365c9b40d6477fb64fadbb35d6bac33dafb436",
        "sponsorName": "Massachusetts General Hospital"
      },
      {
        "sponsorId": "df85596f7d7dbeb2a2e8c43c35f6f8fa02b44690",
        "sponsorName": "Mallincrodt plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "RoActerma",
    "chemicalName": "Tocilizumab",
    "conditionOrDisease": "COVID-19 pneumonia",
    "countries": ["United states"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Phase 3 approved",
    "numSites": "",
    "otherPartners": "Roche and BARDA",
    "phase": "2",
    "preferredName": "Tocilizumab",
    "productId": 127,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2ca60c923f9bd40c651529c4a7b5a6972829d31d",
        "sponsorName": "National Cancer Institute"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Tamiflu",
    "chemicalName": "oseltamivir",
    "conditionOrDisease": "COVID-19,SARS COV-2",
    "countries": ["Thailand"],
    "countryCodes": ["THA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Rajavithi Hospital",
    "phase": "3",
    "preferredName": "oseltamivir",
    "productId": 128,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6929a0f7701affd68fc35e0bb16ed03f8cfbfee6",
        "sponsorName": "Rajavithi Hospital"
      },
      {
        "sponsorId": "ef7f40a7a4970541f7271499b9755b383671309d",
        "sponsorName": "Roche AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Hydroxychloroquine,Lopinavir,Ritonavir,Interferon-\u03b2 1a",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Hydroxychloroquine_Lopinavir_Ritonavir_Interferon\u03b2_1a_",
    "productId": 129,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "eb058ec8d1b15050f17777e54392b41479ffda20",
        "sponsorName": "Shahid Beheshti Univeristy of Medical Sciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "sofosbuvir,ledipasvir",
    "conditionOrDisease": "",
    "countries": ["Iran"],
    "countryCodes": ["IRN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sofosbuvir_ledipasvir",
    "productId": 130,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3d91d8a2763ff7a2305e9571ce331344f8db21d8",
        "sponsorName": "Tehran University of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Beijing_Chaoyang_Hospital_Capital_Medical_University-131",
    "productId": 131,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2edadb0a368326e19a38c17e17aa31d37ca94581",
        "sponsorName": "Beijing Chaoyang Hospital"
      },
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Beijing_Youan_Hospital_Capital_Medical_University-132",
    "productId": 132,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "321cfa99e2d96ffd805132b7d743b6bce706e380",
        "sponsorName": "Beijing Youan Hospital"
      },
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Carrimycin",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "11",
    "otherPartners": "Beijing YouAn Hospital",
    "phase": "4",
    "preferredName": "Carrimycin",
    "productId": 133,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073",
        "sponsorName": "Capital Medical University"
      },
      {
        "sponsorId": "47b3533192dd0db49fc64ee3adb03d999199d9d4",
        "sponsorName": "Shenyang Tonglian Group Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "CMAB806",
    "chemicalName": "Interleukin-6 monoclonal antibody",
    "conditionOrDisease": "cytokine release syndrome of new coronavirus pneumonia (COVID-19)",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "Study goes to May 31st",
    "numSites": "1",
    "otherPartners": "",
    "phase": "Phase 2",
    "preferredName": "Interleukin6_monoclonal_antibody",
    "productId": 134,
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "04d24aea4e5dbc6271f4a311dd77c7f57a66a8bf",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c1d2cca1e1c545b115cedcb4a88a86dfc5cc4c0",
        "sponsorName": "JinYu BioTechnology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": "ChiCTR2000030196"
  },
  {
    "brandName": "CAStem",
    "chemicalName": "Mesenchymal Stem Cells",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 05 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "Phase 2",
    "preferredName": "Mesenchymal_Stem_Cells",
    "productId": 135,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.522832,
        "lng": 114.330432,
        "locationId": "e270168a1d64d24c1bdd9650f1441a4080771d51",
        "name": "53 Dingziqiao Rd, Hong Shan Jie Dao Kou Shang Quan, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "13b42241b3f79920498bebed4eb9a2d8938e153e",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e13a47c3805a5ea782acbdd30bf4d9672426da11",
        "sponsorName": "Beijing 302 Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04288102"
  },
  {
    "brandName": "",
    "chemicalName": "NKG2D-ACE2 CAR-NK Cells",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 21 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 21 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Phase I/II Trial",
    "numSites": "1",
    "otherPartners": "Chongqing Sidemu Biotechnology",
    "phase": "Phase 2",
    "preferredName": "NKG2DACE2_CARNK_Cells",
    "productId": 136,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 29.550499,
        "lng": 106.470884,
        "locationId": "a8f92de9ef8bf3a0575f28c23f93497e533f96e8",
        "name": "62 Shixiao Rd, Shapingba Qu, Chongqing Shi, China",
        "state": "Chongqing Shi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "45c8692c794fd50c930fb0b97c607465d7d554b9",
        "sponsorName": "Chongqing Public Health Medical Center"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04324996"
  },
  {
    "brandName": "",
    "chemicalName": "Long-acting interferon alpha-2a,ribavirin",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 26 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "5",
    "otherPartners": "",
    "phase": "Phase 2",
    "preferredName": "Longacting_interferon_alpha2a_ribavirin",
    "productId": 137,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Foshan Shi",
        "country": "CN",
        "lat": 22.8500072,
        "lng": 113.2578008,
        "locationId": "82ffb1a8664ebc0116d47f67995ddd889910892b",
        "name": "Yungui 7th St, Shunde Qu, Foshan Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Shenzhen Shi",
        "country": "CN",
        "lat": 22.54483,
        "lng": 114.095787,
        "locationId": "d517e71a39c09103e94c4697e2981f1855dc24cd",
        "name": "2 Zhenhua Rd, Futian Qu, Shenzhen Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Dongguan",
        "country": "CN",
        "lat": 23.020673,
        "lng": 113.751799,
        "locationId": "a17da80fcec101e9b484f3b225e6b333bcf3206c",
        "name": "Dongguan, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Jiangmen Shi",
        "country": "CN",
        "lat": 22.605688,
        "lng": 113.115602,
        "locationId": "965f546f0fd0daa314818605e7b49d684a5c9945",
        "name": "China, Guangdong Sheng, Jiangmen Shi, Pengjiang Qu, \u5317\u8857\u6d77\u65c1\u885723\u53f7",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Foshan Shi",
        "country": "CN",
        "lat": 22.960003,
        "lng": 112.978451,
        "locationId": "ce1f3f63da4e04118f4a43bc093054fc47ad2766",
        "name": "China, Guangdong Sheng, Foshan Shi, Nanhai Qu, Qiaojin Hwy, \u6a35\u91d1\u8def",
        "state": "Guangdong Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0aa5baf3a5bfcd9bd34bc49ddd68b3369a8bd29f",
        "sponsorName": "Foshan First Peoples Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": "ChiCTR2000030922"
  },
  {
    "brandName": "",
    "chemicalName": "Triazavirin",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 15 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Originally developed in Russia for Influenza.",
    "numSites": "4",
    "otherPartners": "",
    "phase": "Phase 3",
    "preferredName": "Triazavirin",
    "productId": 138,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.768768,
        "lng": 126.655785,
        "locationId": "1e87d3d1d3d3c65ee4cb35c7a7f5c1df26e1c610",
        "name": "The First Affiliated Hospital of Harbin Medical University, Nangang Qu, Haerbin Shi, China",
        "state": null
      },
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.696577,
        "lng": 126.616301,
        "locationId": "ef4fe4804ec575b54a2374ecc6ab83a1be53261a",
        "name": "246 Xuefu Rd, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China, 150086",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.7003851,
        "lng": 126.6202132,
        "locationId": "b19e9351ad8092f0ffc861404d4fc86ff4e28499",
        "name": "157 Baojian Rd, Nangang Qu, Haerbin Shi, Heilongjiang Sheng, China",
        "state": "Heilongjiang Sheng"
      },
      {
        "city": "Haerbin Shi",
        "country": "CN",
        "lat": 45.7289211,
        "lng": 126.6869291,
        "locationId": "b4c62daa8f4d50e702d91e4b92372cb6906e4fe2",
        "name": "405 Gongbin Rd, Xiangfang Qu, Haerbin Shi, Heilongjiang Sheng, China, 150036",
        "state": "Heilongjiang Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "74eb28bb89c6d76ecbdcbb4b00449a43dd0efd98",
        "sponsorName": "Health commission of Heilongjiang province"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": "ChiCTR2000030001"
  },
  {
    "brandName": "",
    "chemicalName": "azvudine",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "http://www.chictr.org.cn/showprojen.aspx?proj=50507",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "azvudine",
    "productId": 139,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "590809afc11f993a1d02526632882469be2ae713",
        "sponsorName": "Henan Provincial Peoples Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Esbriet",
    "chemicalName": "Pirfenidone",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Pirfenidone",
    "productId": 140,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "abf659ef96c4f7cef8ec83e1e16ec37d171098bb",
        "sponsorName": "Huilan Zhang"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Chloroquine",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1",
    "preferredName": "Chloroquine",
    "productId": 141,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "617b848747bc14a2a9fc203852ab5529565cab2a",
        "sponsorName": "Hwa Mei Hospital"
      },
      {
        "sponsorId": "ac1ac20ca0b9ec951428fe364c421040f1f4829b",
        "sponsorName": "University of Chinese Academy of Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "XueBiJing",
    "chemicalName": "XueBiJing",
    "conditionOrDisease": "Novel Coronavirus Pneumonia",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 18 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Traditional Chinese Medicine,5-herb combination",
    "numSites": "1",
    "otherPartners": "N/A",
    "phase": "1",
    "preferredName": "XueBiJing",
    "productId": 142,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Jingzhou Shi",
        "country": "CN",
        "lat": 30.30907899999999,
        "lng": 112.259189,
        "locationId": "c1dfc2e228b18c107bd11d6ee6b0a2d812ba0867",
        "name": "8 Hangkong Rd, Shashi Qu, Jingzhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de88121edbf4cca2b6df882b71a3a79995714b11",
        "sponsorName": "Jingzhou First Peoples Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "ChiCTR2000030388"
  },
  {
    "brandName": "",
    "chemicalName": "Methylprednisolone",
    "conditionOrDisease": "Acute Respiratory Failure",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Jan 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Zhongda Hospital,Renmin Hospital of Wuhan University",
    "phase": "2",
    "preferredName": "Methylprednisolone",
    "productId": 143,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 39.911431,
        "lng": 116.41481,
        "locationId": "4668e4f128f8361cfd43e7fc078001e08549f90b",
        "name": "9 Dongdan 3rd Alley, Dong Dan, Dongcheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "10172e384c8eaa0f469f305f6d2b50b0eabb14f5",
        "sponsorName": "Peking Union Medical College Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04244591"
  },
  {
    "brandName": "",
    "chemicalName": "Favipiravir,Tocilizumab",
    "conditionOrDisease": "Covid-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Favipiravir - Small molecule,Tocilizumab - protein based,Anti-viral and monoclonal antibody combination",
    "numSites": "9",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "Favipiravir_Tocilizumab",
    "productId": 144,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "6cd49e956f68a2dae4c08cae37744c3710d0ce4a",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "fd3a4586ff06b5fa059c758454d3b9cb21395f4a",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "8f35aa5a9015d3e9da0857a76e9e00b66f3572d2",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "e2eb2a3ad5462b7218d56a840d7abd87d3af64cb",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "b64b036c1d82082684db9fe6c512f70c214249cf",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "07339bbb8b020b3cc679331a646b6dc8ae246150",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "0453ec44649217944a34e00e68ceb324ec9029fd",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "8cc1c2da9a1b99a0e157f81902ffeb9d5691b2eb",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "f5bb1e01fd7ad6afee369e694a1d30567b7eaa13",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5644129,
        "lng": 114.3649819,
        "locationId": "f453332822491fc68b90e370641f687a4c29d12d",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04310228"
  },
  {
    "brandName": "Azvudine",
    "chemicalName": "RO-0622",
    "conditionOrDisease": "Covid-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "RO0622",
    "productId": 145,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Xinyang",
        "country": "CN",
        "lat": 32.014808,
        "lng": 114.906546,
        "locationId": "f38c6ad9798afcf376da51fa7e0621281dc53756",
        "name": "Guangshan County, Xinyang, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b38a8623a43ac6813f56ef17b83f2ca2a213237",
        "sponsorName": "Peoples Hospital of Guangshan County"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": "ChiCTR2000029853"
  },
  {
    "brandName": "Noscovid",
    "chemicalName": "Noscapine",
    "conditionOrDisease": "Covid-19",
    "countries": ["Iran"],
    "countryCodes": ["IRN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 17 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "N/A",
    "phase": "2",
    "preferredName": "Noscapine",
    "productId": 146,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Qazvin",
        "country": "IR",
        "lat": 36.3245163,
        "lng": 49.9972276,
        "locationId": "b0019d2a24a3ac68accf7f8040cd1a7158d3f4da",
        "name": "Qazvin, \u060c\u060c \u0627\u0633\u062a\u0627\u0646 \u0642\u0632\u0648\u06cc\u0646 \u0642\u0632\u0648\u06cc\u0646 \u0645\u06cc\u0646\u0648\u062f\u0631 \u06a9\u0648\u06cc \u0627\u0644\u0647\u06cc\u0647 \u060c \u0628\u0644\u0648\u0627\u0631 22 \u0628\u0647\u0645\u0646\u060c Tavon Square, Iran",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2c3dce78e2656e4bdf014ec95f1f244efcb85b05",
        "sponsorName": "Qazvin University of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "IRCT20160625028622N1"
  },
  {
    "brandName": "OMV-based Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OMVbased_Vaccine",
    "productId": 522,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6d27be324405fd25505d58549d5f688eb822d1a3",
        "sponsorName": "BiOMVis SR"
      },
      {
        "sponsorId": "593791b280e8c3c839e73ca9110644e71cb76369",
        "sponsorName": "University of Trento"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Subunit_Vaccine",
    "productId": 523,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b7d9d4824d0196b796657e8d6d9728d256d6104b",
        "sponsorName": "Applied Biotechnology Institute Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Avastin",
    "chemicalName": "Bevacizumab",
    "conditionOrDisease": "Covid-19 pneumonia",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Renmin Hospital of Wuhan University,Ialy Moriggia Pelascini Gravedona Hospital S.p.A,Wuhan University,Jiangbei Union Hospital of Huazhong University of Science and Technology,Shandong Provincial Chest Hospital",
    "phase": "NOT STATED",
    "preferredName": "Bevacizumab",
    "productId": 147,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Jinan Shi",
        "country": "CN",
        "lat": 36.655439,
        "lng": 117.018034,
        "locationId": "3d3109cf11a7622c0a381b97227bb7ebb7931082",
        "name": "107 Wenhua W Rd, Lixia Qu, Jinan Shi, Shandong Sheng, China",
        "state": "Shandong Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5097a8114e431ac8ebcbd82cdf94884e315a5cba",
        "sponsorName": "Qilu Hospital of Shandong University"
      },
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      },
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04305106"
  },
  {
    "brandName": "",
    "chemicalName": "Leflunomide",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Leflunomide",
    "productId": 148,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14a2146233138c07a64e0baef6cc949f64c7af25",
        "sponsorName": "Renmin Hospital of Wuhan University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Bisolvon",
    "chemicalName": "Bromhexine Hydrochloride",
    "conditionOrDisease": "Covid-19 pneumonia",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "WanBangDe Pharmaceutical Group Co. Ltd.",
    "phase": "NOT STATED",
    "preferredName": "Bromhexine_Hydrochloride",
    "productId": 149,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wenzhou Shi",
        "country": "CN",
        "lat": 28.006211,
        "lng": 120.67225,
        "locationId": "ee6f7b35a67cba50d330a8ad39910c4887064f9c",
        "name": "109 Xueyuan W Rd, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng, China",
        "state": "Zhejiang Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "87b385be246abb1a4c3e0d7f6bbe23e811156173",
        "sponsorName": "Second Affiliated Hospital of Wenzhou Medical University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04273763"
  },
  {
    "brandName": "Avigan",
    "chemicalName": "Interferon beta,Favipiravir",
    "conditionOrDisease": "COVID-19",
    "countries": ["Iran"],
    "countryCodes": ["IRN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 27 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Used to treat Influenza",
    "numSites": "1",
    "otherPartners": "ChemRar,RDIF",
    "phase": "3",
    "preferredName": "Interferon_beta_Favipiravir",
    "productId": 150,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "JP",
        "lat": 36.204824,
        "lng": 138.252924,
        "locationId": "ffb0184c284bba5bb71874602b74e17c909ecee7",
        "name": "Japan",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b58861dc99cd85f531c98907e3577fe93964d0f3",
        "sponsorName": "Shahid Beheshti University of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Prezcobix",
    "chemicalName": "Darunavir,cibicistat",
    "conditionOrDisease": "COVID-19",
    "countries": ["China", "United States"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Treat pneumonia",
    "numSites": "1",
    "otherPartners": "Johnson and Johnson",
    "phase": "3",
    "preferredName": "Darunavir_cibicistat",
    "productId": 151,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Shanghai",
        "country": "CN",
        "lat": 31.230416,
        "lng": 121.473701,
        "locationId": "2ffcff0b6565c93b79a43e023280885d254e979a",
        "name": "Shanghai, China",
        "state": "Shanghai"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      },
      {
        "sponsorId": "0ff0405e4544cd120687a915ea369ae1dac78dca",
        "sponsorName": "Johnsons  Johnson"
      },
      {
        "sponsorId": "667987d4de01dd23efc5563684db4e2117b5d910",
        "sponsorName": "Janssen"
      },
      {
        "sponsorId": "8cd26a383793b281ef40085df75c92792db1b43d",
        "sponsorName": "Gilead"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral - protease inhibitor",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "PD1,thymosin,Camrelizumab",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Cancer therapy",
    "numSites": "",
    "otherPartners": "NIHR",
    "phase": "2",
    "preferredName": "PD1_thymosin_Camrelizumab",
    "productId": 152,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9ba50a6c509f14bcba0e2116a0a021e05e985ae6",
        "sponsorName": "Southeast University  China"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Meplazumab",
    "conditionOrDisease": "COVID-19",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Treat pneumonia",
    "numSites": "1",
    "otherPartners": "National Science and Technology Major Project",
    "phase": "2",
    "preferredName": "Meplazumab",
    "productId": 153,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Huizhou",
        "country": "CN",
        "lat": 22.94223,
        "lng": 114.29824,
        "locationId": "d3d9fb0cef04f53fab3d367204d4cc5bf86a331f",
        "name": "Tangdu, Huiyang District, Huizhou, Guangdong Province, China",
        "state": "Guangdong Province"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "90580332dd2c5e7458dc3f0dc0ba01024427917e",
        "sponsorName": "TangDu Hospital"
      },
      {
        "sponsorId": "2453464d7d85243db737220519ad6c684bfec004",
        "sponsorName": "Jingsu Pacific Meinuoke Biopharmaceutical Co"
      },
      {
        "sponsorId": "fd9f01621385a9d2c18ef56159f02c2acd10e0e0",
        "sponsorName": "Fourth Military Medical University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Gilenya",
    "chemicalName": "Fingolimod",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 22 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Treats MS",
    "numSites": "1",
    "otherPartners": "NIHR",
    "phase": "2",
    "preferredName": "Fingolimod",
    "productId": 154,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Fuzhou",
        "country": "CN",
        "lat": 26.074478,
        "lng": 119.296482,
        "locationId": "d7ed962c8a36ba0116f6db21306ce7c1ef343b72",
        "name": "Fuzhou, Fujian, China",
        "state": "Fujian"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "beea472f9414420dd2ba494bd1b0dbf60d0df7a7",
        "sponsorName": "The First Affiliated Hospital of Fujian Medical University"
      },
      {
        "sponsorId": "a47ed0af8e79c0d5e04834a88fa5c0fa3a019663",
        "sponsorName": "Novartis AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Avigan",
    "chemicalName": "ASCO9F,ritonavir,favipiravir",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "HIV protease inhibitor",
    "numSites": "1",
    "otherPartners": "Self funding,National Natural Science Foundation of China",
    "phase": "2",
    "preferredName": "ASCO9F_ritonavir_favipiravir",
    "productId": 155,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "755c8681b59d717c5d92a9e072f184e1d2313474",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs- HIV protease inhibitor",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Nitric Oxide (g)",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "2",
    "otherPartners": "Private",
    "phase": "2",
    "preferredName": "Nitric_Oxide_g",
    "productId": 156,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "67de1d21b74a15f8719e9e7385782a79674bcbc5",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c8523547da03b9b3e757de3bc960672aa18072e3",
        "sponsorName": "Xijing Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Vitamin C,Sodium Ascorbate",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Prevent cytokine induced damage to lungs",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Vitamin_C_Sodium_Ascorbate",
    "productId": 157,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5644129,
        "lng": 114.3649819,
        "locationId": "30b99ab23dddcd33ba3a66b4ac1d9b79085c73f6",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "6b392ac5dd2d5651f409b4b8472c05341dbb25a3",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4aa837dcf498f3cc77b727f1990dd1d645311b0b",
        "sponsorName": "ZhiYong Peng"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antioxidant",
    "trialId": ""
  },
  {
    "brandName": "CYNK-001",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 29 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Sorrento Therapeutics Inc.",
    "phase": "Phase I",
    "preferredName": "antibody",
    "productId": 158,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Galveston",
        "country": "US",
        "lat": 29.3113238,
        "lng": -94.7781311,
        "locationId": "7945e0eeb4c5bad391dc0191c98a18079451d1e0",
        "name": "301 University Blvd, Galveston, TX 77555, USA",
        "state": "TX"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "db21bb858ca06c7530b53487f0dd905696244c54",
        "sponsorName": "Celularity Inc"
      },
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "STI-4920,CMAB020",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "bispecific ACE-MAB fusion protein",
    "numSites": "",
    "otherPartners": "Sorrento Therapeutics Inc.,Mabpharm Limited",
    "phase": "Pre-clinical testing",
    "preferredName": "antibody",
    "productId": 159,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      },
      {
        "sponsorId": "c9c165926c1b9b7b8832e8afef24f2834d6e595c",
        "sponsorName": "Mabpharm Limited"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Gene MAb\u2122",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "uses Gene MAb\u2122 platform for ab delivery",
    "numSites": "",
    "otherPartners": "Sorrento Therapeutics Inc.",
    "phase": "Discovery",
    "preferredName": "antibody",
    "productId": 160,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "99401ebed0fa84553f3dab49ec5651d6e16ebb72",
        "sponsorName": "SmartPharm Therapeutics Inc"
      },
      {
        "sponsorId": "5fc64f72797f9967b8f89cf58d0d24a43168cffc",
        "sponsorName": "Sorrento Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Anti-Corona Immunoglobulin (IgG)",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 11 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "plasma of recovered people w ab is used in patients",
    "numSites": "",
    "otherPartners": "Kamada",
    "phase": "Pre-clinical testing",
    "preferredName": "antibody",
    "productId": 161,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5929da2b33c19978e9dd493734a7e92160428081",
        "sponsorName": "Kamada Ltd"
      },
      {
        "sponsorId": "3e412b7cf7607d2c373441c8651e88306e8012b0",
        "sponsorName": "Kedrion Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Centivax",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Centivax",
    "phase": "Pre-clinical testing",
    "preferredName": "antibody",
    "productId": 162,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bcb8d1f52e45cce0b2413d1c2485755444633dbb",
        "sponsorName": "Swiftscale Biologics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "antibody",
    "conditionOrDisease": "",
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 10 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Erasmus MC",
    "phase": "Pre-clinical testing",
    "preferredName": "antibody",
    "productId": 163,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fe367a0d5ee946a16335321f006255c41d4c8e7b",
        "sponsorName": "Erasmus MC"
      },
      {
        "sponsorId": "b80905e2bb739693e1253446c2e0849e97ab16dd",
        "sponsorName": "Utrecht University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "darunavir,cobicistat,CYP3A inhibitor",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 30 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Janssen Pharmaceutical Companies,Shanghai Public Health Clinical Center",
    "phase": "Phase I",
    "preferredName": "darunavir_cobicistat_CYP3A_inhibitor",
    "productId": 164,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "78190ce5e186ac701c260b91aa1008a6c4b862de",
        "sponsorName": "Shanghai Public Health Clinical Center"
      },
      {
        "sponsorId": "7745b01b52b6f1cf88a706afd1b056e344c46e24",
        "sponsorName": "Zhongnan Hospital of Wuhan University"
      },
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "Arbidol",
    "chemicalName": "Umifenovir",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 07 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Membrane fusion inhibitor",
    "numSites": "",
    "otherPartners": "China\u2019s Ruijin Hospital",
    "phase": "Phase IV",
    "preferredName": "Umifenovir",
    "productId": 165,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "deef1b7181395ef02ad3b7cd894fb64716ba0215",
        "sponsorName": "Pharmstandard"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Xofluza",
    "chemicalName": "baloxavir marboxil",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "polymerase acidic endonuclease inhibitor",
    "numSites": "",
    "otherPartners": "The First Hospital Affiliated to Zhejiang University's Medical School,Roche",
    "phase": "Phase I",
    "preferredName": "baloxavir_marboxil",
    "productId": 166,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a",
        "sponsorName": "Roche"
      },
      {
        "sponsorId": "50a9bfad2cbb96596fb34d34cdfbd349c1a4fbbc",
        "sponsorName": "The First Hospital Affiliated to Zhejiang Universitys Medical School"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "PLX cell product",
    "chemicalName": "placenta-based cells",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 13 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "placenta-based cell therapy",
    "numSites": "",
    "otherPartners": "Pluristem Therapeutics,BIH Center for Regenerative Therapy,Berlin Center for Advanced Therapies",
    "phase": "Phase I",
    "preferredName": "placentabased_cells",
    "productId": 167,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Brookline",
        "country": "US",
        "lat": 42.3326456,
        "lng": -71.1150656,
        "locationId": "81b0319b4393a05d8f1e245d3405e33de1c802aa",
        "name": "1 Brookline Pl # 123, Brookline, MA 02445, USA",
        "state": "MA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2b9a512817547dd6eca9ae64392478de4df5ea55",
        "sponsorName": "Pluristem Therapeutics"
      },
      {
        "sponsorId": "14df6ecd68ad3a991782c40f386042236234019a",
        "sponsorName": "BIH Center for Regenerative Therapy"
      },
      {
        "sponsorId": "3c023d5d2630d83ff1f51fee219f0e0dec252a08",
        "sponsorName": "Berlin Center for Advanced Therapies"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Thalidomide",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "An approved drug with noted immunosuppressive and anti-angiogenic activity,used for a number of immunological and inflammatory disorders,clinical trials aim to see if these properties of thalidomide can be used to prevent or treat COVID-19 induced lung injury instead of functioning as a direct antiviral,note that there is a second study with the same sponsors and utilizing thalidomide as well - but that includes the use of low does hormones as well and only enrolls 40 participants,discovery start - NDA approval - and on the market are completed with respect to thalidomide itself without taking into account its prospective use in treating COVID-19",
    "numSites": "Undisclosed",
    "otherPartners": "Second Affliated Hospital of Wenzhou Medical University,Wenzou Central Hospital",
    "phase": "2",
    "preferredName": "Thalidomide",
    "productId": 168,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c34399f07cbf1f511eb20748b32ec47045ae18f5",
        "sponsorName": "Celgene Corp"
      },
      {
        "sponsorId": "4337c2a735b1c82b0b730abbf6b584dd7f97e512",
        "sponsorName": "The First Affiliated Hospital of Wenzhou Medical University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04273529,NCT04273581"
  },
  {
    "brandName": "ARB,Cozaar",
    "chemicalName": "Losartan",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Approved drug used to treat hypertension by functioning as an angiotensin II receptor blocker,study intends to track COVID-19 patients' risk status in the ICU using the Sequential Organ Failure Assessment (SOFA) respiratory score following treatment with losartan or a placebo",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Losartan",
    "productId": 169,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.9722477,
        "lng": -93.2615378,
        "locationId": "d94e36c4fde4ff69682007844df36ebc4065b656",
        "name": "730 S 8th St, Minneapolis, MN 55415, USA",
        "state": "MN"
      },
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.96751159999999,
        "lng": -93.23755399999999,
        "locationId": "d8c23d2b47c4c8c592ce59d075db6e0f6ff04acf",
        "name": "2450 Riverside Ave, Minneapolis, MN 55454, USA",
        "state": "MN"
      },
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.97399,
        "lng": -93.2277285,
        "locationId": "649c6f654b1014580917fe9eafe010719b8cd517",
        "name": "Minneapolis, MN 55455, USA",
        "state": "MN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d49e1350f4c21eef623eb4e22b9709b13ac08f82",
        "sponsorName": "University of Minnesota"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04311177,NCT04312009"
  },
  {
    "brandName": "",
    "chemicalName": "sildenafil citrate",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 09 Feb 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Approved drug used to treat pulmonary arterial hypertension,angina,and erectile dysfunction,study evaluates rate of disease remission,rate of entering the critical stage,and time of entering the critical stage after treatment with sildenafil citrate",
    "numSites": "1",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "sildenafil_citrate",
    "productId": 170,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "7c5ede3650ce5497da066c1229cca943516ef552",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04304313"
  },
  {
    "brandName": "",
    "chemicalName": "a lipic acid",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "a_lipic_acid",
    "productId": 171,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d8a6fb8782589eff1784a987131a3510fd1991ff",
        "sponsorName": "Zhongshan Hospital"
      },
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Chloroquine phosphate",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Chloroquine_phosphate",
    "productId": 172,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2d7ffefe148247749f6402c5edc286a5095cc88a",
        "sponsorName": "Jingzhou Central Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Ebastine,Lopinavir,Interferon a",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ebastine_Lopinavir_Interferon_a",
    "productId": 173,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a61efee7bdf9baf309997f1ccf652ee02887c52",
        "sponsorName": "Wuhan Red Cross Hospital"
      },
      {
        "sponsorId": "1be6e3f3520226675b831cc738fab10a9812c4fd",
        "sponsorName": "Minanyang Central Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ADX-629,reproxalap",
    "chemicalName": "reproxalap(reactive aldehyde species (RASP) inhibitor)",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Aldeyra Therapeutics Inc.",
    "phase": "Phase II",
    "preferredName": "reproxalapreactive_aldehyde_species_RASP_inhibitor",
    "productId": 196,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5525922d920320b60e93d8e039b662d088125b7d",
        "sponsorName": "Aldeyra Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Danoprevir,Ritonavir,Interferon",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Danoprevir is an oral hepatitis C virus protease inhibitor approved in China in June 2018,used in a phase 4 trial that began 02/17/2020 to observe its effects on the rate of composite adverse outcomes and time to recovery among other measures",
    "numSites": "1",
    "otherPartners": "Ascletis Pharmaceutials Co. Ltd.",
    "phase": "4",
    "preferredName": "Danoprevir_Ritonavir_Interferon",
    "productId": 174,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Nanchang",
        "country": "CN",
        "lat": 28.682892,
        "lng": 115.858197,
        "locationId": "44a691ebe5ec4b6064c2f064eb8100dd06636306",
        "name": "Nanchang, Jiangxi, China",
        "state": "Jiangxi"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bdb545b6c04a880d9d0382f48b816fee837c1330",
        "sponsorName": "The Ninth Hospital of Nanchang"
      },
      {
        "sponsorId": "e1bafffd3c4ccdf8eaf5841a8838a032654edc76",
        "sponsorName": "Ascletis Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04291729"
  },
  {
    "brandName": "",
    "chemicalName": "Mesenchymal Stem Cells",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "MSCs have been shown to exert antiinflammatory and immunoregulatory functions - promote regeneration of damaged tissues - and inhibit tissue fibrosis,trial aims to explore MSC's potential to treat COVID-19 patients",
    "numSites": "1",
    "otherPartners": "Puren Hospital Affliated to Wuhan University of Science and Technology,Shanghai University,Qingdao Co-orient Watson Biotechnology group co. LTD,Basic Medical Sciences - Chinese Academy of Medical Sciences",
    "phase": "1",
    "preferredName": "Mesenchymal_Stem_Cells",
    "productId": 175,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "c323a6569480170cd75217023ed27d77123ccc67",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba",
        "sponsorName": "Chinese Academy of Medical Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04339660"
  },
  {
    "brandName": "",
    "chemicalName": "Recombinant ACE2",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Study to investigate if there is efficacy signal that warrants a large Phase 2B trial or harm that suggests trial should not be done,study in question has a not applicable phase,status is withdrawn as of 03/17/2020 (which is why many cells were left blank)",
    "numSites": "1",
    "otherPartners": "",
    "phase": "N/A",
    "preferredName": "Recombinant_ACE2",
    "productId": 176,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Guangzhou",
        "country": "CN",
        "lat": 23.12911,
        "lng": 113.264385,
        "locationId": "52f1061ccd4898e7bc7f1e3f779f3cb35981d41e",
        "name": "Guangzhou, Guangdong Province, China",
        "state": "Guangdong Province"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ea78fbfadca996d3b3279e672883c8476ffd78cf",
        "sponsorName": "The First Affiliated Hospital of Guangzhou Medical University"
      }
    ],
    "status": "On Hold",
    "therapeuticApproach": "Other",
    "trialId": "NCT04287686"
  },
  {
    "brandName": "",
    "chemicalName": "Washed micrbiota transplantation",
    "conditionOrDisease": "Condition",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 05 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Molecule type - microbiota. The recent study on using washed microbiota transplantation (WMT) as rescue therapy in critically ill patients with AAD demonstrated the important clinical benefits and safety of WMT. Additionally the recent animal study provided direct evidence supporting that antibiotics could decrease gut microbiota and the lung stromal interferon signature and facilitate early influenza virus replication in lung epithelia. Importantly the above antibiotics caused negative effects can be reversed by fecal microbiota transplantation (FMT) which suggested that FMT might be able to induce a significant improvement in the respiratory virus infection.",
    "numSites": "1",
    "otherPartners": "The Second Hospital of Nanjing Medical University",
    "phase": "Experimental",
    "preferredName": "Washed_micrbiota_transplantation",
    "productId": 177,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Nanjing Shi",
        "country": "CN",
        "lat": 32.043846,
        "lng": 118.774763,
        "locationId": "098fcce824fd9d52a2c10dc177f9434e98a41921",
        "name": "140 Hanzhong Rd, Gulou Qu, Nanjing Shi, Jiangsu Sheng, China, 210029",
        "state": "Jiangsu Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3452304684b286fca6c4db5bb90b92026a7d077b",
        "sponsorName": "The Second Hospital of Nanjing Medical University"
      }
    ],
    "status": "On Hold",
    "therapeuticApproach": "",
    "trialId": "NCT04251767"
  },
  {
    "brandName": "Persantine",
    "chemicalName": "Dipyridamole",
    "conditionOrDisease": "Condition",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Type - vasodilator",
    "numSites": "6",
    "otherPartners": "Major regional immunity cultivation project - 91742109",
    "phase": "4",
    "preferredName": "Dipyridamole",
    "productId": 178,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Guangzhou Shi",
        "country": "CN",
        "lat": 23.096999,
        "lng": 113.23067,
        "locationId": "ae3fc600633bd85631d79bae9236c55a5a29613e",
        "name": "47 Dongjiao N Rd, Fang Cun, Liwan Qu, Guangzhou Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.53535699999999,
        "lng": 114.299525,
        "locationId": "43728c71a41f4e58c75a471560469499eb1b8d80",
        "name": "Wuchang District, Wuhan, China",
        "state": null
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.583826,
        "lng": 114.273585,
        "locationId": "841f44316bec5d0d7a38e963f28a1951b8c33ae7",
        "name": "Jiefang Ave, Xi Bei Hu, Jianghan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.88255699999999,
        "lng": 114.375743,
        "locationId": "4c9687965180b460a2e0067642150993717ff166",
        "name": "Huangpi District, Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Xiaogan",
        "country": "CN",
        "lat": 31.561164,
        "lng": 114.127022,
        "locationId": "a1d999c068fb84431e1edc1e4cbdbaf441cb491a",
        "name": "Dawu County, Hubei, Xiaogan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wenzhou",
        "country": "CN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "5ca60fdf8350ecaac3375eaf6aab2961160e28aa",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ea78fbfadca996d3b3279e672883c8476ffd78cf",
        "sponsorName": "The First Affiliated Hospital of Guangzhou Medical University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": "ChiCTR2000030055"
  },
  {
    "brandName": "",
    "chemicalName": "Bromhexine hydrochloride,Arbidol umifenovir,Favipiravir,Interferon a2b",
    "conditionOrDisease": "Condition",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "On going recruitment",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Bromhexine_hydrochloride_Arbidol_umifenovir_Favipiravir_Interferon_a2b",
    "productId": 179,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wenzhou Shi",
        "country": "CN",
        "lat": 28.006211,
        "lng": 120.67225,
        "locationId": "8b577508c7b657d2b6f2eac771d5c87e71ff3b5c",
        "name": "109 Xueyuan W Rd, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng, China",
        "state": "Zhejiang Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1a54d298d5b18d923897d81e7dd0a48df5240f94",
        "sponsorName": "The Second Affiliated Hospital of Wenzhou Medical University"
      },
      {
        "sponsorId": "9b98ab2f7f83afd2e87f907a0f64dbc3220477b6",
        "sponsorName": "WanBangDe Pharmaceutical Group"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": "NCT04273763"
  },
  {
    "brandName": "",
    "chemicalName": "Dihydroartemisinin,piperaquine,arbidol umifenovir,interferon a",
    "conditionOrDisease": "Condition",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Cancelled by investigator",
    "numSites": "4",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "Dihydroartemisinin_piperaquine_arbidol_umifenovir_interferon_a",
    "productId": 180,
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Independence",
        "country": "US",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "02d556235b183676bbd03eac40507d2b168aa8f2",
        "name": "Independence, KS 67301, USA",
        "state": "KS"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "d2b8768cb04977cf2378eca644c83830105277a0",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.599041,
        "lng": 114.301165,
        "locationId": "e21d4c5f90162636899109b84efd911b800e11e8",
        "name": "China, Hubei Sheng, Wuhan Shi, Jiangan Qu, \u4e09\u9633\u8def",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "5289afb61396c287860d5b7a5cab7e2c34f80bfd",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b2025696e611deea59bde95a78322849a7a75f10",
        "sponsorName": "The First Affiliated Hospital of Nanchang University"
      }
    ],
    "status": "Failed",
    "therapeuticApproach": "Antiviral drugs-not specified,Anti-malarial",
    "trialId": "ChiCTR2000030082"
  },
  {
    "brandName": "Intravenous Immunoglobulin",
    "chemicalName": "Human Immunoglobulin (pH4)",
    "conditionOrDisease": "Pneumonia",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology",
    "phase": "2",
    "preferredName": "Human_Immunoglobulin_pH4",
    "productId": 181,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 39.9127464,
        "lng": 116.4142481,
        "locationId": "c9fb77bbb6d5aadd87f486951043b69d97324621",
        "name": "Dongdan, Beijing, Dongcheng, Beijing, China",
        "state": "Beijing"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "10172e384c8eaa0f469f305f6d2b50b0eabb14f5",
        "sponsorName": "Peking Union Medical College Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04261426"
  },
  {
    "brandName": "RoActemra",
    "chemicalName": "Tocilizumab",
    "conditionOrDisease": "Covid-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 08 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Being used in above trial",
    "numSites": "9",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "Tocilizumab",
    "productId": 182,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Hefei Shi",
        "country": "CN",
        "lat": 31.84583099999999,
        "lng": 117.268745,
        "locationId": "f6b443f8a43894d08c4bae509700d423c7fc8a45",
        "name": "218 Jixi Rd, Shushan Qu, Hefei Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": null,
        "country": "CN",
        "lat": 39.931765,
        "lng": 116.380416,
        "locationId": "51bb1b8c5afd883e443a2b2ba01f7f7b8790b37a",
        "name": "8 Xishiku St, Xicheng Qu, Beijing Shi, China",
        "state": "Beijing Shi"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "57f9f2d832db51e5806541152d3bec783cb674bf",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "a883026a21de191e792eaa27b2521ab0548ef798",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "54be44d6200d9c6f2d1e7b32ca0d3c06cac0e951",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "4ba7777c723e0fb91db624245dfbaf9635dc6cd9",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "c5bc2dc6b89bb88846fd3d85ff947c6760f0e273",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "5bb17ffc4f87aebbb220a51b3068fe759518780e",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "3826145f31a8296329467787192c0c9a3d685b6c",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5644129,
        "lng": 114.3649819,
        "locationId": "3a08bf18dac2eed494a40fff3e1d70be7899f730",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      },
      {
        "sponsorId": "1cc9d3179b66670e4a36a366afbbe7179bae5329",
        "sponsorName": "Genentech Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04310228"
  },
  {
    "brandName": "Anulohuaxian",
    "chemicalName": "Anulohuaxian",
    "conditionOrDisease": "Covid-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Traditional Chinese Medicine",
    "numSites": "8",
    "otherPartners": "N/A",
    "phase": "0",
    "preferredName": "Anulohuaxian",
    "productId": 183,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Fuyang Shi",
        "country": "CN",
        "lat": 33.164296,
        "lng": 115.628262,
        "locationId": "f01b437281a99d71218de65d04fd21ae3ae44dad",
        "name": "Wenming Rd, Taihe Xian, Fuyang Shi, Anhui Sheng, China",
        "state": "Anhui Sheng"
      },
      {
        "city": "Ezhou Shi",
        "country": "CN",
        "lat": 30.3987825,
        "lng": 114.8819099,
        "locationId": "7f68e72f6e6f0fd2191abd079a6be5b505e7c0c8",
        "name": "9 Wenxing Ave, Echeng Qu, Ezhou Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "5549c251830f888466a7a3a11721b1a3abb6f519",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.6668794,
        "lng": 114.2868443,
        "locationId": "04af587e3b1aa23ce89ea6f3938a6b97a06cdd09",
        "name": "China, Hubei Sheng, Wuhan Shi, Dongxihu Qu, \u94f6\u6f6d\u8def1\u53f7",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "b7391abe42cf6ad8708c494fa638d407046c364f",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5130043,
        "lng": 114.4202756,
        "locationId": "066cfc849e1a1e3acceb8c4bae93687216f299e1",
        "name": "1037 Luoyu Rd, Hongshan Qu, Wuhan Shi, Hubei Sheng, China, 430074",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.592849,
        "lng": 114.305539,
        "locationId": "256fc7d8a15837eb08fa4ebddee37a0cc963ec4a",
        "name": "Wuhan, Hubei, China",
        "state": "Hubei"
      },
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.5644129,
        "lng": 114.3649819,
        "locationId": "8dc53f4f250ad1bcc15742253264059a8366a341",
        "name": "169 Donghu Rd, Wuchang Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      },
      {
        "city": "Wenzhou",
        "country": "CN",
        "lat": 27.939761,
        "lng": 120.695887,
        "locationId": "765afaaf4a054140db1680bde0d7e7972d971b8f",
        "name": "Ouhai District, Wenzhou, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3b26f3f63704a702040cad0b3d5f4ff56f7360a",
        "sponsorName": "Peking University First Hospital"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": "NCT04334265"
  },
  {
    "brandName": "",
    "chemicalName": "Allogeneic human dental pulp stem cells",
    "conditionOrDisease": "Covid-19 pneumonia",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 06 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Beijing SH Bio-Tech Corporation - Beijing - China,Utooth Biological Technology Co. Ltd. - Hubei - China",
    "phase": "1",
    "preferredName": "Allogeneic_human_dental_pulp_stem_cells",
    "productId": 184,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.53535699999999,
        "lng": 114.299525,
        "locationId": "32c3f7079998da36d2f6e0137d9b2bff3055fcb9",
        "name": "Wuchang District, Wuhan, China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14a2146233138c07a64e0baef6cc949f64c7af25",
        "sponsorName": "Renmin Hospital of Wuhan University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04336254"
  },
  {
    "brandName": "IBIO-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Being repurposed to treat idiopathic pulmonary fibrosis,Previously granted orphan drug designation for treatment of systemic sclerosis investigated to systemic scleroderma",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IBIO100",
    "productId": 185,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "505b07d6981f93ee187513e197589f4c16f04b35",
        "sponsorName": "iBio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "chloroquine,azithromycin",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chloroquine_azithromycin",
    "productId": 186,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9f993454bdb55447c232ff4e925773960b482c3a",
        "sponsorName": "Population Health Research"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Favipiravir,Baloxavir marboxil",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Favipiravir_Baloxavir_marboxil",
    "productId": 187,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a81e304214bfeeb11d72efbec071b026a7bec070",
        "sponsorName": "First Hospital Affiliated"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Jakafi,Jakavi",
    "chemicalName": "Ruxolitinib",
    "conditionOrDisease": "COVID 19",
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Being evaluated for treatment of COVID 19 associated cytokine storm",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ruxolitinib",
    "productId": 188,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b5b8fac5162ad1d88a07970c29180291cab2655",
        "sponsorName": "Tongji Hospital"
      },
      {
        "sponsorId": "28de4f9051af1771961895dd1ee280ee55497988",
        "sponsorName": "Incyte Corporation"
      },
      {
        "sponsorId": "a47ed0af8e79c0d5e04834a88fa5c0fa3a019663",
        "sponsorName": "Novartis AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": "NCT04355793"
  },
  {
    "brandName": "Peginterferon Lambda-1a",
    "chemicalName": "Peginterferon Lambda-1a",
    "conditionOrDisease": "COVID 19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Peginterferon_Lambda1a",
    "productId": 189,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "683d20f6c6f23f9c1e0851b35e3f725262584fe3",
        "sponsorName": "Stanford University"
      },
      {
        "sponsorId": "4b56e1109e3c62392ddb122d219ce7bd5514472d",
        "sponsorName": "Eiger Biopharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04331899"
  },
  {
    "brandName": "LV-SMENP-DC",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Vaccine to treat and prevent severe Covid-19 pneumonia,Innovative COVID19 minigenes engineered based on multiple viral genes using an efficient lentiviral vector system to express viral proteins and immune modulatory genes to modify dendritic cells and to activate T cells",
    "numSites": "3",
    "otherPartners": "Shenzhen Third People's Hospital,Shenzhen Second People's Hospital",
    "phase": "2",
    "preferredName": "LVSMENPDC",
    "productId": 190,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Shenzhen",
        "country": "CN",
        "lat": 22.543096,
        "lng": 114.057865,
        "locationId": "897b525b72fdd4a1879df7a8fff360e016154321",
        "name": "Shenzhen, Guangdong Province, China",
        "state": "Guangdong Province"
      },
      {
        "city": "Shenzhen",
        "country": "CN",
        "lat": 22.635796,
        "lng": 114.130144,
        "locationId": "e8bfbfd7b25d7b5c2016f567e355632e631f7aa8",
        "name": "Longgang, Shenzhen, China",
        "state": null
      },
      {
        "city": "Shenzhen Shi",
        "country": "CN",
        "lat": 22.556599,
        "lng": 114.086145,
        "locationId": "b8b509c0926c473ef34074a64a2ee8cf4f093f05",
        "name": "3002 Sungang W Rd, Futian Qu, Shenzhen Shi, Guangdong Sheng, China",
        "state": "Guangdong Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT04276896"
  },
  {
    "brandName": "Pathogen-specific aAPC",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells",
    "numSites": "3",
    "otherPartners": "Shenzhen Third People's Hospital,Shenzhen Second People's Hospital",
    "phase": "1",
    "preferredName": "Pathogenspecific_aAPC",
    "productId": 191,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT04299724"
  },
  {
    "brandName": "Peptide-based therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "48Hour Discovery Inc.",
    "phase": "discovery",
    "preferredName": "Peptidebased_therapeutic",
    "productId": 192,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "970c9dcb0770cc2be64dd33cbfa88ac640f9e606",
        "sponsorName": "48Hour Discovery Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Pharmetrx therapeutics",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The compounds were identified using PharmetRx\u00ae,Afecta's proprietary artificial intelligence platform,and demonstrate bioactivity via two key therapeutic mechanisms of action-(1) immunomodulation similar to that of hydroxychloroquine or (2) inhibition of viral replication or attachment to host cells.",
    "numSites": "",
    "otherPartners": "Afecta Pharmaceuticals,Inc.",
    "phase": "Preclinical",
    "preferredName": "Pharmetrx_therapeutics",
    "productId": 193,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "18ae58c4daf5de7939f10accf1067398c78fbd00",
        "sponsorName": "Afecta Pharmaceuticals"
      },
      {
        "sponsorId": "72a5f6c42a6c39ea891ecb24d22128fd281d0e18",
        "sponsorName": "Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Active Agent",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 04 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Aicuris Anti-infective Cures GmbH",
    "phase": "discovery",
    "preferredName": "Active_Agent",
    "productId": 194,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f2b34e7e5c8d41cfa0c7e4ca7543514b6c633fe9",
        "sponsorName": "Aicuris Antiinfective Cures GmbH"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Antiviral component",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 14 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "The compounds seek to inhibit replication of multiple viruses,including Influenza virus,SARS-CoV,MERS-CoV,Ebolavirus and Marburg virus.",
    "numSites": "",
    "otherPartners": "Aikido Pharma Inc.; the University of Maryland,Baltimor",
    "phase": "Preclinical",
    "preferredName": "Antiviral_component",
    "productId": 195,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "39b3f1f3677b274c50b99d83330f4862d0b8f6a8",
        "sponsorName": "Aikido Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "DAS-181",
    "chemicalName": "recombinant sialidase",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 06 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Ansun Biopharma Inc.,Renmin Hospital of Wuhan University",
    "phase": "Phase I",
    "preferredName": "recombinant_sialidase",
    "productId": 198,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "US",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "9203f213f897ede437de94ee11ada7c1439672f0",
        "name": "United States",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5e79a7dfd885e0baf118378ff6d6ac832c4a44f3",
        "sponsorName": "Ansun Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "SARS-CoV-2 targeting recombinant methioninase",
    "chemicalName": "Methioninase",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA", "China"],
    "countryCodes": ["USA", "CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Anticancer Inc.,AntiCancer Beijing",
    "phase": "On hold",
    "preferredName": "Methioninase",
    "productId": 199,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "84e8fc3396832ade5506a951a3b3ebbaebd87cde",
        "sponsorName": "Anticancer Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Solnatide",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 28 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 04 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Solnatide IMP has been designed for activation of the pulmonary epithelial sodium channel (ENaC) and for the restoration of the injured endothelial-epithelial barrier of pulmonary alveoli.",
    "numSites": "",
    "otherPartners": "Apeptico Forschung und Entwicklung GmbH,The Austrian Research Promotion Agency",
    "phase": "Phase II",
    "preferredName": "Solnatide",
    "productId": 200,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Wien",
        "country": "AT",
        "lat": 48.2196989,
        "lng": 16.3515215,
        "locationId": "694ece0e1d84bf580c1f5fd41599ce6388881349",
        "name": "Spitalgasse 23, 1090 Wien, Austria",
        "state": "Wien"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f8b9528ccb10701b24f862db161ec27fbc4847fd",
        "sponsorName": "Apeptico Forschung und Entwicklung GmbH"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Cannabinoid-based therapy",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "cannabinoids may act as anti-androgens",
    "numSites": "",
    "otherPartners": "Applied Biology Inc.,Applied Bonanics LLC",
    "phase": "",
    "preferredName": "Cannabinoidbased_therapy",
    "productId": 201,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "30a0bfe60f04ff11e51d1901a52fbea2c76f2b5d",
        "sponsorName": "Applied Biology Inc"
      },
      {
        "sponsorId": "0112e7fffc5a7da4b036b0306729e2a12720f796",
        "sponsorName": "Applied Bonanics LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "AT-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Aldose Reductase Inhibitor,New York Hospital Investigator Initiated Studies used under an emergency IND",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AT001",
    "productId": 202,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3304021f998972cba57fa873b78bbbcda69f3122",
        "sponsorName": "Applied Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Small molecules",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "3 molecules targeting two viral replication enzymes- 3CL-Protease and RNA dependent RNA Polymerase,Pre-Clinical studies will be taken over by the University of Hong Kong,Covar Pharmaceuticals is another collaborator",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Small_molecules",
    "productId": 203,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "552bb9ce9d50b56342d0722bdf6a2e671ba4796e",
        "sponsorName": "Aptorum Group Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "ALT-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "eNAMPTOR is a platform of three products which includes ALT-100",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ALT100",
    "productId": 204,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4e3c43064be49069b8902b88fe3a123622091b1f",
        "sponsorName": "Aqualung Therapeutics Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "ASC-09,ritonavir",
    "chemicalName": "TMC-310911,ritonavir",
    "conditionOrDisease": "COVID19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "HIV-1 Protease Inhibitor,Another clinical trial with oseltamivir retracted due to insufficient patients,ASC09-Ritonavir vs Lopinavir-Ritonavir trial sponsor is First Affiliated Hospital of Zhejiang University and Ascletis is collaborator",
    "numSites": "",
    "otherPartners": "",
    "phase": "0",
    "preferredName": "TMC310911_ritonavir",
    "productId": 205,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9c77c2ee252590839e7e90f484ab0c46df479dbb",
        "sponsorName": "Ascletis Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": "NCT04261907"
  },
  {
    "brandName": "Calquence",
    "chemicalName": "acalabrutinib",
    "conditionOrDisease": "COVID19",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Acerta Pharma B.V. discovered acalabrutinib and is a collaborator on the clinical trial",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "acalabrutinib",
    "productId": 206,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Barcelona",
        "country": "ES",
        "lat": 41.3850639,
        "lng": 2.1734035,
        "locationId": "3fd363f921101b21e62e2e167756f571fcaf80bf",
        "name": "Barcelona, Spain",
        "state": "CT"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2c75b2d91db07786aabe9dcac98ed68f752804f1",
        "sponsorName": "AstraZeneca plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": "NCT04346199"
  },
  {
    "brandName": "Virazole",
    "chemicalName": "ribavirin inhalation solution",
    "conditionOrDisease": "COVID19",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Control # 238007 for Canadian Clinical Trial Website - works best with Internet Explorer,first posted on Clinicaltrials.gov 04/22/2020",
    "numSites": "",
    "otherPartners": "Hospira Inc.",
    "phase": "1",
    "preferredName": "ribavirin_inhalation_solution",
    "productId": 207,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a88af720747218a96a8aad641b4265d2da310f54",
        "sponsorName": "Bausch Health Cos Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": "NCT04356677"
  },
  {
    "brandName": "Niclocide",
    "chemicalName": "niclosamide",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Voluntarily withdrawn from market by Bayer in 1996,Another Brand name is Yomesan",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "niclosamide",
    "productId": 208,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "67da3aa3718d35ed721af558ab42d840a58dfdbe",
        "sponsorName": "Bayer AG"
      },
      {
        "sponsorId": "541210ab7a6daa7079e19f753dbf3002c81ab5a8",
        "sponsorName": "Union Therapeutics AS"
      },
      {
        "sponsorId": "3f0f11935fb0a109bff465cc279e3b68c954fede",
        "sponsorName": "Ana Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Nanobody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 20 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Beroni Group submitted Emergency Use Authorization for COVID-19 Rapid Test Detection Kit to FDA in March",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nanobody",
    "productId": 209,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b738e5214e4eac0d75fea1d6f1cfdd47e57c0e9b",
        "sponsorName": "Beroni Group"
      },
      {
        "sponsorId": "28bd9f926647c0b6e60a19fd1317a5fdb10635eb",
        "sponsorName": "Tianjin University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "rhu-pGSN",
    "chemicalName": "recombinant human plasma gelsolin",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Next step is to move into Phase 2b",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "recombinant_human_plasma_gelsolin",
    "productId": 210,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a6c2d1473eb80756c87eca409671a57e3947b727",
        "sponsorName": "Bioaegis Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Final product aim is a Nanobody-an antibody but contains only a single very small unit needed for recognition and disruption of the COVID-19 targets",
    "numSites": "",
    "otherPartners": "Wuxi-Jiangsu local government",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 211,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "69fd255e06de9b1173c6fdf9c2a593c7a7784d3e",
        "sponsorName": "Bioduro LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Vazegepant",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 25 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 25 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "CGRP receptor antagonist that is to be administered intranasally,currently in phase 2/3 trial to evaluate efficacy and potential for quick onset",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2/3",
    "preferredName": "Vazegepant",
    "productId": 212,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Washington",
        "country": "US",
        "lat": 38.9075519,
        "lng": -77.07279849999999,
        "locationId": "892f5f26266aa3411c82efb9308f70263b795903",
        "name": "37th and O Street, N.W., Washington, DC 20057, USA",
        "state": "DC"
      },
      {
        "city": "Philadelphia",
        "country": "US",
        "lat": 39.9496698,
        "lng": -75.1579974,
        "locationId": "a2fbc7e898608a890c588eb5013f6994c6f02f96",
        "name": "111 S 11th St Ste 6200, Philadelphia, PA 19107, USA",
        "state": "PA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9416a898d6c70803634f7f9d56ed68eda301ff71",
        "sponsorName": "Biohaven Pharmaceutical Holding Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04346615"
  },
  {
    "brandName": "anti-viroporin therapeutics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Biotron is currently testing whether their small molecules that target viroporins (virus-encoded proteins) will be effective against SARS CoV-2,the E protein of SARS CoV-2 was shown to be a viroporin and can potentially be a good target",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviroporin_therapeutics",
    "productId": 213,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b9c81254affc60230c18ca7f16da8eb9fd4cc3e6",
        "sponsorName": "Biotron Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "BOLD-100",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Small molecule that downregulates GRP78 with the intention to treat cancer,completed phase 1 that involved 41 cancer patients with tolerable safety profile,currently under investigation for potential therapeutic effects among COVID-19 patients: downregulating GRP78 shows promise because SARS CoV-2 can bind to GRP78,note that there are no details on the phase 1 trial aside from the number of subjects",
    "numSites": "",
    "otherPartners": "University of Ottawa",
    "phase": "",
    "preferredName": "BOLD100",
    "productId": 214,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d66e29eb51e46ebb67035da91e045d8c5ced9d8d",
        "sponsorName": "Bold Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China", "United States"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Working on discovering monoclonal antibodies against SARS CoV-2,aims to begin clinical trials within 6 months",
    "numSites": "",
    "otherPartners": "Brii Biosciences",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 215,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a635c9162245b5b265427b6b347bf36ec00ab510",
        "sponsorName": "Brii Biosciences"
      },
      {
        "sponsorId": "597be3ec42623eb2b339b165717d84c7c3137601",
        "sponsorName": "Columbia University"
      },
      {
        "sponsorId": "bfce396095503d26f651c5dad224c79f44d87649",
        "sponsorName": "Tsinghua University"
      },
      {
        "sponsorId": "8bdecc942a48de24772aedb84f5bd52bc0737054",
        "sponsorName": "3rd Peoples Hospital of Shenzhen"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "CM-4620-IE",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Originally developed to treat acute pancreatitis,currently undergoing phase 2 to observe efficacy in COVID-19 patients,functions by inhibiting CRAC channels to alleviate inflammation",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "CM4620IE",
    "productId": 216,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Detroit",
        "country": "US",
        "lat": 42.3678016,
        "lng": -83.0854662,
        "locationId": "e77658ef4625246e1abcfe7e86553b5decd91d9e",
        "name": "2799 W Grand Blvd, Detroit, MI 48202, USA",
        "state": "MI"
      },
      {
        "city": "St Louis Park",
        "country": "US",
        "lat": 44.9300754,
        "lng": -93.3619384,
        "locationId": "e63f86e33519618b43659f73dea22f28ca764f64",
        "name": "6500 Excelsior Blvd, St Louis Park, MN 55426, USA",
        "state": "MN"
      },
      {
        "city": "St Paul",
        "country": "US",
        "lat": 44.9547542,
        "lng": -93.09443069999999,
        "locationId": "3310dd7d28194373c996b8d2d898eccda24d3177",
        "name": "640 Jackson St, St Paul, MN 55101, USA",
        "state": "MN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "878b8442cb543076e452c2d646f57de1f361f6f6",
        "sponsorName": "Calcimedica Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04345614"
  },
  {
    "brandName": "CAP-1002",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Currently not approved for clinical investigation but FDA has granted expanded access protocol to treat up to 20 more COVID-19 patients after 6 compassionate care cases were treated successfully,plans to launch a randomized and placebo-controlled trial,drug is a cardiac cell therapy that modifies immune activity to promote cellular regeneration",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CAP1002",
    "productId": 217,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2488a9c05ed2f222808e0d9c70595368ed86a7a6",
        "sponsorName": "Capricor Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Carterra will use proprietary LSA platform to simultaneously screen and characterize antibodies to quickly determine ones that are effective against SARS CoV 2",
    "numSites": "",
    "otherPartners": "Coronavirus Immunotherapy Consortium (CoVIC)",
    "phase": "",
    "preferredName": "antibodies",
    "productId": 218,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ef5993e2d91aec68e38a7180d305dc11099e9ba5",
        "sponsorName": "Carterra Inc"
      },
      {
        "sponsorId": "c4a8ae6729d9974f1941051e2956e64de583ec66",
        "sponsorName": "La Jolla Institute for Immunology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Namilumab",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": [
      "Company based in the United Kingdom",
      "Trial occuring in Italy"
    ],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "At the Humanitas Research Hospital",
    "numSites": "",
    "otherPartners": "Humanitas Research Group",
    "phase": "2",
    "preferredName": "Namilumab",
    "productId": 247,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "62b5112b8c89d1a47c69aa94e5bc89d7166f157b",
        "sponsorName": "Izana Bioscience Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Multiple repurposed therapeutics - Pharnext",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "University Hospital Institute M\u00e9diterran\u00e9e Infection",
    "phase": "",
    "preferredName": "Multiple_repurposed_therapeutics__Pharnext",
    "productId": 277,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8ef7261cae683e2f3ccfe5dbf762a36c5ef48adb",
        "sponsorName": "Pharnext SA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "CK-0802",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Intends to collaborate with BARDA and has submitted a proposal for a Phase 1/2 trial for CK-0802 as a treatment for COVID-19 mediated ARDS,CK-0802 is an allogenic cell therapy that consists of TREG cells derived from umbilical cord blood units,hypothesized to improve ARDS by interrupting cytokine storm and resolving inflammation,pre-clinical studies showed favorable results,has been used in clinical trials for other inflammatory disorders",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CK0802",
    "productId": 219,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "92d27d31ee16c9150c4ce4a2d09f18d71707dba3",
        "sponsorName": "Cellenkos Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Mesenchymal stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Mesenchymal_stem_cells",
    "productId": 220,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e2adf519c2fb405939c957dd6389845849f22ca",
        "sponsorName": "CellTex Therapeutics Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "LIGHT",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "LIGHT",
    "productId": 221,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96d364e5af844fa0968bbd605a149ba3cfd69ca8",
        "sponsorName": "Cerecor Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "NOT a treatment or a vaccine but tecnology. The tecnology is called Chromovert and is used to accelerate drug discovery against hard-to-express biological target.  It has been successfully used to identify a novel non-addictive pain blocker that is in clinical development and it has identified a number of compounds in its pipeline that may help address COVID-19-related disease",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Chromocell_Corp-222",
    "productId": 222,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4f6dba72f4ca74bcc6cb4c053fcddbbd0605b4a8",
        "sponsorName": "Chromocell Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "2-DG",
    "chemicalName": "2-deoxy-D-glucose",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "research was done by University of Frankfurt",
    "numSites": "",
    "otherPartners": "WPD Pharmaceuticals Inc.",
    "phase": "",
    "preferredName": "2deoxyDglucose",
    "productId": 223,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b843740e853ec52aa48f7c4d941b036355d61f11",
        "sponsorName": "CNS Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "protase inhibtors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "the compouds are protase inhibitors with a novel mechanism of action",
    "numSites": "",
    "otherPartners": "Kansas State University Research Foundation",
    "phase": "",
    "preferredName": "protase_inhibtors",
    "productId": 224,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "85acfe2552787d1aab27f27a6db39a840956ca36",
        "sponsorName": "Cocrystal Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "NOT a treatment or vaccine the intervention is artifical intelligance. Cyclica used its proprietary deep learning engine MatchMakerTM to screen a collection of more than 6700 FDA-approved drugs and drug candidates.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cyclica_Inc_Institute_of_Materia_Medica-225",
    "productId": 225,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96aa111d21b571477bd2e5134e5c70c2765f72d4",
        "sponsorName": "Cyclica Inc"
      },
      {
        "sponsorId": "90e13d0c6853ec68204942687ed0ccac12474d86",
        "sponsorName": "Institute of Materia Medica"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "NK immunotherapies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Macromoltek",
    "phase": "",
    "preferredName": "NK_immunotherapies",
    "productId": 226,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96da9064b2e31d835251dbc8767057c31f3e37cf",
        "sponsorName": "Cytovia Inc"
      },
      {
        "sponsorId": "f9bfea84937e5d2a1fc4c5dd3aa3872a28df26f8",
        "sponsorName": "Macromoltek Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Trans Sodium Crocetinate",
    "chemicalName": "Transcrocetinate",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Virginia Health,the Integrated Translational Research Institute of Virginia",
    "phase": "",
    "preferredName": "Transcrocetinate",
    "productId": 227,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "51372c96cd390e9e8158f561b56bea3bddd3f04d",
        "sponsorName": "Diffusion Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "LY-3127804",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "LY3127804",
    "productId": 228,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3304b2181ddd0c29d7e4e948394439adc182494",
        "sponsorName": "Eli Lilly and Co"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Olumiant",
    "chemicalName": "Baricitinib",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Institute of Allergy and Infectious Diseases",
    "phase": "",
    "preferredName": "Baricitinib",
    "productId": 229,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3304b2181ddd0c29d7e4e948394439adc182494",
        "sponsorName": "Eli Lilly and Co"
      },
      {
        "sponsorId": "d70d811c8de3a7e0ae950118837789ce8599f09b",
        "sponsorName": "Incyte Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "COVID-HIG,COVID-EIG",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Biomedical Advanced Research and Development Authority,Emergent and the National Institute of Allergy and Infectious Diseases",
    "phase": "",
    "preferredName": "COVIDHIG_COVIDEIG",
    "productId": 230,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fb6f2b512443fdfe4d4b85aa2d74466d4ef9bcb4",
        "sponsorName": "Emergent Biosolutions Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Allocetra",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Isreal"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Israel Innovation Authority",
    "phase": "",
    "preferredName": "Allocetra",
    "productId": 231,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "35f03ea5c43e45df3a66c005c91958a6ddad2bc3",
        "sponsorName": "Enlivex Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "ENU-200",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Oral drug intended for asymptomatic and mild to moderate cases",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ENU200",
    "productId": 232,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5d1294f0cbab726f6c4136eaea842857641103a9",
        "sponsorName": "Ennaid Therapeutics LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Interferon-beta-1a,traumakine",
    "chemicalName": "FP-1201-lyo",
    "conditionOrDisease": "COVID-19",
    "countries": ["Finland"],
    "countryCodes": ["FIN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Tested with ritonavir and lopinavir in the WHO Solidarity Trial,the researchers who completed the first study is currently conducting two more",
    "numSites": "1",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "FP1201lyo",
    "productId": 233,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Tehran",
        "country": "IR",
        "lat": 35.68008950000001,
        "lng": 51.3881482,
        "locationId": "1858050185e38022fa10c98ddb466cce1d129b48",
        "name": "Tehran, \u0627\u0633\u062a\u0627\u0646 \u062a\u0647\u0631\u0627\u0646 \u062a\u0647\u0631\u0627\u0646 \u062e\u06cc\u0627\u0628\u0627\u0646 \u06a9\u0627\u0631\u06af\u0631 \u062c\u0646\u0648\u0628\u06cc\u060c \u0686\u0647\u0627\u0631\u0631\u0627\u0647 \u0644\u0634\u06af\u0631\u060c\u060c \u062e\u06cc\u0627\u0628\u0627\u0646 \u0645\u062e\u0635\u0648\u0635\u060c Iran",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a14a930a99f757de7464f323c64a61c4425eeab9",
        "sponsorName": "Faron Pharmaceuticals Oy"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": "NCT04343768"
  },
  {
    "brandName": "FW-1022",
    "chemicalName": "niclosamide",
    "conditionOrDisease": "Sars-CoV2",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Oral drug targeting GI symptoms,expected to reach clinical trials in mid-2020 in the European Union and United States",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "niclosamide",
    "productId": 234,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cbb02257499f9c2c7d7271d953b3560d56ea08ab",
        "sponsorName": "Firstwave Bio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": "NCT04372082"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 16 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Labs of Jason McLellan (University of Texas at Austin,US); Markus Hoffman and Stefan Pohlmann (German Primate Center - Leibniz Institute for Primate Research,Gottingen,Germany)",
    "phase": "",
    "preferredName": "Flanders_Institute_for_Biotechnology-235",
    "productId": 235,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "57edd5513cc69010f620c128c8a4cd203199a017",
        "sponsorName": "Flanders Institute for Biotechnology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "rCIG",
    "chemicalName": "gammaglobulin",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Polyclonal antibodies",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "gammaglobulin",
    "productId": 236,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "88873a8fec57e2eafb81051d4b164951b8b32ded",
        "sponsorName": "Gigagen Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Truvada",
    "chemicalName": "emtricitabine,tenofovir",
    "conditionOrDisease": "Coronavirus infection",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "62",
    "otherPartners": "Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital",
    "phase": "3",
    "preferredName": "emtricitabine_tenofovir",
    "productId": 237,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Madrid",
        "country": "ES",
        "lat": 40.4059152,
        "lng": -3.6709491,
        "locationId": "bc34b9cbea3226b04152e25f1c846e61aa3ccfee",
        "name": "Calle del Dr. Esquerdo, 136, planta 7\u00aa, 28007 Madrid, Spain",
        "state": "Comunidad de Madrid"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cbb34f9aed92e21ff89501b842a385faabf9c8c6",
        "sponsorName": "Gilead Sciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": "NCT04334928"
  },
  {
    "brandName": "Trike therapeutic",
    "chemicalName": "GTB-3550 (OXS-3550)",
    "conditionOrDisease": "High-risk myelodysplastic syndromes,acute myelogenous leukemia,systemic mastocytosis,mast cell leukemia",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 21 Jan 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently in clinical trial for acute myeloid lukemia",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "GTB3550_OXS3550",
    "productId": 238,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Minneapolis",
        "country": "US",
        "lat": 44.97399,
        "lng": -93.2277285,
        "locationId": "216421a66a8ad23a3e9c63067e00d1d02706effa",
        "name": "Minneapolis, MN 55455, USA",
        "state": "MN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "19311beed76e39b72841d55b12b1026f4994706e",
        "sponsorName": "GT Biopharma Inc"
      },
      {
        "sponsorId": "66f07a8584ac1fa31540d4786854faf6c4aa3957",
        "sponsorName": "Cytovance Biologics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": "NCT03214666"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Harrington_Discovery_Institute-239",
    "productId": 239,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bf94ba6ac350c9a5c8dc12ad79ceb170e893d9a7",
        "sponsorName": "Harrington Discovery Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "HLCM-051",
    "chemicalName": "",
    "conditionOrDisease": "Respiratory distress syndrome,adult",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "2",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "HLCM051",
    "productId": 240,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "\u5f18\u524d\u5e02",
        "country": "JP",
        "lat": 40.5996478,
        "lng": 140.4659418,
        "locationId": "e838aabef3630a861acb628fd3f6bc6c26ed9872",
        "name": "Japan, \u3012036-8563 \u9752\u68ee\u770c\u5f18\u524d\u5e02\u5927\u5b57\u672c\u753a\uff15\uff13",
        "state": "\u9752\u68ee\u770c"
      },
      {
        "city": "Kumamoto",
        "country": "JP",
        "lat": 32.7649934,
        "lng": 130.7008681,
        "locationId": "2823eaf2b54bf49ed5ea7400db20ed166f3016e4",
        "name": "5-ch\u014dme-3-\uff13\u756a\uff11\u53f7 Chikami, Minami-ku, Kumamoto, 861-4193, Japan",
        "state": "Kumamoto"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7d37b38fc6903794e0d2745bf6a891faddf43237",
        "sponsorName": "Healios KK"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT03807804"
  },
  {
    "brandName": "HB-adMSCs",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "Clinical study mentioned is one of three,two more are in earlier stages",
    "numSites": "1",
    "otherPartners": "Medrio",
    "phase": "2",
    "preferredName": "HBadMSCs",
    "productId": 241,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Sugar Land",
        "country": "US",
        "lat": 29.6018105,
        "lng": -95.625022,
        "locationId": "b327b3d535afe77be03ce54227550c1b17f6ecd6",
        "name": "16700 Creekbend Dr, Sugar Land, TX 77478, USA",
        "state": "TX"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b6a4863d0716a8f9abb22fd5f19ab102949816cc",
        "sponsorName": "Hope Biosciences LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04349631"
  },
  {
    "brandName": "Lenzilumab",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Lenzilumab",
    "productId": 242,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a81896aa5b137b226eae204c475800cdbc8c227f",
        "sponsorName": "Humanigen Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04351152"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Considering the use of endonuclease inhibitors that have been proven useful in blocking the SARS virus",
    "numSites": "",
    "otherPartners": "Iktos SAS",
    "phase": "",
    "preferredName": "SRI_International-243",
    "productId": 243,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9363c36807614b06638e420a1f2fa93b6641816b",
        "sponsorName": "SRI International"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ImmunCyte_Life_Sciences_Inc_Thermogenesis_Holdings_Inc-244",
    "productId": 244,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "72e5c81b2b4be368383395ef98cef3e64c31d8cf",
        "sponsorName": "ImmunCyte Life Sciences Inc"
      },
      {
        "sponsorId": "2d735c3d9d663fcc08e98c3576299ec02b7f8090",
        "sponsorName": "Thermogenesis Holdings Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Lodonal - CYTO 106,IRT-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Initially developed for use in HIV,Has shown efficacy in decreasing replication of H1N1 influenza",
    "numSites": "",
    "otherPartners": "Immune therapeutics Inc.",
    "phase": "",
    "preferredName": "Lodonal__CYTO_106_IRT101",
    "productId": 245,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6ea4d83cf95f6a8d357720443be824816569a0f0",
        "sponsorName": "Cytocom Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Avdoralimab",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 27 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "In phase 1 development for treatment of solid tumors including hepatocellular carcinoma and non-small cell lung cancer",
    "numSites": "1",
    "otherPartners": "Assistance Publique Hopitaux De Marseille",
    "phase": "2",
    "preferredName": "Avdoralimab",
    "productId": 246,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Marseille",
        "country": "FR",
        "lat": 43.296482,
        "lng": 5.36978,
        "locationId": "50e67240aabc691776b8ab1256da3ab20f8bdfe7",
        "name": "Marseille, France",
        "state": "Provence-Alpes-C\u00f4te d'Azur"
      },
      {
        "city": null,
        "country": "FR",
        "lat": 46.227638,
        "lng": 2.213749,
        "locationId": "e899c8e4d1653c9d9c52bda9cd3fc5bc1d361249",
        "name": "France",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b337560632de8abae925da303babdc79ea05dadb",
        "sponsorName": "Innate Pharma SA"
      },
      {
        "sponsorId": "587b66a05b02fcac9b73edf0cbb79d9cd55ecd52",
        "sponsorName": "Marseille Immunopole"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04371367"
  },
  {
    "brandName": "Centhaquine",
    "chemicalName": "PMZ-2010",
    "conditionOrDisease": "",
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PMZ2010",
    "productId": 276,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ccbaab96d082b74ca31a6f4f904d47ead69db5d3",
        "sponsorName": "Pharmazz INc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Adjucanted recombinant protein",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Adjucanted_recombinant_protein",
    "productId": 524,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7b065d405ef1284ec1cbfd5ce6fb3719c2d87f0e",
        "sponsorName": "Anhui Zhifei Longcom Biopharmaceutical"
      },
      {
        "sponsorId": "63cba1aff0183a31e1f1c916b451513c8733fdf4",
        "sponsorName": "Institute of Microbiology"
      },
      {
        "sponsorId": "bc4227127320dc16e7fb7686767c7506d2a670a6",
        "sponsorName": "Chinese Academy of Sciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Airuka",
    "chemicalName": "",
    "conditionOrDisease": "Pneumonia,COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 10 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Originally intended for the treatment of Hodgkin Lymphoma and hepatocellular carcinoma",
    "numSites": "1",
    "otherPartners": "Southeast University",
    "phase": "2",
    "preferredName": "Airuka",
    "productId": 248,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Lakeland",
        "country": "US",
        "lat": 28.0301306,
        "lng": -81.9179961,
        "locationId": "1e3a884c0fb01a68a9f80bc42ae2e8159ccae374",
        "name": "1000 Longfellow Blvd, Lakeland, FL 33801, USA",
        "state": "FL"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "44eafbed318ddb4f38d794fb4efd9f98455cbe54",
        "sponsorName": "Jingsu HengRui Medicine Co"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04268537"
  },
  {
    "brandName": "Tocilizumab biosimilar",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 25 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Originally intended for the treatment of Rheumatoid arthritis and systemic juvenile idiopathic arthritis",
    "numSites": "1",
    "otherPartners": "Central South Hospital of Wuhan University",
    "phase": "2",
    "preferredName": "Tocilizumab_biosimilar",
    "productId": 249,
    "repurposed": "",
    "siteLocations": [
      {
        "city": "Arkansas City",
        "country": "US",
        "lat": 37.1329945,
        "lng": -97.0384445,
        "locationId": "916b9e6ee58a00e76358f0bf5f40db821421fda2",
        "name": "6401 Patterson Pkwy, Arkansas City, KS 67005, USA",
        "state": "KS"
      },
      {
        "city": "Wuhan",
        "country": "CN",
        "lat": 30.5360485,
        "lng": 114.3643219,
        "locationId": "9d8a4f29a738cf7a7c9d597757e9ced1f1cab20f",
        "name": "Wuchang District, Wuhan, Hubei, China, 430072",
        "state": "Hubei"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "324d178c669e71e0405a90eac0b5a43232854ad4",
        "sponsorName": "Jinyu Biotechnology Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": "ChiCTR2000030196"
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["China", "USA"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Antibody treatment for the neutralization of COVID-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "Pre-Clinical",
    "preferredName": "Antibodies",
    "productId": 250,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cf093c3c3034066cc4fc396f460d2433806ea0c3",
        "sponsorName": "Junshi Biosciences Ltd"
      },
      {
        "sponsorId": "e494e00fc769e5a7fbfae8fa40eb4e348fb6dd3b",
        "sponsorName": "Institute of Microbiology of the Chinese Academy of Sciences"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Xpovio",
    "chemicalName": "selinexor",
    "conditionOrDisease": "COVID-19",
    "countries": ["Global"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 30 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "33",
    "otherPartners": "Karyopharm Therapeutics Inc ",
    "phase": "2",
    "preferredName": "selinexor",
    "productId": 251,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "US",
        "lat": 37.09024,
        "lng": -95.712891,
        "locationId": "812640ac85f51475328771e625dbc83e6f0dea11",
        "name": "United States",
        "state": null
      },
      {
        "city": null,
        "country": "AT",
        "lat": 47.516231,
        "lng": 14.550072,
        "locationId": "1e0b45bf37bffb771c524f169fc1f9bb13232d16",
        "name": "Austria",
        "state": null
      },
      {
        "city": null,
        "country": "FR",
        "lat": 46.227638,
        "lng": 2.213749,
        "locationId": "b3bd4c6c877170f3db6ec256be27ed359f0b30e7",
        "name": "France",
        "state": null
      },
      {
        "city": null,
        "country": "IL",
        "lat": 31.046051,
        "lng": 34.851612,
        "locationId": "0740a79543f64141803fb8c9a06b823227ce957d",
        "name": "Israel",
        "state": null
      },
      {
        "city": null,
        "country": "ES",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "d86da26be15d6dfc2b2863a5921623caaa1b02fb",
        "name": "Spain",
        "state": null
      },
      {
        "city": null,
        "country": "GB",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "08f6380fa1efd6c36a328d216520f58589a9ea28",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e6cb84b316561809b01b60e49451ae9585f9599e",
        "sponsorName": "Karyopharma Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04349098"
  },
  {
    "brandName": "ARM/NK Therapy",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies,Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Kleo Pharmaceuticals Inc.,Green Cross Labcell",
    "phase": "Pre-Clinical",
    "preferredName": "ARMNK_Therapy",
    "productId": 252,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "65a4395646171957f48b542bb3f8a88cb60f8744",
        "sponsorName": "Kleo Pharmaceuticals Inc"
      },
      {
        "sponsorId": "5d01024199c1e46eb25ce5e44ac99c1bd0431f67",
        "sponsorName": "Green Cross Labcell"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Panaphix",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["South Korea"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Komipharm International",
    "phase": "Pre-Clinical",
    "preferredName": "Panaphix",
    "productId": 253,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "KR",
        "lat": 35.907757,
        "lng": 127.766922,
        "locationId": "e2d2743bfe2a4bb2761153527f5878a5e40492bc",
        "name": "South Korea",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "80d5660a048cb4f5f9120ad0ee6693d572076feb",
        "sponsorName": "Komipharm International Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "Giapreza",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Italy", "United Kingdom"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "La Jolla Pharmaceutical Co.",
    "phase": "",
    "preferredName": "Giapreza",
    "productId": 254,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "eaeb4d2f6090de798cc599bb33c63aece3ea3e59",
        "sponsorName": "La Jolla Pharmaceutical Co"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Lemellosome",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Novel treatment based on using lipid vesicles for nucleic acid delivery",
    "numSites": "",
    "otherPartners": "Lamellasome Biomedical",
    "phase": "Discovery",
    "preferredName": "Lemellosome",
    "productId": 255,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a1a954d36a30fd0780c3b830f4faea0c8c2affb2",
        "sponsorName": "Lamellar Biomedical Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "LAU-7b",
    "chemicalName": "fenretinide",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Novel drug for CF,but Phase 2 will include 200 COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fenretinide",
    "productId": 256,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7fccb09ede9fdc5e7fac92574b058cb03352c217",
        "sponsorName": "Laurent Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "LB-1148",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "LB1148",
    "productId": 257,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "939a860ac278db9d975ccb0616222eeeef87f0e8",
        "sponsorName": "Leading Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Sanofi SA,Amneal Pharmaceuticals INc.,Rising Pharma Holdings Inc.,University of Minnesota,University of Oxford,IHU-M\u00e9diterran\u00e9e Infection,Sandoz Inc.,Bayer AG,University of Washington,Patient-Centerede Outcomes Research Institute,World Health Organization,New York State Department of Health,National Institute or Respiratory Diseases - Mexico,",
    "chemicalName": "chloroquine or hydroxychloroquine",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "On March 28th,FDA issued emergency use authorization of chloroquine phosphate and hydroxychloroquine sulfate",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "chloroquine_or_hydroxychloroquine",
    "productId": 258,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "86b83695165cca282e4f9c439eda39501ae4f0df",
        "sponsorName": "Lupus Therapeutics"
      }
    ],
    "status": "On Market",
    "therapeuticApproach": "Antimalarial drugs",
    "trialId": ""
  },
  {
    "brandName": "Thiolanox",
    "chemicalName": "",
    "conditionOrDisease": "Respiratory Tract InfectionsCorona Virus Infection",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Inhaled gaseous Nitric Oxide",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Thiolanox",
    "productId": 259,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Vancouver",
        "country": "CA",
        "lat": 49.2609056,
        "lng": -123.1259083,
        "locationId": "8cc18dc73cba10d6be80161e6937c5e8e4541550",
        "name": "2775 Laurel St, Vancouver, BC V5Z 1M9, Canada",
        "state": "BC"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1bae5c9e81061a3096b953a0c281893f63528dcf",
        "sponsorName": "Mallinckrodt plc"
      },
      {
        "sponsorId": "6911212feb8516a3c67e4d56ab144214fba04e7c",
        "sponsorName": "Novoteris LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": "NCT03331445"
  },
  {
    "brandName": "Prototype powders",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Pulmonary Drug Delievery",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Prototype_powders",
    "productId": 260,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "98d35ba7fbc9135eb8b0efad1c369b7efd428d50",
        "sponsorName": "Mannkind Corp"
      },
      {
        "sponsorId": "7879cb30e61a74d5398a4ad84131b67c7bdef5e5",
        "sponsorName": "Immix Biopharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Canadian Institutes for Health Research",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 261,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c3b31ebe3bec88be1939ba82b92fd751109ba63c",
        "sponsorName": "Medicago Inc"
      },
      {
        "sponsorId": "89ce3145e138aa498d0b8624253df8d652b51d01",
        "sponsorName": "Laval University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "MN-166",
    "chemicalName": "ibudilast",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ibudilast",
    "productId": 262,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "93b330b91c5cf5de4858a317eb4e5d88f5c33274",
        "sponsorName": "Medicinova Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Ivermectin",
    "chemicalName": "",
    "conditionOrDisease": "COVID",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "N/A",
    "preferredName": "Ivermectin",
    "productId": 263,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "New Delhi",
        "country": "IN",
        "lat": 28.6139391,
        "lng": 77.2090212,
        "locationId": "f7f043eb22e9283fd59f59cf80fe4e6135a85852",
        "name": "New Delhi, Delhi, India",
        "state": "DL"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "62af02d502c3b46af39cf1393ded764d02cf2dd3",
        "sponsorName": "Medincell SA"
      },
      {
        "sponsorId": "4504468bad51eef6a2ac6172fa89a91614df3c56",
        "sponsorName": "Merck"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": "NCT04373824"
  },
  {
    "brandName": "WP-1122",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "WP1122",
    "productId": 264,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bfc86f4330be66b8207ed43b7e662f038bf16e6e",
        "sponsorName": "Moleculin Biotech Inc"
      },
      {
        "sponsorId": "47b17e1c6508ca65a8f74513d8a91bf7fea67bd1",
        "sponsorName": "University of Texas Medical Branch"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Colchicine",
    "chemicalName": "",
    "conditionOrDisease": "Corona Virus Infection",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Colchicine",
    "productId": 265,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "SF",
        "country": "US",
        "lat": 37.7749295,
        "lng": -122.4194155,
        "locationId": "75a00dcda5c624ce07ff53e19b0dc3536b128f4d",
        "name": "San Francisco, CA, USA",
        "state": "CA"
      },
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7381644,
        "lng": -73.97821569999999,
        "locationId": "0e29c89b4f351da3b4d110ad19b6e4d5ad46c84b",
        "name": "345 E 24th St, New York, NY 10010, USA",
        "state": "NY"
      },
      {
        "city": "Montr\u00e9al",
        "country": "CA",
        "lat": 45.5737308,
        "lng": -73.57797959999999,
        "locationId": "0413cc8450f5a7ab6fa4320eed11cc7671569b4f",
        "name": "5000 Rue B\u00e9langer, Montr\u00e9al, QC H1T 1C8, Canada",
        "state": "QC"
      },
      {
        "city": "Madrid",
        "country": "ES",
        "lat": 40.4811633,
        "lng": -3.6873977,
        "locationId": "a9c59609801a2be4c43979a039c54d9a60c4121e",
        "name": "Paseo de la Castellana, 261, 28046 Madrid, Spain",
        "state": "Comunidad de Madrid"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "249179236abc76c285b00f0d0d7abc1e9abfdaa2",
        "sponsorName": "Montreal Heart Institute"
      },
      {
        "sponsorId": "21765278273510ad7dc80a80afe9b1cf27f3e6d5",
        "sponsorName": "NYU Grossman School of Medicine"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04322682"
  },
  {
    "brandName": "CD-16,N-803,mesenchymal stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "CD-16 off-the-shelf natural killer cells to enhance antibody killing of infected cells given alone or combined with Convalescent Plasma (CP) in combination with ImmunityBio\u2019s IL-15 superagonist N-803 and Avelumab",
    "numSites": "",
    "otherPartners": "Nantkwest Inc.,Immunitybio Inc.",
    "phase": "Pre-clinical",
    "preferredName": "CD16_N803_mesenchymal_stem_cells",
    "productId": 266,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "13fabd5b14178a13d0539b59d6a9be0b068e4309",
        "sponsorName": "Nantkwest Inc"
      },
      {
        "sponsorId": "8bfec75fcf441b5e6dfde4d8556e152456e80321",
        "sponsorName": "Immunitybio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Pritumumab",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 19 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 03 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "a natural human IgG1 kappa antibody that has been derived from a B cell isolated from regional draining lymph node of a cervical carcinoma patient",
    "numSites": "",
    "otherPartners": "Nascent Biotech Inc.",
    "phase": "Pre-clinical",
    "preferredName": "Pritumumab",
    "productId": 267,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b3867b6cd9697e882535adad3e08532327c9d976",
        "sponsorName": "Nascent Biotech Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Nitricil therapeutic",
    "chemicalName": "nitric oxide",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Fri, 20 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Wainwright & Co. LLC",
    "phase": "Pre-clinical",
    "preferredName": "nitric_oxide",
    "productId": 268,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ddee329111caa7d96be4e5aea7fa3ccfaccac422",
        "sponsorName": "Novan Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "ST-266",
    "chemicalName": "cell-free platform biologic containing hundreds of anti-inflammatory proteins",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Noveome Biotherapeutics Inc.,US government",
    "phase": "Pre-clinical",
    "preferredName": "cellfree_platform_biologic_containing_hundreds_of_antiinflammatory_proteins",
    "productId": 269,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8c4038c7c0eddd116fc3688efef61be78abbacb4",
        "sponsorName": "Noveome Biotherapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "RNAi therapeutic",
    "chemicalName": "small interfering RNAs",
    "conditionOrDisease": "",
    "countries": ["South Korea"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "The siRNAs would operate within the RNAi pathway where it interferes with the expression of the genes with complementary nucleotide sequences by degrading mRNA after transcription resulting in no translation.",
    "numSites": "",
    "otherPartners": "OliX Pharmaceuticals Inc",
    "phase": "Pre-clinical",
    "preferredName": "small_interfering_RNAs",
    "productId": 270,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96c730a852872cf66c35cb125b2d7d05d8530e76",
        "sponsorName": "Olix Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "KTH-222",
    "chemicalName": "inhibit the MAPK pathway by controlling initiation of the signaling cascade while synthetic drugs block only specific parts of the pathway",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "anticancer drug",
    "numSites": "",
    "otherPartners": "Kalos Therapeutics,Oncology Pharma Inc.",
    "phase": "Pre-clinical",
    "preferredName": "inhibit_the_MAPK_pathway_by_controlling_initiation_of_the_signaling_cascade_while_synthetic_drugs_block_only_specific_parts_of_the_pathway",
    "productId": 271,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "94591eec9484636deee6e0aa9cf402169c390282",
        "sponsorName": "Oncology Pharma Inc"
      },
      {
        "sponsorId": "eb7a2deb781669d168a882d3eb969a94f3b7b5d9",
        "sponsorName": "Kalos Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "VNAR antibodies",
    "chemicalName": "Single domain variable new antigen receptor (VNAR) antibodies",
    "conditionOrDisease": "",
    "countries": ["USA", "UK"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Lundbeck,Ossianix Inc.",
    "phase": "Pre-clinical",
    "preferredName": "Single_domain_variable_new_antigen_receptor_VNAR_antibodies",
    "productId": 272,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e0168852b1423a84cb2e4cc6a63702915618d555",
        "sponsorName": "Ossianix Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Ostrich antibodies",
    "chemicalName": "ostrich IgY antibodies",
    "conditionOrDisease": "",
    "countries": ["USA", "Japan"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 30 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Ostrich Pharma USA",
    "phase": "Phase 1",
    "preferredName": "ostrich_IgY_antibodies",
    "productId": 273,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Noblesville",
        "country": "US",
        "lat": 40.04405250000001,
        "lng": -86.07337919999999,
        "locationId": "3e4dd59474f565221375b7afc70fb0eb134b1583",
        "name": "5691 Pebble Village Ln, Noblesville, IN 46062, USA",
        "state": "IN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "81131cc14196ec0102f65dd04174c541d8ed0900",
        "sponsorName": "Ostrich Pharma USA Ostrigen"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Leukine",
    "chemicalName": "Sargramostim",
    "conditionOrDisease": "Covid-19 ARDS",
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "SKIPPED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "SKIPPED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "SKIPPED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "1",
    "otherPartners": "University Hospital Ghent,Flanders Institute of Biotechnology",
    "phase": "4",
    "preferredName": "Sargramostim",
    "productId": 274,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Gent",
        "country": "BE",
        "lat": 51.0243757,
        "lng": 3.7261488,
        "locationId": "dfadce2c7ab84da58712c5cc88ba7db8f25ccc19",
        "name": "Corneel Heymanslaan 10, 9000 Gent, Belgium",
        "state": "Vlaanderen"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8b5205e0d7efb338bddea3c077306518cd3232bc",
        "sponsorName": "Partner Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "Eudra CT 2020-001254-22"
  },
  {
    "brandName": "Microbiome therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Microbiome_therapeutic",
    "productId": 275,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8a2aaacc01bd11f71c410206ebedcdc6087bc015",
        "sponsorName": "Persephone Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "RBD-based",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "RBDbased",
    "productId": 525,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4dc81db10d5b875528cfc231d9c3e0179fdff8a1",
        "sponsorName": "Neovii"
      },
      {
        "sponsorId": "c70d6300461b60aa0d62ede7a42516869f6aeada",
        "sponsorName": "Tel Aviv University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Neumifil",
    "chemicalName": "Sp2CBMTD",
    "conditionOrDisease": "",
    "countries": ["Scotland"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Carbohydrate bonding module (CBM40) blocks sialic acid receptors in respiratory tract and prevents virus from entering host cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "Pre-clinical",
    "preferredName": "Sp2CBMTD",
    "productId": 278,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "983efe23794f5ea689b6644c79f8581943a74fe3",
        "sponsorName": "Pneumagen Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "CoreCyte",
    "chemicalName": "Umbilical Cord Mesenchymal Stem Cells",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Umbilical Cord Mesenchymal Stem Cells isolated from Wharton's Jelly,Applied for FDA approval for immediate use for Covid-19 on 04/09/2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Umbilical_Cord_Mesenchymal_Stem_Cells",
    "productId": 279,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "761c8b0485e032a24d29f63f18726bb53f50bdc1",
        "sponsorName": "Predictive Biotech"
      },
      {
        "sponsorId": "0a520daf69e8730cf20a260e53d5354fd23003aa",
        "sponsorName": "Predictive Technology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "PRTX-007",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Activates TLR7 to stimulate innate immune system",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PRTX007",
    "productId": 280,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "59184ad543e6f439787b2e2ac1527ea53b1e5ac1",
        "sponsorName": "Primmune Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Singapore"],
    "countryCodes": ["SGP"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 25 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Heidelberg University Hospital,T\u00fcbingen University Hospital,the German Cancer Research Center (DKFZ),the NMI Natural and Medical Sciences Institute,NUS Enterprise,10x Genomics,NovogeneAIT",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 281,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "245b051b6523c597e8560495815affabbbd6151f",
        "sponsorName": "Proteona Pte Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Yeliva",
    "chemicalName": "opaganib",
    "conditionOrDisease": "Covid-19",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Phase 2 trial IND application made",
    "numSites": "UKNOWN",
    "otherPartners": "",
    "phase": "2a",
    "preferredName": "opaganib",
    "productId": 282,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Charlotte",
        "country": "US",
        "lat": 35.2205194,
        "lng": -80.8575444,
        "locationId": "3efef15128e0003a6132bf6e1af7c7aed07c78cd",
        "name": "1327 S Mint St, Charlotte, NC 28203, USA",
        "state": "NC"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e8c8185248be3a1b2daf8211acc52922e6293844",
        "sponsorName": "Redhill Biopharma Ltd"
      },
      {
        "sponsorId": "f01ab327db3d24c889ea79c039140f87ed85ab74",
        "sponsorName": "Apogee Biotechnology Group Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "UNKNOWN"
  },
  {
    "brandName": "Upamostat",
    "chemicalName": "RHB-107",
    "conditionOrDisease": "",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Passed phase 1 and 2 clinical trials for other diseases currently being tested in-vitro for Covid-19",
    "numSites": "",
    "otherPartners": "NIAID",
    "phase": "Pre-clinical",
    "preferredName": "RHB107",
    "productId": 283,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e8c8185248be3a1b2daf8211acc52922e6293844",
        "sponsorName": "Redhill Biopharma Ltd"
      },
      {
        "sponsorId": "4f42e3229651f0892787042619eb74da72a1a688",
        "sponsorName": "Link Health Group"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Apabetalone",
    "chemicalName": "2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxy-1,4-dihydroquinazolin-4-one",
    "conditionOrDisease": "COVID19",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 15 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Tue, 17 Mar 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 23 Mar 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Mon, 03 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Private,NIHR",
    "phase": "3",
    "preferredName": "242hydroxyethoxy35dimethylphenyl57dimethoxy14dihydroquinazolin4one",
    "productId": 284,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e60afe62e3596c8891ede53bfdc0f1c2a71320a",
        "sponsorName": "Resverlogix Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Bucillamine",
    "chemicalName": "",
    "conditionOrDisease": "COVID19",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Antirheumatic",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Bucillamine",
    "productId": 285,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "df3723439d2a920860a172a5dd962f7ec0f7cc36",
        "sponsorName": "Revive Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "EIDD-2801",
    "chemicalName": "",
    "conditionOrDisease": "COVD19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 07 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 10 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Oral antiviral",
    "numSites": "",
    "otherPartners": "Wayne and Wendy Holman",
    "phase": "1",
    "preferredName": "EIDD2801",
    "productId": 286,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4086aa4aca201f3493eee784dbab92ad400778f",
        "sponsorName": "Ridgeback Biotherapeutics LP"
      },
      {
        "sponsorId": "490f2c2447baa96b61de933f67b94a46fd87a097",
        "sponsorName": "Drug Innovations at Emory LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Gimsilumab",
    "chemicalName": "MORAb-022",
    "conditionOrDisease": "COVID19",
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 19 Feb 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "MORAb022",
    "productId": 287,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c0cd5a7a71a7a2120e0b79f29aacd606755aff2a",
        "sponsorName": "Roivant Sciences Ltd"
      },
      {
        "sponsorId": "f062e8029186acd42f78d91ab787d4579d4c5484",
        "sponsorName": "Altasciences Co Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "SAB-185",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "BARDA",
    "phase": "",
    "preferredName": "SAB185",
    "productId": 288,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "21fe6f5f8237968ddc20622797f630647c872671",
        "sponsorName": "Sab Biotherapeutics"
      },
      {
        "sponsorId": "586353dc7d3f7de1b8b0aaf247aaacaa7293cc9f",
        "sponsorName": "CSL Behring LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "S-Protein/ACE2 Targeted prohylactic polypeptide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Apeiron Biologics",
    "phase": "",
    "preferredName": "SProteinACE2_Targeted_prohylactic_polypeptide",
    "productId": 289,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "AT",
        "lat": 47.516231,
        "lng": 14.550072,
        "locationId": "1376dcec5339e24a851f7ea139202863d5a7ebc9",
        "name": "Austria",
        "state": null
      },
      {
        "city": null,
        "country": "DE",
        "lat": 51.165691,
        "lng": 10.451526,
        "locationId": "cd30cf6f2f4fe8e39272407e567997bfc3204d27",
        "name": "Germany",
        "state": null
      },
      {
        "city": null,
        "country": "DK",
        "lat": 56.26392,
        "lng": 9.501785,
        "locationId": "0d2e84f430c0cfcbfb14487025f34b437fc3205f",
        "name": "Denmark",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8812b6d8e3894f01681250e96efa2ff723ccf680",
        "sponsorName": "Sichuan Kelun Pharmaceutical Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Lipocurc",
    "chemicalName": "Liposomal curcumin",
    "conditionOrDisease": "COVID19",
    "countries": ["USA"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 12 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Cancer Treatment",
    "numSites": "",
    "otherPartners": "Paracelsus Medical University,Discretionary Research Fund",
    "phase": "2",
    "preferredName": "Liposomal_curcumin",
    "productId": 290,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "US",
        "lat": 41.2033216,
        "lng": -77.1945247,
        "locationId": "6bdd81808267041c1fc86962649fccc6cff0b807",
        "name": "Pennsylvania, USA",
        "state": "PA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3a23c78238689fa6d8b86e48413a0fbe0d9d35c1",
        "sponsorName": "Signpath Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Antiviral",
    "chemicalName": "Interferon Alpha",
    "conditionOrDisease": "COVID19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sun, 26 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "NIHR",
    "phase": "1/2",
    "preferredName": "Interferon_Alpha",
    "productId": 291,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "CN",
        "lat": 35.86166,
        "lng": 104.195397,
        "locationId": "c392fcb5b25c8e379a74af77905db91f1cd42ed0",
        "name": "China",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "74c3cd3bc3fa22bf3900e0d4e84bb19508cb9132",
        "sponsorName": "Sinopharm Group"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Antiviral",
    "chemicalName": "Glycosides",
    "conditionOrDisease": "COVID19",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Private",
    "phase": "",
    "preferredName": "Glycosides",
    "productId": 292,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Val-de-Reuil",
        "country": "FR",
        "lat": 49.258212,
        "lng": 1.187725,
        "locationId": "ee3a04890dbd2231138d87b64dd9a36310528307",
        "name": "Voie de l Innovation, PharmaParc 2, 27100 Val-de-Reuil, France",
        "state": "Normandie"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b943d0928f25a94239b30d1f795032375383033f",
        "sponsorName": "Sirona Biotechem Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Therapeutic",
    "chemicalName": "Compounds that block the activity of the SARS-CoV-2 MPro protease",
    "conditionOrDisease": "COVID19",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Compounds_that_block_the_activity_of_the_SARSCoV2_MPro_protease",
    "productId": 293,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a116938a80ab1812d2085339b93325c5e6a0805b",
        "sponsorName": "Sosei Group Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Lung airway cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada", "China"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Neither a treatment nor a prophylactic,mainly used to propagate the SARS-CoV-2 which allowed scientists at China's CDC to isolate the virus and obtain the gene sequence,clinical milestones and studies will not be filled out for this reason,development was finished before 03/25/2020 (which is when article about this breakthrough was published)",
    "numSites": "",
    "otherPartners": "CDC - China",
    "phase": "",
    "preferredName": "Lung_airway_cells",
    "productId": 294,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "49edcacef773406a08e3a11e32fb4caf84388c84",
        "sponsorName": "Stemcell Technologies Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Epaspire",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Purified EPA in a capsule currently in a Phase 3 clinical trial in Europe for treatment of FAP,well established safety profile and observed suppression of inflammatory cytokines that may contribute to COVID-19 progression,this allowed the quick initiation of Phase 3 COVID-19 trials and led to the goal of using EPAspire to reduce the complications of COVID-19",
    "numSites": "Undisclosed",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Epaspire",
    "productId": 295,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "06ec5df840715222bbeb972210bfa28ff5aceb2c",
        "sponsorName": "The KD Pharma Group SA"
      },
      {
        "sponsorId": "b47bc7cc175c3bb7640659ad687ac2f480ba8fd6",
        "sponsorName": "SLA Pharma AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04335032"
  },
  {
    "brandName": "TD-0903",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Lung-selective inhaled JAK inhibitor that has the potential to block cytokines and chemokines associated with ALI and ARDS,shown to have effective and broad inhibition of JAK-STAT signaling in rodent models,CTA was submitted in the UK on 04/09/2020 - approval pending and phase 1 will begin immediately after",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1",
    "preferredName": "TD0903",
    "productId": 296,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Manchester",
        "country": "GB",
        "lat": 53.4807593,
        "lng": -2.2426305,
        "locationId": "0745f2a3ab0a7d84a218e91c1c0a0885a22a796c",
        "name": "Manchester, UK",
        "state": "England"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "262d9fad81968c24466a839589f81bece22471db",
        "sponsorName": "Theravance"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": "NCT04350736"
  },
  {
    "brandName": "ARMS-I",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Other",
    "notes": "ARMS-I is a microbe-impermeable barrier with anti-viral action designed to prevent upper respiratory infections,currently holds an IND as a potential flu prophylaxis,clinical trial (unspecified phase but characteristics inmply phase 2) to investigate whether ARMS-I will help protect against COVID-19 in frontline health workers,no entry in clinicaltrials.gov yet",
    "numSites": "Unspecified",
    "otherPartners": "ARMS Pharmaceutical LLC,Cleveland Foundation,Case Western Reserve University",
    "phase": "2",
    "preferredName": "ARMSI",
    "productId": 297,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Cleveland",
        "country": "US",
        "lat": 41.5050672,
        "lng": -81.605476,
        "locationId": "a1aa5fb56833056d5c56b395c7c861c8d7811058",
        "name": "University Hospitals, 2101 Adelbert Rd, Cleveland, OH 44106, USA",
        "state": "OH"
      },
      {
        "city": "Warren",
        "country": "US",
        "lat": 41.2221809,
        "lng": -80.7967887,
        "locationId": "e2cab3ee9563da105cb88e9874261359b28ff161",
        "name": "1977 Niles Rd SE, Warren, OH 44484, USA",
        "state": "OH"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "081649a78e8f049d5576bf2c9694fd3841668997",
        "sponsorName": "Cleveland University Hospitals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "Tradipitant",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 13 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Tradipitant is currently undergoing clinical trials for other conditions such as gastroparesis,tradipitant is an NK-1R antagonist that is being tested to see if it can treat inflammatory lung injury associated with COVID-19",
    "numSites": "1",
    "otherPartners": "University of Illinois at Chicago",
    "phase": "3",
    "preferredName": "Tradipitant",
    "productId": 298,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "New York",
        "country": "US",
        "lat": 40.7736341,
        "lng": -73.9608549,
        "locationId": "5a9d0f0edbbd53bf08f1bad5909da240a3b61c88",
        "name": "130 E 77th St, New York, NY 10075, USA",
        "state": "NY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d2734c3b72bd97da45e8be5b00151cb1c2fe5838",
        "sponsorName": "Vanda Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04326426"
  },
  {
    "brandName": "Monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 24 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "$14 million contract from US Department of Defense for Ology Bioservices and Vanderbilt to collaborate on antibody discovery against COVID-19,Twist to build a synthetic antibody discovery library based on sequences from a recovered COVID-19 patient from Vandebilt",
    "numSites": "",
    "otherPartners": "Twist Bioscience Corp.,DARPA,NIAID,Ology Bioservices Inc.",
    "phase": "",
    "preferredName": "Monoclonal_antibodies",
    "productId": 299,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3505691a86b3a9dacf9bb0dd76bfd49b7cd40e83",
        "sponsorName": "Vanderbilt University"
      },
      {
        "sponsorId": "bb9ed07e215d6bebb274790c7ee0711a0da9f41e",
        "sponsorName": "AstraZeneca"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Genosyl DS",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Genosyl DS is a tankless nitric oxide delivery system that obtained FDA approval on 12/20/19,FDA recently granted expanded access emergency use on 03/26/20 for the Genosyl DS to be used in treating cardiopulmonary symptoms associated with COVID-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Genosyl_DS",
    "productId": 300,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9ec0b02ebf735a301023bce110203311a36cbe28",
        "sponsorName": "Vero Biotech"
      }
    ],
    "status": "On Market",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "DNA Plasmid Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Takara Bio Inc.",
    "phase": "",
    "preferredName": "DNA_Plasmid_Vaccine",
    "productId": 334,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      },
      {
        "sponsorId": "17be17f24c77c426a72f3b040131c995834c2be1",
        "sponsorName": "AnGes"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "VIR-7832",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "VIR-7831 and VIR-7832 are leading antibody candidates that have demonstrated high affinity for the SARS-CoV-2 spike protein,companies aim to directly enter phase 2 clinical trial within the next three to five months,currently still in the development phase",
    "numSites": "",
    "otherPartners": "Wuxi Biologics,National Institute of Allergy and Infectious Diseases,Xencor Inc.,Glaxosmithkline plc,Samsung Biologics Co. Ltd.",
    "phase": "",
    "preferredName": "VIR7832",
    "productId": 301,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6c32fa743ed510db10e7c97fd975d2a2a5700a4a",
        "sponsorName": "Vir Biotechnology Inc"
      },
      {
        "sponsorId": "7b6f419a075a9d4cfc1742367fdc3d11cc35f994",
        "sponsorName": "Biogen Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Elpida",
    "chemicalName": "elsafavirine",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 08 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Elpida is a non-nucleoside reverse transcriptase inhibitor that received market approval from the Russian Ministry of Health to treat HIV on 06/30/2017,initated Phase 2 clinical study to evaluate efficacy of Elpida in adults with COVID-19 on 04/08/2020 but currently has no entry on clinicaltrials.gov",
    "numSites": "Unspecified",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "elsafavirine",
    "productId": 302,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "RU",
        "lat": 61.52401,
        "lng": 105.318756,
        "locationId": "4746188731bd1b1c14bb2037e4cdd65e4c22355d",
        "name": "Russia",
        "state": null
      },
      {
        "city": null,
        "country": null,
        "lat": 52.0055148,
        "lng": 37.95874939999999,
        "locationId": "7c58f9ad10cf340a031849975fa294c8436a8e60",
        "name": "Eastern Europe",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3e65bda0e3a4586a7154c208c474b7fc79f60ab1",
        "sponsorName": "Viriom Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Viscient is using 3D bioprinting tech to create lung tissue to support research efforts on finding and testing COVID-19 therapies - clinical trial in a dish, as of 04/20/2020 - still working on a way to develop infected lung tissue",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Viscient_Biosciences_Inc-303",
    "productId": 303,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8d59671a4747cb2aa6f2acfa1c51b5de8644ae5b",
        "sponsorName": "Viscient Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "CB1 antagonist",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CB1_antagonist",
    "productId": 304,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96dc8ffb76c357cda9bf1ea512a6b3faedc50ed5",
        "sponsorName": "Viripharm Biopharmaceuticals LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "KL4 surfactant",
    "chemicalName": "Sinapultide",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Sinapultide",
    "productId": 305,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b9d4687e32bd1665b98b110c465c991959943db7",
        "sponsorName": "Windtree Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Mesenchymal stem cells",
    "chemicalName": "UC-MSCs",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "",
    "preferredName": "UCMSCs",
    "productId": 306,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Wuhan Shi",
        "country": "CN",
        "lat": 30.583826,
        "lng": 114.273585,
        "locationId": "593ecb8dddf9b9e180e3ea096b2e9e6dfb32d1a2",
        "name": "Jiefang Ave, Xi Bei Hu, Jianghan Qu, Wuhan Shi, Hubei Sheng, China",
        "state": "Hubei Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "14038d17d9fa18917792c69af98837142687f2af",
        "sponsorName": "Wuhan Hamilton Biotechnology Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04273646"
  },
  {
    "brandName": "Antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibody",
    "productId": 307,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "aceff18e5b0594f0ed960779ae931d91cbc7fa9f",
        "sponsorName": "VIBUGent Center for Medical Biotechnology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Plasma treatment",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Plasma_treatment",
    "productId": 308,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d1a873903a92cac9d889e8f9ff8977b7f9e100ce",
        "sponsorName": "Xbiotech Inc"
      },
      {
        "sponsorId": "96240c6492e03d5753e52d4da6fa236a7e4dc6f2",
        "sponsorName": "Biobridge Global"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "XRx-101",
    "chemicalName": "Oxypurinol",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Oxypurinol",
    "productId": 309,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3942d9eba6d7c598d2d7548e1f99237e337f7f56",
        "sponsorName": "Xortx Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "Antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antiviral",
    "productId": 310,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "40539840e055053cf646a7a6c2d6f01184a9f4a3",
        "sponsorName": "Xphyto Therapeutics Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Slovakia"],
    "countryCodes": ["SVK"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 311,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0fc1c2eb025301d74761cfdaad2e702a05e14ea7",
        "sponsorName": "Axon Neuroscience SE"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Dendritic cell vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Dendritic_cell_vaccine",
    "productId": 312,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "08a21a27c82e51464712adac2679fb2dc228d69b",
        "sponsorName": "Betta Pharmaceuticals Co Ltd"
      },
      {
        "sponsorId": "5971cf2c808d095d9d239606be69759cc12a3ff5",
        "sponsorName": "Beijing Dingcheng Taiyuan Biotechnology"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 313,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "61c10d4a8a5dee7e9c508ca4cf94e5fb4aedf2a3",
        "sponsorName": "Chongqing Zhifei Biological Products Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Fusogenix DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "Disease",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Direct introduction of a plasmid encoding the antigen(s) against which an immune response is sought and relies on the production of the target antigen in the patient\u2019s own cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "Fusogenix_DNA_Vaccine",
    "productId": 314,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "792d66b4f6751aa1d3eabedb66b4e1a4b26c759b",
        "sponsorName": "Entos Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "ERC\u2019s SARS-Cov-2 Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "Condition,disease",
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 09 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Other",
    "notes": "Vaccine containing virions,viral proteins at different stages of viral replication,whole human cells and cellular fragments,composing all elements of viral replication",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "ERC\u2019s_SARSCov2_Vaccine",
    "productId": 315,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2bae05a8f1ef431f06f3f32e8a5b62ac2088a4e7",
        "sponsorName": "Epitopoietic Research Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Coroflu",
    "chemicalName": "",
    "conditionOrDisease": "Disease",
    "countries": ["India", "United States"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Modification of M2SR by adding part of the coding region for the coronavirus spike protein",
    "numSites": "",
    "otherPartners": "Flugen Inc,Bharat Biotech International Ltd - India,University of Wisconsin-Madison",
    "phase": "Discovery",
    "preferredName": "Coroflu",
    "productId": 316,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d0615a827003e8423ac0ea3c03f9fbd824fc52b3",
        "sponsorName": "Flugen Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Ii-Key-SARS 2 peptide vaccine",
    "chemicalName": "",
    "conditionOrDisease": "Disease",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 27 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "China Technology Exchange,Beijing Zhonghua Investment Fund Management Co. LTD,Biology Institute of Shandong Academy of Sciences,Sinotek-Advocates International Industry Development (Shenzhen) Co. LTD",
    "phase": "Discovery",
    "preferredName": "IiKeySARS_2_peptide_vaccine",
    "productId": 317,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bd241b032c9ac50523b8215691176cc94b2966b6",
        "sponsorName": "Generex Biotechnology Group"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Z-VacciRNA",
    "chemicalName": "",
    "conditionOrDisease": "Disease",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "ZVacciRNA",
    "productId": 318,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de3c929194d9aac1196f6a1b8c9e5983cfa58911",
        "sponsorName": "Guanhao Biotech Co Ltd"
      },
      {
        "sponsorId": "f12c99eed6736f965feb517d2d827d893d1cd2b0",
        "sponsorName": "Zy Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 319,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "344b517c43ad6d6219c6a66b35a3d655b2918e54",
        "sponsorName": "Hualan Biological Engineering"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 320,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "07b42758a4b70d9b70f8e828e2488a0d0c69160d",
        "sponsorName": "ID Pharma Co Ltd"
      },
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Virus Suppressing Factor",
    "chemicalName": "HzVSFv13",
    "conditionOrDisease": "Condition",
    "countries": ["Korea"],
    "countryCodes": ["PRK"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 28 Mar 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 21 Feb 2020 00:00:00 GMT",
        "milestoneId": 51,
        "name": "nda",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "Phase 1",
    "preferredName": "HzVSFv13",
    "productId": 321,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "KR",
        "lat": 37.5795356,
        "lng": 126.9990276,
        "locationId": "d52d392df862ed1eb15ae51e4b271efda6ae08a4",
        "name": "101 Daehak-ro, Yeongeon-dong, Jongno-gu, Seoul, South Korea",
        "state": "Seoul"
      },
      {
        "city": null,
        "country": "KR",
        "lat": 35.8473237,
        "lng": 128.5848209,
        "locationId": "96f53034735b4d5c2320f4254521cd5b246953d6",
        "name": "170 Hyeonchung-ro, Daemyeong 5(o)-dong, Nam-gu, Daegu, South Korea",
        "state": "Daegu"
      },
      {
        "city": null,
        "country": "KR",
        "lat": 36.31695,
        "lng": 127.4157208,
        "locationId": "606fa36947986792ae2ec91a5f82d119732b0679",
        "name": "282 Munhwa-ro, Daesa-dong, Jung-gu, Daejeon, South Korea",
        "state": "Daejeon"
      },
      {
        "city": null,
        "country": "KR",
        "lat": 37.5622702,
        "lng": 126.941068,
        "locationId": "f1906d692f8d851d6ad206af36f4b1c768739a69",
        "name": "50-1 Yonsei-ro, Sinchon-dong, Seodaemun-gu, Seoul, South Korea",
        "state": "Seoul"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1b6935230a67257c55ec98d018cd779af0ce72b1",
        "sponsorName": "Immunemed"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Nucleic Acid Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nucleic_Acid_Vaccine",
    "productId": 322,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "32698ef58730c0db442e4711afe4d8872c1122fa",
        "sponsorName": "Immunomic Therapeutics Inc"
      },
      {
        "sponsorId": "668459853f4364a918946339a776e7b4d8542169",
        "sponsorName": "Epivax Inc"
      },
      {
        "sponsorId": "4a67621b1cdb93f9e5a800f34f028cee1e42d049",
        "sponsorName": "Pharmajet"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "DPX-COVID-19",
    "chemicalName": "",
    "conditionOrDisease": "Disease",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 18 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "Epitope based vaccine,Design of a Phase 1 clinical study in 48 healthy subjects completed,clinical sites identified in Nova Scotia and Quebec",
    "numSites": "",
    "otherPartners": "",
    "phase": "Discovery",
    "preferredName": "DPXCOVID19",
    "productId": 323,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "48214836aaae1d030dc63fd584ec75a89c69a299",
        "sponsorName": "IMV Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "IPT-001",
    "chemicalName": "peptide vaccine",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptide_vaccine",
    "productId": 324,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e307a242cd4a80ef8961828e2bd56978153ba4c4",
        "sponsorName": "Intellistem Technologies Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Polypeptide vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Polypeptide_vaccine",
    "productId": 325,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e01b4e370f661002ed37476bd661968f309a64db",
        "sponsorName": "Liaoning Chengda Biotechnology"
      },
      {
        "sponsorId": "bfce396095503d26f651c5dad224c79f44d87649",
        "sponsorName": "Tsinghua University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "peptide mini-scaffold",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "High-affinity peptide scaffold that blocks interactions of SARS-CoV-2 to ACE2 receptor",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "peptide_miniscaffold",
    "productId": 326,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4f3b270f3c1a96d8081041d6786e25d3ccc38629",
        "sponsorName": "Ligandal Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Taiwan"],
    "countryCodes": ["TWN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Institutes of Health",
    "phase": "",
    "preferredName": "Medigen_Biotechnology_Corp-327",
    "productId": 327,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c76c86ae23d07fd42bbc979f6877c5fb8af70eb6",
        "sponsorName": "Medigen Biotechnology Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "UK Government COVID-19 research funding package",
    "phase": "",
    "preferredName": "Mologic_Ltd-328",
    "productId": 328,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dd2867855c9bba29ec1a2f9db4b0e7896eb33b42",
        "sponsorName": "Mologic Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "NantKwest vaccine",
    "chemicalName": "second-generation AD5 platform",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Clinical trials expected to start this quarter",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "secondgeneration_AD5_platform",
    "productId": 329,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "13fabd5b14178a13d0539b59d6a9be0b068e4309",
        "sponsorName": "Nantkwest Inc"
      },
      {
        "sponsorId": "8bfec75fcf441b5e6dfde4d8556e152456e80321",
        "sponsorName": "Immunitybio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "University if Hawai'i at Manoa",
    "phase": "",
    "preferredName": "Soligenix_Inc-330",
    "productId": 330,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7795392453455f76046eb84a28aa370b14026e0c",
        "sponsorName": "Soligenix Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "S Protein Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "S_Protein_Vaccine",
    "productId": 331,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8badc8865679f144a1d2fbf604740245348ebc8e",
        "sponsorName": "US Army Medical Research and Development Command"
      },
      {
        "sponsorId": "5dfde89cd058e25942ead74f974aa75a0b3ed04c",
        "sponsorName": "Walter Reed Army Institute of Research"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "COVID-19 XWG-03",
    "chemicalName": "truncated S-protein",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Originally started being developed to treat HPV",
    "numSites": "",
    "otherPartners": "GlaxoSmithKline",
    "phase": "",
    "preferredName": "truncated_Sprotein",
    "productId": 332,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f3e18d1badc8e3e140a4e145313f20f56e471293",
        "sponsorName": "Xiamen Innovax Biotech Co Ltd"
      },
      {
        "sponsorId": "bf45296df9f69d118ce8ad2b5fd20dcd2bb45568",
        "sponsorName": "Xiamen University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "ZIP-1642",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Belgium"],
    "countryCodes": ["BEL"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ZIP1642",
    "productId": 333,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "12f2c56c2a8c8e754b73a3d0736ac5246e1fc2ca",
        "sponsorName": "Ziphius Therapeutics NV"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Ilaris",
    "chemicalName": "canakinumab",
    "conditionOrDisease": "COVID-19 Pneumonia",
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Not yet recruiting for observational study,Very limited information on Novartis website about using Ilaris for COVID,just listed as one of numerous drugs under investigation for people with COVID infection",
    "numSites": "",
    "otherPartners": "",
    "phase": "Observational",
    "preferredName": "canakinumab",
    "productId": 335,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b08c1310d27c7a8b020bed114122bccabe38726f",
        "sponsorName": "Novartis"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04348448"
  },
  {
    "brandName": "Gamifant",
    "chemicalName": "emapalumab",
    "conditionOrDisease": "Hyperinflammation and respiratory distress in COVID-19 patients",
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 02 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "4",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "emapalumab",
    "productId": 336,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Brescia",
        "country": "IT",
        "lat": 45.5564352,
        "lng": 10.2310468,
        "locationId": "7454f3b6413aea1564cc13f1ce144d1cb4744d47",
        "name": "Piazzale Spedali Civili, 1, 25123 Brescia BS, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Milano",
        "country": "IT",
        "lat": 45.458872,
        "lng": 9.1950515,
        "locationId": "0f8314bedf8e77cf002a383e52a5fe6dfbc04bf0",
        "name": "Via Francesco Sforza, 35, 20122 Milano MI, Italy",
        "state": "Lombardia"
      },
      {
        "city": "Parma",
        "country": "IT",
        "lat": 44.8016341,
        "lng": 10.3083481,
        "locationId": "05f14861197e3c28481e56d7ab7f3ac250852db3",
        "name": "Viale Antonio Gramsci, 14, 43126 Parma PR, Italy",
        "state": "Emilia-Romagna"
      },
      {
        "city": "Roma",
        "country": "IT",
        "lat": 41.866501,
        "lng": 12.4564793,
        "locationId": "b476a520d304a47f7672b31c820c755529c8331b",
        "name": "Via Portuense, 292, 00149 Roma RM, Italy",
        "state": "Lazio"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4be4dbabdaa77091d49b0c6b38bd5a8ef5b04a9d",
        "sponsorName": "Swedish Orphan Biovitrum Sobi"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04324021"
  },
  {
    "brandName": "Antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Crowdsourcing",
    "phase": "",
    "preferredName": "Antibody",
    "productId": 337,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9ceaf8fbcb1950d5b4df0acbe1671777bd9893a0",
        "sponsorName": "Distributed Bio"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "UK Government,University of Kent,Hong Kong University,National Institute for Biological Standards and Control",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 338,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a",
        "sponsorName": "Chelsea and Westminster Hospital"
      },
      {
        "sponsorId": "1a693dd5acf9f3ae07a65241da0b2f2102ed1377",
        "sponsorName": "Imperial College London"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Antibody Therapeutic Innovent Biologics",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibody_Therapeutic_Innovent_Biologics",
    "productId": 339,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d6b2121d955a97b23570b0c2284d3d758aca0355",
        "sponsorName": "Innovent Biologics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "recombinant chimeric monoclonal antibody",
    "chemicalName": "IC14",
    "conditionOrDisease": "COVID-19,ARDS",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Expanded access available",
    "numSites": "1",
    "otherPartners": "",
    "phase": "Expanded access",
    "preferredName": "IC14",
    "productId": 340,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Milano",
        "country": "IT",
        "lat": 45.5069106,
        "lng": 9.267293800000001,
        "locationId": "655899bd60ddf79c3176b723739e4eb370125ef9",
        "name": "Via Olgettina Milano, 58, 20132 Milano MI, Italy",
        "state": "Lombardia"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9676cb2db18bbea317e9ea9e591807187950be72",
        "sponsorName": "Implicit Bioscience"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04346277"
  },
  {
    "brandName": "Vicromax",
    "chemicalName": "merimepodib",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Submitted IND to FDA for Phase 2 trial for COVID-19 patients,Three Phase 2 trials completed in other idications,completed animal testing and phase 1 trials for other indications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "merimepodib",
    "productId": 341,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7f3751a18145834311154ab95bfefa71b80ad512",
        "sponsorName": "ViralClear Pharmaceuticals"
      },
      {
        "sponsorId": "0d1321a5cc1c5a48c7918152a67c04e65aaf4844",
        "sponsorName": "BioSig Technologies"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "ISR-50",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Sweden"],
    "countryCodes": ["SWE"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Hope to have animal testing done in 2nd quarter and human testing complete in 4th quarter",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ISR50",
    "productId": 342,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "987e067b08e440461ef8fc126e195d7d57d749c7",
        "sponsorName": "ISR Immune System Regulation"
      },
      {
        "sponsorId": "5dcd0fc710b300f98746062aff74be3806516be0",
        "sponsorName": "TCER AB"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "antiviral Fc conjugates",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Uses Antiviaral Fc Conjugates (AVCs)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "antiviral_Fc_conjugates",
    "productId": 343,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "124c17c54d9555bc7787cea6f6043207f25479ba",
        "sponsorName": "Cidara Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Antiviral combination",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "It is indicted that combinations of FDA-approved drugs will be teste but unknown as to which ones.",
    "numSites": "",
    "otherPartners": "European Union's Horizon 2020 program",
    "phase": "",
    "preferredName": "Antiviral_combination",
    "productId": 344,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3ca1363324c98b475983319168e4c05919716630",
        "sponsorName": "SCORE Consortium"
      },
      {
        "sponsorId": "8717ea76eb52afd496f981afcc95aa693b0fbbd9",
        "sponsorName": "Helmholtz Centre for Infection Research"
      },
      {
        "sponsorId": "da5d8fe85f181501e049f3e20e8e1e2e438b9267",
        "sponsorName": "Janssen Pharmaceutica NV"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Multistem",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "The Multistem cells express a range of therapeutically-relevant proteins that act like drugs,Planning to start Phase 2/3 Clinical Trial by 06/30/2020,Completed Phase 1/2 Clinical Trial on July 2019,Fast-Track Designation by the FDA",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Multistem",
    "productId": 345,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a3a12b6d931e87c4b8d0d2273853f647cf3c65f",
        "sponsorName": "Athersys"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Inhalded mRNA",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Switzerland", "Germany"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sat, 04 Jan 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Manufacturing intended to initiate summer 2020,Expected clinical testing in 4th quarter of 2020 pending regulatory approval",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inhalded_mRNA",
    "productId": 346,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1d194ed49d10f544c68a1c9d4116020692ba8b5b",
        "sponsorName": "Neurimmune"
      },
      {
        "sponsorId": "c6ddaeaa6ff1e400a4d8f29afd9415df2398bd02",
        "sponsorName": "Ethris"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Novaferon",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently licensed in China for treatment of Hepatitis B,Started recruiting for Phase 4 Clinical Trial(Hu'nan) for COVID-19 patients,Also in testing in another Phase 4 Clinical Trail (Zhejiang) for COVID-19 patients",
    "numSites": "2",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "Novaferon",
    "productId": 347,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Changsha",
        "country": "CN",
        "lat": 28.301619,
        "lng": 113.005226,
        "locationId": "5783c73de639b809a4fe58170e5c10627f2d6ad5",
        "name": "Kaifu District, Changsha, Changsha, Hunan, China",
        "state": "Hunan"
      },
      {
        "city": "Changsha Shi",
        "country": "CN",
        "lat": 28.187002,
        "lng": 112.993998,
        "locationId": "a78d08a3e64fec43f4e7ead21bafc5940cd823ac",
        "name": "139 Renmin Middle Rd, Yuan Jia Ling Shang Quan, Furong Qu, Changsha Shi, Hunan Sheng, China",
        "state": "Hunan Sheng"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "818e1de4129b2f52a53d8da808ff6c036588610d",
        "sponsorName": "The First Hospital of Changsha"
      },
      {
        "sponsorId": "815809b19bd18eae88cb00c73fd9f3bbc9764dd3",
        "sponsorName": "The Second Xiangya Hospital of Central South University"
      },
      {
        "sponsorId": "9e8c8e9d300f14660fbd928824d2e2e27fbba9ce",
        "sponsorName": "First Affiliated Hospital of Zhejiang University Medical School"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": "ChiCTR2000029496"
  },
  {
    "brandName": "BIO-11006",
    "chemicalName": "",
    "conditionOrDisease": "ARDS",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently tested in a pilot Phase 2a clinical trial",
    "numSites": "5",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "BIO11006",
    "productId": 348,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Chicago",
        "country": "US",
        "lat": 41.8952146,
        "lng": -87.623156,
        "locationId": "3ded62c65fb085990bdca56fed4ebbd648b0aa32",
        "name": "150 E Huron St #900, Chicago, IL 60611, USA",
        "state": "IL"
      },
      {
        "city": "Chapel Hill",
        "country": "US",
        "lat": 35.906058,
        "lng": -79.052199,
        "locationId": "f24002644a11eca58d124de450ee656372733e5a",
        "name": "321 S Columbia St, Chapel Hill, NC 27516, USA",
        "state": "NC"
      },
      {
        "city": "Winston-Salem",
        "country": "US",
        "lat": 36.1355052,
        "lng": -80.2791958,
        "locationId": "05b0d83fa8ae6ac124a5881d1c6ed8c7b2d1d6bd",
        "name": "1834 Wake Forest Rd, Winston-Salem, NC 27109, USA",
        "state": "NC"
      },
      {
        "city": "Philadelphia",
        "country": "US",
        "lat": 39.9522188,
        "lng": -75.1932137,
        "locationId": "ad927094ab25db2d502704333e9763096ac28b5d",
        "name": "Philadelphia, PA 19104, USA",
        "state": "PA"
      },
      {
        "city": "Nashville",
        "country": "US",
        "lat": 36.1447034,
        "lng": -86.8026551,
        "locationId": "4f6a99811ae80ab7239f49c8aad853f82250e1fa",
        "name": "2201 West End Ave, Nashville, TN 37235, USA",
        "state": "TN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ee0168c868efcb79c99cceb1ad9c4b367356e247",
        "sponsorName": "Biomarck Pharmaceuticals"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": "NCT03202394"
  },
  {
    "brandName": "Nafamostat",
    "chemicalName": "nafamostat mesylate",
    "conditionOrDisease": "COVID-19",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently recruiting for Phase 2/3 clinical trial in Padova-Italy,Set to start a unknown phase clinical trial at National Center for Global Health and Medicine in April 2020,Requested EUA from FDA with planned Phase 1/2 clinical trial in United States at unknown start time",
    "numSites": "",
    "otherPartners": "",
    "phase": "2/3",
    "preferredName": "nafamostat_mesylate",
    "productId": 349,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ab1e8ad3d379bcd134e4e3f47f828591f21bca7b",
        "sponsorName": "University of Tokyo"
      },
      {
        "sponsorId": "e5fd2e305fd3cf838a58fa49356e6a687de59229",
        "sponsorName": "Ensysce Biosciences"
      },
      {
        "sponsorId": "e22bdba3cbf2ef89fffeee543c2f866f142cd77f",
        "sponsorName": "National Center for Global Health Medicine"
      },
      {
        "sponsorId": "fee8ee418bcb93a56059c6670596e6c18214fd42",
        "sponsorName": "University Hospital Padova"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": "NCT04352400"
  },
  {
    "brandName": "Activase",
    "chemicalName": "alteplase",
    "conditionOrDisease": "ARDS",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "FDA-approved for treating blood clots but currently in Phase 2 clinical trial for COVID-19 patients,Therapeutic Approach is human tissue plasminogen activator",
    "numSites": "3",
    "otherPartners": "National Institutes of Health,Department of Defense Peer Reviewed Medical Research Program",
    "phase": "2",
    "preferredName": "alteplase",
    "productId": 350,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Aurora",
        "country": "US",
        "lat": 39.7452818,
        "lng": -104.8375727,
        "locationId": "12756911f50195bb7418b44a189561726477a9c2",
        "name": "13001 East 17th Place Mail Stop F413 Room CG001, Aurora, CO 80045, USA",
        "state": "CO"
      },
      {
        "city": "Denver",
        "country": "US",
        "lat": 39.7282404,
        "lng": -104.9910801,
        "locationId": "6fcfcdcd0442efcaa322ddd739b6f58ab263192a",
        "name": "777 Bannock St, Denver, CO 80204, USA",
        "state": "CO"
      },
      {
        "city": "Boston",
        "country": "US",
        "lat": 42.3397365,
        "lng": -71.1049051,
        "locationId": "95e7b888ba70d981ca80c45fca326749de364dbe",
        "name": "330 Brookline Ave, Boston, MA 02215, USA",
        "state": "MA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b03aa77c14c56ff5b4f5d3426dfb679c28ea44f9",
        "sponsorName": "Beth Israel Deaconess"
      },
      {
        "sponsorId": "4c60ee4e3a2c0a8b5e660916048f460f70033ae3",
        "sponsorName": "University of Colorado Anschultz Medical Campus"
      },
      {
        "sponsorId": "aeb9a00ace7546f0b60499cf3dd4a85be50b4e0d",
        "sponsorName": "Denver Health"
      },
      {
        "sponsorId": "3ef65938333d443798d2043926bf988ac4c3c305",
        "sponsorName": "Genentech"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04357730"
  },
  {
    "brandName": "Kineret",
    "chemicalName": "anakinra",
    "conditionOrDisease": "COVID-19",
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Currently testing in Phase 4 clinical trial named REMAP-CAP that was updated to include a sub-platform  REMAP-COVID for COVID-19 patients,Also testing in numerous other Phase 2/3 clinical trials",
    "numSites": "89",
    "otherPartners": "",
    "phase": "4",
    "preferredName": "anakinra",
    "productId": 351,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "AU",
        "lat": -25.274398,
        "lng": 133.775136,
        "locationId": "4fada7b91c419d193a8fa223f8f27d9a3a93d622",
        "name": "Australia",
        "state": null
      },
      {
        "city": null,
        "country": "BE",
        "lat": 50.503887,
        "lng": 4.469936,
        "locationId": "584f77a50f8c7760f739cb91bd26d1a22ba61b2e",
        "name": "Belgium",
        "state": null
      },
      {
        "city": null,
        "country": "CA",
        "lat": 56.130366,
        "lng": -106.346771,
        "locationId": "fb7322a1145eaf464eada95a7c447409200adc79",
        "name": "Canada",
        "state": null
      },
      {
        "city": null,
        "country": "HR",
        "lat": 45.1,
        "lng": 15.2000001,
        "locationId": "687e0166255006a0215e07794cbc6b6da55da270",
        "name": "Croatia",
        "state": null
      },
      {
        "city": null,
        "country": "DE",
        "lat": 51.165691,
        "lng": 10.451526,
        "locationId": "a7a788c0f42b874dd5d2fdc7b7ce30ec81fb8aea",
        "name": "Germany",
        "state": null
      },
      {
        "city": null,
        "country": "HU",
        "lat": 47.162494,
        "lng": 19.5033041,
        "locationId": "94559f4441ed1035a8d682d29b5b99c965d4ad77",
        "name": "Hungary",
        "state": null
      },
      {
        "city": null,
        "country": null,
        "lat": 53.1423672,
        "lng": -7.692053599999999,
        "locationId": "f2d20a969b6eb76f95053ebbc07d204dc8a0038e",
        "name": "Ireland",
        "state": null
      },
      {
        "city": null,
        "country": "NL",
        "lat": 52.132633,
        "lng": 5.291265999999999,
        "locationId": "968c0aee2bd1935956363f429c61763da85c8cb7",
        "name": "Netherlands",
        "state": null
      },
      {
        "city": null,
        "country": "NZ",
        "lat": -40.900557,
        "lng": 174.885971,
        "locationId": "0238cd2f2ba16d7d82d2483077be7b3cc597c8c3",
        "name": "New Zealand",
        "state": null
      },
      {
        "city": null,
        "country": "PT",
        "lat": 39.39987199999999,
        "lng": -8.224454,
        "locationId": "df9d81da15ed33ce2ddf55fb63db71c10dfcb206",
        "name": "Portugal",
        "state": null
      },
      {
        "city": null,
        "country": "RO",
        "lat": 45.943161,
        "lng": 24.96676,
        "locationId": "8c080a2ca9b4c13af788e67ced4dcf88b13834d8",
        "name": "Romania",
        "state": null
      },
      {
        "city": null,
        "country": "ES",
        "lat": 40.46366700000001,
        "lng": -3.74922,
        "locationId": "c1ea8a5ce4f1f072370cd02c436997b8aadb7b48",
        "name": "Spain",
        "state": null
      },
      {
        "city": null,
        "country": "GB",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "08e4bb5cebaa171db5a19495b3ef298ef8cfd40c",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "584eb38a0c9689f77c37d2ae76a472d221834c3c",
        "sponsorName": "Swedish Orphan Biovitrum"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT02735707"
  },
  {
    "brandName": "PP-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Drug has just completed a Phase 2 clinical trial for treatment of severe eye disesases,Article states that clinical trials for COVID-19 could begin shortly.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PP001",
    "productId": 352,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d84536309abcf2b1a75abfa06c2300e2a5917cb8",
        "sponsorName": "Panoptes Pharma GmbH"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Xeljanz",
    "chemicalName": "tofacitinib",
    "conditionOrDisease": "Pneumonia",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "FDA approved to treat arthritis and colitis,Currently testing in Phase 2 clinical trial for COVID-19 related pneuomia",
    "numSites": "1",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "tofacitinib",
    "productId": 353,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Torrette, Ancona",
        "country": "IT",
        "lat": 43.6026491,
        "lng": 13.4538759,
        "locationId": "c2a1b598b9c29311a59731177dcd0bdcddbd9dcf",
        "name": "Via Conca, 71, 60030 Torrette, Ancona AN, Italy",
        "state": "Marche"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "531d5b28f1f18f219741627c0f2a1e09d355e46a",
        "sponsorName": "Pfizer"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": "NCT04332042"
  },
  {
    "brandName": "BLD-2660",
    "chemicalName": "",
    "conditionOrDisease": "Sars-CoV2",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Caplain (protease) inhibitor,used to be a drug to treat fibrosis",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "BLD2660",
    "productId": 354,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "89667736796d6828f9626bcd8b0fbb2b3f0c30ba",
        "sponsorName": "Blade Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": "NCT04334460"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "",
    "milestones": [],
    "moleculeType": "",
    "notes": "this consortium includes many different groups that are making different drugs,one main group involved is AdaptVac (line 79)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PREVENTnCoV_consortium-355",
    "productId": 355,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "af0e9043938d3ffd18d4aa4f263c303abe7a87c1",
        "sponsorName": "PREVENTnCoV consortium"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["India"],
    "countryCodes": ["IND"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Biological_E_Ltd-356",
    "productId": 356,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "18d359f3a6a2fc44b7f04abc4ab8baad62117955",
        "sponsorName": "Biological E Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaxine_Pty_Ltd_Flinders_University-357",
    "productId": 357,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b103c316060fe38a9bb6cb32740cba7009ff4993",
        "sponsorName": "Vaxine Pty Ltd"
      },
      {
        "sponsorId": "5b15122e16efd5040af4ad925335499c22697ac0",
        "sponsorName": "Flinders University"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "University_of_Cambridge_DIOSynVax-358",
    "productId": 358,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "83c94185cc09e66de46b286461805b6666ee47e1",
        "sponsorName": "University of Cambridge"
      },
      {
        "sponsorId": "7d21b3cf2e2c033e713858c5883640d91677f72e",
        "sponsorName": "DIOSynVax"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Russia"],
    "countryCodes": ["RUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "St_Petersburg_Scientific_Research_Institute_of_Vaccines_and_Serums-359",
    "productId": 359,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1c450dbef9738d9b66fe108c2438eedf9206b820",
        "sponsorName": "St Petersburg Scientific Research Institute of Vaccines and Serums"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "in collaboration with the National Research Council of Canada (NRC),advances on VBI's enveloped virus-like particle vaccines (eVLP vaccines)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VBI_Vaccines-360",
    "productId": 360,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ccba56f09bfbe72461df11aa67398b87f33bc6a5",
        "sponsorName": "VBI Vaccines"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Russia"],
    "countryCodes": ["RUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BIOCAD_IEM-361",
    "productId": 361,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7a849d71160735d95f7cfb3ca259e2bb33ed4fb8",
        "sponsorName": "BIOCAD"
      },
      {
        "sponsorId": "05fc10448e3ccf081b100a8e2f7113e804fec492",
        "sponsorName": "IEM"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "intends to help lower the cost for producing vaccines for Covid-19",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IAVI_Batavia-362",
    "productId": 362,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "44d1bb59e8c48cd0b43da165d6d9606f2583b5fe",
        "sponsorName": "IAVI"
      },
      {
        "sponsorId": "f2e8788350358421b65552cc2679a931104ad1ab",
        "sponsorName": "Batavia"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Has been able to induce high levels of antibodies within a week in animals",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Saiba_GmbH-363",
    "productId": 363,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a558e81d8b75a91096450dac109735d6cb004a49",
        "sponsorName": "Saiba GmbH"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Vaccines require no refrigeration",
    "numSites": "",
    "otherPartners": "University of Bristol's Emergency Research Group",
    "phase": "",
    "preferredName": "Imophoron_Ltd_University_of_Bristol-364",
    "productId": 364,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "47418e382f699611afcc07ba422a212ac3cd258e",
        "sponsorName": "Imophoron Ltd"
      },
      {
        "sponsorId": "2142575a70dd242d662f1604a63d59f331c865ae",
        "sponsorName": "University of Bristol"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "PRTX-007",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Tue, 31 Mar 2020 00:00:00 GMT",
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Activates TLR7 to stimulate innate immune system",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PRTX007",
    "productId": 365,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "59184ad543e6f439787b2e2ac1527ea53b1e5ac1",
        "sponsorName": "Primmune Therapeutics"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "AB00-1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Acts on ACE-2 to inhibit the entry of the virus into the cell and workds on NSP15 to prevent its replication,Intends to begin human clinical trials this year",
    "numSites": "",
    "otherPartners": "",
    "phase": "Pre-Clinical",
    "preferredName": "AB001",
    "productId": 366,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "939b55ffb6ce9f4b830c8776c83f2f2116fd16d3",
        "sponsorName": "Agastiya Biotech LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Ultomiris",
    "chemicalName": "ravulizumab-cwvz",
    "conditionOrDisease": "COVID 19 Severe Pneumonia,Acute Lung Injury,or Acute Respiratory Distress Syndrome",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "A terminal complement inhibitor of C5",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "ravulizumabcwvz",
    "productId": 367,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "41794d8c7643f99fc7895546d19147d1b41daf20",
        "sponsorName": "Alexion Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": "NCT04369469"
  },
  {
    "brandName": "Metablok",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "LSALT Peptide",
    "notes": "The primary endpoint is to prevent acute respiratory distress syndrome in patients infected with COVID19,DPEP-1 inhibitor treating inflammation in the lungs liver and kidneys",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Metablok",
    "productId": 368,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6ae7877eca7b978170ddee9d611fbce51b4868f7",
        "sponsorName": "Arch Biopartners Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT03772678"
  },
  {
    "brandName": "MEDI-3506",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["https://www.astrazeneca.com/"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Targeting Interluekin 33",
    "numSites": "",
    "otherPartners": "Medimmune,ACCORd",
    "phase": "",
    "preferredName": "MEDI3506",
    "productId": 369,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e4db405906dfdb58ac2ee1ccf9877fc1ad52116d",
        "sponsorName": "Aztrazeneca plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Farxiga",
    "chemicalName": "dapagliflozin",
    "conditionOrDisease": "COVID19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 43,
        "name": "phase_3",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "A sodium glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2,currently recruiting,estimated completion date October 2020",
    "numSites": "1",
    "otherPartners": "Saint Luke's Health System,AstraZeneca,George Clinical Pty Ltd",
    "phase": "3",
    "preferredName": "dapagliflozin",
    "productId": 370,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "KCMO",
        "country": "US",
        "lat": 39.0476518,
        "lng": -94.59045540000001,
        "locationId": "49ad2cb7ae57c545cba00ddfb4b709fed2847707",
        "name": "4401 Wornall Rd, Kansas City, MO 64111, USA",
        "state": "MO"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e4db405906dfdb58ac2ee1ccf9877fc1ad52116d",
        "sponsorName": "Aztrazeneca plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "",
    "trialId": "NCT04350593"
  },
  {
    "brandName": "IgM Antibodies,IgA Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [
      "Atreca - United States",
      "BeiGene-China",
      "IGMBiosciences - United States"
    ],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Idenitfying the sequeneces of antibodies made by B cells found in blood from acutely infected COVID-19 patients and engineering IgM and IgA antibodies (from the identified sequence) with greater binding power per antibody.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "IgM_Antibodies_IgA_Antibodies",
    "productId": 371,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "300c03c87517131e06a725327908570fd8798f8b",
        "sponsorName": "Atreca Inc"
      },
      {
        "sponsorId": "5a19a0834e482d0229a397f62492ab8dfcd271d9",
        "sponsorName": "Beigene Ltd"
      },
      {
        "sponsorId": "4852c490222a54deb2d41b655f588096c92cb6ad",
        "sponsorName": "IGM Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Audax_Medical_Inc-372",
    "productId": 372,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "06fe14bef7ae50a2f1a152d1eba019ce4b0b33bf",
        "sponsorName": "Audax Medical Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Bemcentinib",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["Norway"],
    "countryCodes": ["NOR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Department of Health and Social Care (DHSC),UK Research and Innovation (UKRI)",
    "phase": "2",
    "preferredName": "Bemcentinib",
    "productId": 373,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e99b1e4fd130967b98ec911ffe343851949fc17b",
        "sponsorName": "Bergenbio ASA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "COVID-19 treatments",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "AI company that helps identify drugs (Project Prodigy AI)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "COVID19_treatments",
    "productId": 374,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8ff2bf908543da634f6c955434fd59ba86816e6d",
        "sponsorName": "Biovista Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "CLBS-119",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Repairs lung damage",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CLBS119",
    "productId": 375,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "28d929d86c67592db08f4897b313d80028476e9e",
        "sponsorName": "Caladrius Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Dociparstat sodium",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Dociparstat_sodium",
    "productId": 376,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b205baf63638325039ee5a5cb8163c92032c7373",
        "sponsorName": "Chimerix Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Itanapraced",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Itanapraced",
    "productId": 377,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b3fae6fd4eeae1f99462dfff0a75d2eab3c4253a",
        "sponsorName": "Cerespir Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Niagen",
    "chemicalName": "nicotinamide riboside",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nicotinamide_riboside",
    "productId": 378,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e44b4742cbdb4c8802c4d11e460311b5195d0a43",
        "sponsorName": "Chromadex Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Pacritinib",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Pacritinib",
    "productId": 379,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9f40c9583b5968ab1adbdf1d8a099bc79d1c1c88",
        "sponsorName": "CTI Biopharma Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "CYC-065",
    "chemicalName": "Fadraciclib",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Edinburgh,LifeArc",
    "phase": "",
    "preferredName": "Fadraciclib",
    "productId": 380,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae",
        "sponsorName": "Cyclacel Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "CYC-202,R-roscovitine",
    "chemicalName": "Seliciclib",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "University of Edinburgh,LifeArc",
    "phase": "",
    "preferredName": "Seliciclib",
    "productId": 381,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "083cc5ab8a9ad04ea7d576a9f70799ae43c5aaae",
        "sponsorName": "Cyclacel Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "Ryanodex",
    "chemicalName": "dantrolene sodium",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Growth inhibitor by modulating free intracellular calcium levels in host cells",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "dantrolene_sodium",
    "productId": 382,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6bd89fd19b2baf31fb93f1a63de6b53953ee9577",
        "sponsorName": "Eagle Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "EB05 and EB06",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "NI-0101 and NI-0801 programs at lightchain bioscience work as TLR4 and CXCL10 antagonists respectively - being licensed to Edesa Biotech Inc",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "EB05_and_EB06",
    "productId": 383,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "df7336e82b3ee964918b55e0124c5c863386b59e",
        "sponsorName": "Edesa Biotech Inc"
      },
      {
        "sponsorId": "9898e6e8a31d2229ba186cbe74951fc0875a5ae1",
        "sponsorName": "Light Chain Bioscience"
      },
      {
        "sponsorId": "18504c03801e154a688184f061e282ba41d0c0e4",
        "sponsorName": "Novimmune SA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Zotatifin",
    "chemicalName": "eFT226",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Eukaryotic initiation factor 4A inhibitor which is used by the virus for replication",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "eFT226",
    "productId": 384,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d2b4445d416dbf8501b919b961f16cb45cf218d9",
        "sponsorName": "Effector Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Portugal and England"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 385,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "09467ddba3462cd3be13db3493e74a1cd13ee832",
        "sponsorName": "Fairjourney Biologics SA"
      },
      {
        "sponsorId": "e461e3fcff3dfbf264418228bb2872ec75a77d64",
        "sponsorName": "Iontas Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Northern Ireland"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Part of the Northern Ireland Coronavirus Antibody Development Alliance (\u201cNICADA\u201d)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 386,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4c15e115bbf73c231a08f5b902eca1c36dbc7fe1",
        "sponsorName": "Fusion Antibodies plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Company is using its proprietary humanized mice called Advanced peripheral blood Hematopoietic Chimera",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 387,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3f5e70ee0770a61cea95a52724b629ed752e8d50",
        "sponsorName": "Hemogenyx Pharmaceuticals plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "IMU-838",
    "chemicalName": "vidofludimus calcium",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Inhibitor of dihydroorotate dehydrogenase- an enzyme of pyrimidine de novo biosynthesis",
    "numSites": "",
    "otherPartners": "",
    "phase": "2/3",
    "preferredName": "vidofludimus_calcium",
    "productId": 388,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8ebeaa89bdf967acb860530de89f2bf521947797",
        "sponsorName": "Immunic Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": "NCT04379271"
  },
  {
    "brandName": "Xpro-1595 ",
    "chemicalName": "dominant-negative TNF Inhibitor",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Supposed to treat respiratory symptoms without being immunosuppressive-TNF has been linked to cytokine storm in COVID-19 patients",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "dominantnegative_TNF_Inhibitor",
    "productId": 389,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dab857f942f999776776bf0b8f3c12093bcdf582",
        "sponsorName": "Inmune Bio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04370236"
  },
  {
    "brandName": "Cannabidiol-loaded exosomes",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Aim is to use exosome as a targeted delivery sytem to release cannabidiol into the lungs for anti-inflammatory effects",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cannabidiolloaded_exosomes",
    "productId": 390,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f5509fdc8d977098de524cfe1324119bca44d958",
        "sponsorName": "Innocan Pharma Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "INS-1007",
    "chemicalName": "Brensocatib",
    "conditionOrDisease": "COVID-19",
    "countries": ["Scotland"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Multi-center Investigator Initiated Trial,Drug is a Dipeptidyl Peptidase 1 inhibitor which ultimately aims to reduce neutrophil-mediated damage via serine proteases in the lungs",
    "numSites": "10",
    "otherPartners": "Insmed Inc.",
    "phase": "3",
    "preferredName": "Brensocatib",
    "productId": 391,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": null,
        "country": "GB",
        "lat": 55.378051,
        "lng": -3.435973,
        "locationId": "1dfbeccbcffda32af4bca6ec7b3b4050b90c9e40",
        "name": "United Kingdom",
        "state": null
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3705775d63e9f24d20b5c6e4736f7f613881237f",
        "sponsorName": "University of Dundee"
      },
      {
        "sponsorId": "e97f167fe7a9cdf40d469f7fe1f8fc68fcce2030",
        "sponsorName": "Insmed Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "EudraCT # 2020-001643-13"
  },
  {
    "brandName": "Sonlicromanol",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Netherlands"],
    "countryCodes": ["NLD"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently in Phase 2b clinical trial for mitochondrial diseases,Sponsor looking for partners to start trial in COVID-19 patients as of April 15th",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Sonlicromanol",
    "productId": 392,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "515553435142eb535852e295f3bd6c501327f36b",
        "sponsorName": "Khondrion BV"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "VAP-1 Inhibitors",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in Discovery Phase,Screening for novel VAP-1 inhibitor compounds for inflammatory conditions",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VAP1_Inhibitors",
    "productId": 393,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e738bf6a692bdb6a103840a21c304833dc861452",
        "sponsorName": "Kubota Vision Inc"
      },
      {
        "sponsorId": "267bf8e98b940f881544a2ce9ccf3dca31f50926",
        "sponsorName": "Leo Pharma AS"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "XAV-19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": "Wed, 15 Apr 2020 00:00:00 GMT",
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Agreetment signed for first clinical batch of drug as of April 15th",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "XAV19",
    "productId": 394,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e051009634417c8e337feeb1e73c8c03b2ff106c",
        "sponsorName": "LFB SA"
      },
      {
        "sponsorId": "39f19090c785e55de80ad34b54bc88b1ea610d27",
        "sponsorName": "Kenothera SAS"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Carragelose Inhalation therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "Inhalation solution based on iota-carrageenan polymers derived from red seaweed with physical mode of action,Currently approved OTC in EU/Asia & other markets (non-US),Recieved funding for Phase 1 clinical trial and then a proof-of-concept study on viral pneumonia patients",
    "numSites": "",
    "otherPartners": "Austrian Research Promotion Agency",
    "phase": "",
    "preferredName": "Carragelose_Inhalation_therapy",
    "productId": 395,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b76c240d33285d07cee07c91c6542ec704092b3e",
        "sponsorName": "Marinomed Biotech AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": ""
  },
  {
    "brandName": "Antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Engineered trispecific antiviral proteins therapeutic that targets epitopes of viral spikeprotein needed for infection,Currently undergoing expedited preclinical testing for lead candidate,Target of manufactured drug product in Q3 2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antiviral",
    "productId": 396,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "156f730ad2e8e71aaec7362be122a0c821d51c14",
        "sponsorName": "Molecular Partners AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-antiretrovirals",
    "trialId": ""
  },
  {
    "brandName": "Veyonda",
    "chemicalName": "idronoxil",
    "conditionOrDisease": "",
    "countries": ["Austrialia"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently has IND approval as anti-cancer agent,Currently trying to get FDA approval to pursue clinical study for COVID-19 patients.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "idronoxil",
    "productId": 397,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "98fbd4c7c935e48e7246ffa9696377e27973373d",
        "sponsorName": "Noxopharm Co"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Peptides",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Ireland"],
    "countryCodes": ["IRL"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Curently using AI platform screen for peptide candidates (Takes 4-5 months)",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Peptides",
    "productId": 398,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "de93cb0c4a3bc024e5f42b0cf2117729b320a781",
        "sponsorName": "Nuritas Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "2X-121",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Denmark"],
    "countryCodes": ["DNK"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 24 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in Phase 2 clinical trial for ovarian cancer,Started pre-clinical testing at Northern Arizona University as of 04/24/2020",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "2X121",
    "productId": 399,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "7c3734e76aa183a3eb2e24a57c0009a112b44055",
        "sponsorName": "Oncology Ventures AS"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Foipan",
    "chemicalName": "Camostat mesylate",
    "conditionOrDisease": "COVID-19",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "Currently approved in Japan to treat pancreatic inflammation,Currently in Phase 2a clinical trial for COVID-19 patients,Anti-inflammatory properties and shown in vitro virus inhibitory ability",
    "numSites": "",
    "otherPartners": "",
    "phase": "2a",
    "preferredName": "Camostat_mesylate",
    "productId": 400,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4c42301126ac99d75b7be429df5e77830bc45d8b",
        "sponsorName": "Ono Pharmaceuticals Inc"
      },
      {
        "sponsorId": "3066c4c7f3115869a60b33c425a7528be9a6e3bf",
        "sponsorName": "Yale University"
      },
      {
        "sponsorId": "7024be22f1d029e9b85014aef3977d4a224b9e27",
        "sponsorName": "Liebniz Institute for Primate Research"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": "NCT04353284"
  },
  {
    "brandName": "Vafidemstat",
    "chemicalName": "",
    "conditionOrDisease": "ARDS",
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 27 Apr 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "Currently in a Phase 2 clinical trial",
    "numSites": "3",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "Vafidemstat",
    "productId": 401,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "54df2e1eb201b7a6fc15d098af3042d22ffa6dde",
        "sponsorName": "Oryzon Genomics SA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "EudraCT Number:\t2020-001618-39"
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "Mannin Research,Cyclica",
    "phase": "",
    "preferredName": "Q_Biomed_Inc_Mannin_Research-402",
    "productId": 402,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b275b8324ed9b360015738d5c52283b783d3e511",
        "sponsorName": "Q Biomed Inc"
      },
      {
        "sponsorId": "6369487c22ff53cc21139097558058341e98e631",
        "sponsorName": "Mannin Research"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "this is a dataset,not a therapy",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recursion_Pharmaceuticals_Inc-403",
    "productId": 403,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "11fe98d508be31415b00d71b9e4504f2beb1ee7a",
        "sponsorName": "Recursion Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "RTB-101",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "candidate is an inhibitor of target of rapamycin complex 1 (TORC-1)",
    "numSites": "",
    "otherPartners": "Restorbio stockholders will receive net proceeds from the commercialization",
    "phase": "",
    "preferredName": "RTB101",
    "productId": 404,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2afef1b9b3945cdfc232fc3cd9fc8ed8d184003f",
        "sponsorName": "Restorbio Inc"
      },
      {
        "sponsorId": "b284e0fd16c925a93e4f38c453f4c70e7636b223",
        "sponsorName": "Adicet Bio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "RT-001",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "RT-001 is a chemically stabilized fatty acid",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "RT001",
    "productId": 405,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "db62040470630e8a5c0d95e03ff88dcb0d440132",
        "sponsorName": "Retrotope Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "NT-300",
    "chemicalName": "Nitazoxanide",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 43,
        "name": "phase_3",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "3",
    "preferredName": "Nitazoxanide",
    "productId": 406,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1a4907ea590dbc75efbbb16b2e8f00a1c68f3cf6",
        "sponsorName": "Romark Laboratories LC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-broad spectrum",
    "trialId": "NCT04343248"
  },
  {
    "brandName": "olokizumab,RPH-104",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Russia", "United States"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "in phase 2/3",
    "numSites": "",
    "otherPartners": "",
    "phase": "2",
    "preferredName": "olokizumab_RPH104",
    "productId": 407,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "101d14f6d9ef50bd326177b2fd9683e6cfe02662",
        "sponsorName": "RPharm JSC"
      },
      {
        "sponsorId": "1e8c65f7ae6e1857da235f503ee96eecdfc212b5",
        "sponsorName": "Cromos Pharma LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Cocktail",
    "trialId": ""
  },
  {
    "brandName": "POL-6014",
    "chemicalName": "Ionodelestat",
    "conditionOrDisease": "",
    "countries": ["Switzerland"],
    "countryCodes": ["CHE"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Cold Spring Harbor Laboratory (CSHL)",
    "phase": "",
    "preferredName": "Ionodelestat",
    "productId": 408,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6e39bc194deb64616e841179d70de0e3e8f6e7ad",
        "sponsorName": "Santhera Pharmaceuticals Holding AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Antisense oligonucleotides",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "will be using Sarepta\u2019s RNA technology to identify the antisense oligonucleotides",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antisense_oligonucleotides",
    "productId": 409,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "318a3819bc03871596e0a772e1caa9643afd627c",
        "sponsorName": "Sarepta Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "",
    "numSites": "",
    "otherPartners": "Hokkaido University Research Center for Zoonosis Control",
    "phase": "",
    "preferredName": "Shionogi__Co_Ltd-410",
    "productId": 410,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "49af49978e8b9f02c1384c21ddd1c7526817f753",
        "sponsorName": "Shionogi  Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Unknown",
    "trialId": ""
  },
  {
    "brandName": "Cynarine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Other",
    "notes": "The company\u2019s artificial intelligence (AI)-based screening technology,SOMAIPRO,was used to discover the inhibitors of 3CL proteases",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Cynarine",
    "productId": 411,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "prexasertib",
    "conditionOrDisease": "",
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.",
    "numSites": "",
    "otherPartners": "Ewha Woman's University",
    "phase": "",
    "preferredName": "prexasertib",
    "productId": 412,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": ""
  },
  {
    "brandName": "Xerava",
    "chemicalName": "eravacycline",
    "conditionOrDisease": "",
    "countries": ["Spain"],
    "countryCodes": ["ESP"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 02 Feb 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "SOM Biotech used artificial intelligence (called SOMAIPRO) to find molecules that could act as inihibitors of 3CL which could potentially treat COVID-19. They are waiting on an IND before proceeding with Phase 1 Clinical Trials.",
    "numSites": "",
    "otherPartners": "Ewha Woman's University",
    "phase": "",
    "preferredName": "eravacycline",
    "productId": 413,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a10386ee1438edc352e3ecdce639f4e60b04794a",
        "sponsorName": "Som Biotech SL"
      },
      {
        "sponsorId": "83cfc31290e69df07985c4197a3d92ab4c6b2d1c",
        "sponsorName": "Tetraphase Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "Llama-derived antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Sysvax Inc. is investigating several different COVID-19 vaccine approaches.",
    "numSites": "",
    "otherPartners": "Quacell Biotechnology Co. LTD",
    "phase": "",
    "preferredName": "Llamaderived_antibodies",
    "productId": 414,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "94b9fb08c2b9a96fe640774a647230d6d7a7b34c",
        "sponsorName": "Sysvax Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "PPP-003",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Tetra BioPharma aims to have completed pre-clinical stuudies by fall of 2020 and begin human clinical trials in Montreal.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PPP003",
    "productId": 415,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d64052c9fc506bd796cd3404142772d1197adf54",
        "sponsorName": "Tetra BioPharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Allorx stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Cell therapies",
    "notes": "Vitro Biopharma has submitted an IND application and is waiting on results before beginning Phase I human clinical trials.",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Allorx_stem_cells",
    "productId": 416,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2a124d615112a39893fb8a499cdb57c08486b0e4",
        "sponsorName": "Vitro Diagnostics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "VBI-S",
    "chemicalName": "",
    "conditionOrDisease": "Hypotension in Hypovolemic Septic Shock",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Sat, 01 Feb 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "VBI-S aims to lower blood pressure and oxygenation from septic shock,which is a common cause of death in COVID patients",
    "numSites": "1",
    "otherPartners": "Ascendia Pharmaceuticals",
    "phase": "2a",
    "preferredName": "VBIS",
    "productId": 417,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Fort Wayne",
        "country": "US",
        "lat": 41.079273,
        "lng": -85.1393513,
        "locationId": "af38cd886bb79815557edc95f46dd32d9868e195",
        "name": "Fort Wayne, IN, USA",
        "state": "IN"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96b4ec30be2b8b138d6a097ca033241b0479fed5",
        "sponsorName": "Vivacelle Bio Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": "NCT04257136"
  },
  {
    "brandName": "Vyripharm Biopharmaceuticals LLC therapeutic",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "The drug will combine anti-viral and anti-CB1 antagonist analogues for nuclear medicine imaging applications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vyripharm_Biopharmaceuticals_LLC_therapeutic",
    "productId": 418,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "078da56adc71e2a029154078183324f8f351e10a",
        "sponsorName": "Vyripharm Biopharmaceuticals LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Mesencure",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Israel"],
    "countryCodes": ["ISR"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 19 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "BONUS BioGroup",
    "phase": "",
    "preferredName": "Mesencure",
    "productId": 419,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "21fffcbea9a29011a432f5076a9bf80e04b86566",
        "sponsorName": "Wize Pharma Inc"
      },
      {
        "sponsorId": "33a0699dc37b7638ed3184d943514267306a6b62",
        "sponsorName": "Bonus Biogroup Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "Knockdown Coronavirus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 06 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Knockdown_Coronavirus",
    "productId": 450,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cd1a1a7e1700bd67f76dbb0979cfb550367890c2",
        "sponsorName": "Aum Lifetech Inc"
      },
      {
        "sponsorId": "2f3a07259231f646a8c98cf47cd635cd2837ff4e",
        "sponsorName": "Aum Biotech LLC"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "MAPS vaccine",
    "chemicalName": "",
    "conditionOrDisease": "Pneumococcal Disease",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Pneumonia",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "27",
    "otherPartners": "Astellas Pharma Inc.",
    "phase": "2",
    "preferredName": "MAPS_vaccine",
    "productId": 420,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Banning",
        "country": "US",
        "lat": 33.9305885,
        "lng": -116.9454506,
        "locationId": "f8b323cbd44a05f8701cd5db52011decfb17d22e",
        "name": "264 N Highland Springs Ave #4, Banning, CA 92220, USA",
        "state": "CA"
      },
      {
        "city": "San Diego",
        "country": "US",
        "lat": 32.7503742,
        "lng": -117.1577202,
        "locationId": "be35f8dd442b54efab76712346ca909c2dbb0ce1",
        "name": "770 Washington St STE 300, San Diego, CA 92103, USA",
        "state": "CA"
      },
      {
        "city": "San Marcos",
        "country": "US",
        "lat": 33.1414326,
        "lng": -117.2022196,
        "locationId": "3a71ba9196aaf8256f5a7672f8970bf828e909e9",
        "name": "365 S Rancho Santa Fe Rd #202, San Marcos, CA 92078, USA",
        "state": "CA"
      },
      {
        "city": "Hollywood",
        "country": "US",
        "lat": 26.03195,
        "lng": -80.23431,
        "locationId": "5cc3566aac236f219e42069d2f63eec0639b556a",
        "name": "7261 Sheridan St #210, Hollywood, FL 33024, USA",
        "state": "FL"
      },
      {
        "city": "Stockbridge",
        "country": "US",
        "lat": 33.5055533,
        "lng": -84.2252365,
        "locationId": "eba14c1fc38417d88c176df9ad6fdc6841c87e00",
        "name": "175 Country Club Dr # 100A, Stockbridge, GA 30281, USA",
        "state": "GA"
      },
      {
        "city": "Savannah",
        "country": "US",
        "lat": 32.0090943,
        "lng": -81.1066159,
        "locationId": "91ab378e919c753ff2b8d575ac41919509e2d96c",
        "name": "340 Eisenhower Dr Suite #1200, Savannah, GA 31406, USA",
        "state": "GA"
      },
      {
        "city": "St. Louis",
        "country": "US",
        "lat": 38.6685688,
        "lng": -90.4389032,
        "locationId": "0bf1887b87df3f8e683f9fbcb1f4610f64fbe057",
        "name": "711 Old Ballas Rd # 105, St. Louis, MO 63141, USA",
        "state": "MO"
      },
      {
        "city": "Norfolk",
        "country": "US",
        "lat": 42.0488645,
        "lng": -97.4258863,
        "locationId": "a3962b452984309448f8d21c3458f5f5e87a146d",
        "name": "1410 N 13th St, Norfolk, NE 68701, USA",
        "state": "NE"
      },
      {
        "city": "Binghamton",
        "country": "US",
        "lat": 42.083712,
        "lng": -75.91614299999999,
        "locationId": "b4702ed7805d9d74485c488f58693d7944eff633",
        "name": "93 Pennsylvania Ave, Binghamton, NY 13903, USA",
        "state": "NY"
      },
      {
        "city": "Hickory",
        "country": "US",
        "lat": 35.750034,
        "lng": -81.34101570000001,
        "locationId": "22e3b9876650720d8fddefd168bfd769ab73d4e7",
        "name": "221 13th Ave Pl NW Suite 201, Hickory, NC 28601, USA",
        "state": "NC"
      },
      {
        "city": "Rocky Mount",
        "country": "US",
        "lat": 35.9382655,
        "lng": -77.7905826,
        "locationId": "099924b7a335fb07f1df9bc86cb68163e4324345",
        "name": "Rocky Mount, NC 27801, USA",
        "state": "NC"
      },
      {
        "city": "Atlanta",
        "country": "US",
        "lat": 33.8190689,
        "lng": -84.4361114,
        "locationId": "e80e072fa15663c9b1cd8f8d15d7286c3364030d",
        "name": "Atlanta, GA 30318, USA",
        "state": "GA"
      },
      {
        "city": "Statesville",
        "country": "US",
        "lat": 35.7979554,
        "lng": -80.8827969,
        "locationId": "b4e3fffa7c11f26e5980c5d12717b0eb58a6a20c",
        "name": "646 Hartness Rd, Statesville, NC 28677, USA",
        "state": "NC"
      },
      {
        "city": "Wilmington",
        "country": "US",
        "lat": 34.202131,
        "lng": -77.929341,
        "locationId": "d734040347b0e58a3c63f2a8c422ad4d383db36f",
        "name": "1202 Medical Center Dr, Wilmington, NC 28403, USA",
        "state": "NC"
      },
      {
        "city": "Winston-Salem",
        "country": "US",
        "lat": 36.077044,
        "lng": -80.2952708,
        "locationId": "2d1fde815cfe6dd7f3c33e40fca36766d2c3abee",
        "name": "1901 S Hawthorne Rd #306, Winston-Salem, NC 27103, USA",
        "state": "NC"
      },
      {
        "city": "Winston-Salem",
        "country": "US",
        "lat": 36.0907016,
        "lng": -80.30947979999999,
        "locationId": "c6b455483d79697e2ff4dafecfbdc1767e88226c",
        "name": "4400 Silas Creek Pkwy #300, Winston-Salem, NC 27104, USA",
        "state": "NC"
      },
      {
        "city": "Yukon",
        "country": "US",
        "lat": 35.5067215,
        "lng": -97.76254410000001,
        "locationId": "382faf083521a45baa14daddfa7f3f9ae86bf9d4",
        "name": "Yukon, OK, USA",
        "state": "OK"
      },
      {
        "city": "Knoxville",
        "country": "US",
        "lat": 36.0022871,
        "lng": -83.9836662,
        "locationId": "2ba051387bf8ade65bfc21d0142df7de8cea952e",
        "name": "1200 Merchant Dr, Knoxville, TN 37912, USA",
        "state": "TN"
      },
      {
        "city": "Cedar Park",
        "country": "US",
        "lat": 30.505198,
        "lng": -97.8202888,
        "locationId": "88721b2a9543967c4986b5b250f7769f15424887",
        "name": "Cedar Park, TX, USA",
        "state": "TX"
      },
      {
        "city": "Irving",
        "country": "US",
        "lat": 32.8361738,
        "lng": -96.9544488,
        "locationId": "1ef74765ef970917bd187ac06efa459cd05c4586",
        "name": "800 W Airport Fwy #810, Irving, TX 75062, USA",
        "state": "TX"
      },
      {
        "city": "Fort Worth",
        "country": "US",
        "lat": 32.751388,
        "lng": -97.33066,
        "locationId": "fb4be15c29fc4dec33d56cca028f795b9ee37491",
        "name": "209 W 8th St, Fort Worth, TX 76102, USA",
        "state": "TX"
      },
      {
        "city": "Fort Worth",
        "country": "US",
        "lat": 32.8222237,
        "lng": -97.4190954,
        "locationId": "ff91990d178383e27d66611fbb448b23e7ad4aef",
        "name": "4504 Boat Club Rd #400a, Fort Worth, TX 76135, USA",
        "state": "TX"
      },
      {
        "city": "Houston",
        "country": "US",
        "lat": 29.7098598,
        "lng": -95.4746682,
        "locationId": "60a7a7bc86dbf2995105ca78c8280127aeb4759d",
        "name": "6550 Mapleridge St #201, Houston, TX 77081, USA",
        "state": "TX"
      },
      {
        "city": "McKinney",
        "country": "US",
        "lat": 33.1317376,
        "lng": -96.7171669,
        "locationId": "5ad39ae9614775dc2837f59d3521f2e086222ccf",
        "name": "8080 TX-121 Suite 300, McKinney, TX 75070, USA",
        "state": "TX"
      },
      {
        "city": "Tomball",
        "country": "US",
        "lat": 30.0849793,
        "lng": -95.6235351,
        "locationId": "96a6307f88000221b59b995101527d8e2c756769",
        "name": "13406 Medical Complex Dr Suite 53, Tomball, TX 77375, USA",
        "state": "TX"
      },
      {
        "city": "San Angelo",
        "country": "US",
        "lat": 31.4165254,
        "lng": -100.4703926,
        "locationId": "22b9d53600f0e4d083fbd42baab2fe49d442394e",
        "name": "3605 Executive Dr, San Angelo, TX 76904, USA",
        "state": "TX"
      },
      {
        "city": "San Antonio",
        "country": "US",
        "lat": 29.5073566,
        "lng": -98.56287379999999,
        "locationId": "161a065b07ba72fbca3b02f31c157e938f380cf6",
        "name": "5430 Fredericksburg Rd Ste 200, San Antonio, TX 78229, USA",
        "state": "TX"
      },
      {
        "city": "Tomball",
        "country": "US",
        "lat": 30.0866695,
        "lng": -95.6264094,
        "locationId": "37aabd3ef7452a4a4862e948b622ae654447c9dc",
        "name": "710 Lawrence St, Tomball, TX 77375, USA",
        "state": "TX"
      },
      {
        "city": "Norfolk",
        "country": "US",
        "lat": 36.8507689,
        "lng": -76.28587259999999,
        "locationId": "7d8175029a8bca7f199b29375946f51e6ced6500",
        "name": "Norfolk, VA, USA",
        "state": "VA"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d4c4eaf123ba9a0ed44f528ea27f445b3ebffc82",
        "sponsorName": "Affinivax Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT03803202"
  },
  {
    "brandName": "Chimigen vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "Akshaya's Chimigen vaccine platform is being reappropriated for COVID-19 in combination with Cytovance's GMP insect cell microbial manufacturing platform",
    "numSites": "",
    "otherPartners": "Cytovance Biologics",
    "phase": "",
    "preferredName": "Chimigen_vaccine",
    "productId": 421,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8f43d7087cc0c2a8d9687603029d4f8c7c3e6446",
        "sponsorName": "Akshaya Bio Inc"
      },
      {
        "sponsorId": "66f07a8584ac1fa31540d4786854faf6c4aa3957",
        "sponsorName": "Cytovance Biologics"
      },
      {
        "sponsorId": "979bfa8ba62f21bb1e1f2b82b0e6aeb823504607",
        "sponsorName": "Shenzhen Hepalink Pharmaceutical Group Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Brilacidin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "A defense Protein (HDP)/Defensin-Mimetic drug candidate previously being investigated for inflammatory bowel disease and oral mucositis and Acute Bacterial Skin and Skin Structure Infection,Has antiviral and immunomodulatory/anti-inflammatory and antimicrobial properties,Phase 2 trial completed for other indications",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Brilacidin",
    "productId": 422,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1d734ed76d96923533eb179ad68641d15e10b3a1",
        "sponsorName": "Innovation Pharmaceuticals Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "PDS02023",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 01 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Unknown",
    "notes": "Leveraging existing Versamune\u00ae platform",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PDS02023",
    "productId": 423,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e3a55329a850b005a641bf3bda030265211c6969",
        "sponsorName": "PDS Biotechnology Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Adenoviral vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Italy"],
    "countryCodes": ["ITA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Vaccine candidate expected to target the spike protein of SARS-CoV-2,Vaccine technology is based on a novel ReiThera-proprietary simian adenoviral vector with strong immunological potency and low pre-existing immunity in humans",
    "numSites": "",
    "otherPartners": "Leukocare AG,Univercells SA",
    "phase": "",
    "preferredName": "Adenoviral_vector_vaccine",
    "productId": 424,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b79c8bf08e2131d6f17af795021cda7e20aa3f7",
        "sponsorName": "Reithera Srl"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Unknown",
    "notes": "Candidate to target the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain of the spike (S) protein to generate both T cell responses and virus neutralizing antibodies",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_Vaccine",
    "productId": 425,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "092bd155058a125cab87c808b5adaf8207b382dd",
        "sponsorName": "Scancell Holdings plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Pathogen-specific aAPC",
    "chemicalName": "",
    "conditionOrDisease": "COVID 19",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes to the artificial antigen presenting cells",
    "numSites": "3",
    "otherPartners": "Shenzhen Third People's Hospital,Shenzhen Second People's Hospital",
    "phase": "1",
    "preferredName": "Pathogenspecific_aAPC",
    "productId": 426,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "36892fb1d881bf4eb83d3e08c9a4f8319cf53660",
        "sponsorName": "Shenzhen GenoImmune Medical Institute"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT04299724"
  },
  {
    "brandName": "OraPro-COVID-19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "It is a viral vectored adenovirus 5 containing the spike protein DNA from SARS-CoV-2,As of 04/30/2020 they announced successful completion of initial animal safety trials. Website says they'll soon be raising funds for clinical trials and manufacturing. Clinical trials are expected to start in June",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OraProCOVID19",
    "productId": 427,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d3558ec7487260af8eeda161f466322bb598e734",
        "sponsorName": "Stabilitech Biopharma Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Vivagel,SPL-7013",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "Uses dendrimers--not sure how to classify the molecule type,Repurposing the active ingredient (SPL7013) but would come up with new products/formulations for COVID-19 application",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vivagel_SPL7013",
    "productId": 428,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8d39bbb89598527ce93987da7ed5e69cefec828b",
        "sponsorName": "Starpharma Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "VLP Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["China"],
    "countryCodes": ["CHN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "Company is developing recombinant protein vaccine (detailed in this row) as well as a nanobody therapeutic and working to increase the half-life of COVID treatments,CEO says he expects vaccine will be IND-ready in the end of 2020 or early 2021",
    "numSites": "",
    "otherPartners": "Quacell Biotechnology Co. Ltd.",
    "phase": "",
    "preferredName": "VLP_Vaccine",
    "productId": 429,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "94b9fb08c2b9a96fe640774a647230d6d7a7b34c",
        "sponsorName": "Sysvax Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Baculovirus Expression Vector System vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Sun, 01 Mar 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Japan Agency for Medical Research and Development (AMED)",
    "phase": "",
    "preferredName": "Baculovirus_Expression_Vector_System_vaccine",
    "productId": 430,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "85a7bc9d8e40313776bed1f5693ea229f6014f09",
        "sponsorName": "UMN Pharma Inc"
      },
      {
        "sponsorId": "49af49978e8b9f02c1384c21ddd1c7526817f753",
        "sponsorName": "Shionogi  Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Ixiaro",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Whole-pathogen vaccines",
    "notes": "I don't think they would be using Ixiaro --at least not as-is-- as a COVID vaccine -- change Product Name? Also why I left the New/Repurposed column blank",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ixiaro",
    "productId": 431,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "059f2a3d5a1e49d84849751adc693a806e10964c",
        "sponsorName": "Valneva SE"
      },
      {
        "sponsorId": "8e7b2da49f08d6b67425d83fea0307211169ec91",
        "sponsorName": "Dynavax Technologies Corp"
      }
    ],
    "status": "",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Pepticrad vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Finland"],
    "countryCodes": ["FIN"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Wed, 22 Apr 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "It seems to be focused on tumor immunity rather virus immunity",
    "numSites": "",
    "otherPartners": "Valo Therapeutics",
    "phase": "",
    "preferredName": "Pepticrad_vaccine",
    "productId": 432,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "647f2087ef04f50197602c4a93c8cd00e43f1216",
        "sponsorName": "Valo Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "brandName": "Vaxipatch vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Fri, 01 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "The product is a combination of a new COVID-19 vaccine and new delivery system",
    "numSites": "",
    "otherPartners": "Verndari,Inc.",
    "phase": "",
    "preferredName": "Vaxipatch_vaccine",
    "productId": 433,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d55c14eadb5f58261f7259e0d7eeaa8926742a23",
        "sponsorName": "Verndari Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Austria"],
    "countryCodes": ["AUT"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Viravaxx,Medical University of Vienna",
    "phase": "",
    "preferredName": "Viravaxx_AG-434",
    "productId": 434,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b49bbd5f20c2dcea7a6b4e32bbe73978f88a8fce",
        "sponsorName": "Viravaxx AG"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "Masitinib",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Mon, 04 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "AB Science SA",
    "phase": "Phase II",
    "preferredName": "Masitinib",
    "productId": 435,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": "Paris",
        "country": "FR",
        "lat": 48.86537389999999,
        "lng": 2.3010134,
        "locationId": "19b38f871d3c6172f8f33d184de519b6c79f0447",
        "name": "3 Avenue George V, 75008 Paris, France",
        "state": "IDF"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "789e5231b8f9ca65a7723cb16dd32889a34ed5bc",
        "sponsorName": "AB Science SA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Kinase inhibitors",
    "trialId": "2020-001635-27"
  },
  {
    "brandName": "MRx-4DP0004",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United Kingdom"],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Fri, 01 May 2020 00:00:00 GMT",
        "milestoneId": 42,
        "name": "phase_2",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "1",
    "otherPartners": "4D pharma plc",
    "phase": "Phase II",
    "preferredName": "MRx4DP0004",
    "productId": 436,
    "repurposed": "New",
    "siteLocations": [
      {
        "city": null,
        "country": "GB",
        "lat": 53.806631,
        "lng": -1.7966408,
        "locationId": "f88543f240bc8bc212273ef9dec5099f00d90423",
        "name": "Duckworth Ln, Bradford BD9 6RJ, UK",
        "state": "England"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "cc2e5994616b4b7838fad454261c03059f72adda",
        "sponsorName": "4D Pharma plc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": "NCT04363372"
  },
  {
    "brandName": "ATYR-1923",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 21 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "aTyr Pharma,Inc.",
    "phase": "",
    "preferredName": "ATYR1923",
    "productId": 437,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9fe0e590c2f59e3993488b50e1454cf4b33f89cc",
        "sponsorName": "Atyr Pharma Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "PH-94B",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "VistaGen Therapeutics",
    "phase": "",
    "preferredName": "PH94B",
    "productId": 438,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ed125bf42550b194df6aae1e7e4306bf089a81c5",
        "sponsorName": "Vistagen Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other",
    "trialId": ""
  },
  {
    "brandName": "Cymerus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Australia"],
    "countryCodes": ["AUS"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Fri, 08 May 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "Cynata Therapeutics",
    "phase": "",
    "preferredName": "Cymerus",
    "productId": 439,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e0209d6491b3ecdcf4e0f1ab73af91ca49a735f9",
        "sponsorName": "Cynata Therapeutics Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "7HP-349",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "Other",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": "Tue, 14 Apr 2020 00:00:00 GMT",
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "7 Hills Pharma",
    "phase": "",
    "preferredName": "7HP349",
    "productId": 440,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a3b71c8e66306bb94d3f940d89f1664a0561c909",
        "sponsorName": "7 Hills Pharma"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "brandName": "Plasma therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [
      "United States",
      "Japan",
      "Ukraine",
      "Netherlands",
      "South Korea"
    ],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "CoVIg-19 Plasma Alliance",
    "phase": "",
    "preferredName": "Plasma_therapy",
    "productId": 441,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4fb6f98d06346dfb8480801ffdeb277e7bf9a142",
        "sponsorName": "Adma Biologics Inc"
      },
      {
        "sponsorId": "d57dd60076a98933462c35466d4808237238cb98",
        "sponsorName": "Biopharma Plasma LLC"
      },
      {
        "sponsorId": "fb88543fd60aa16c3c184e6208739bc678ea7909",
        "sponsorName": "GC Pharma"
      },
      {
        "sponsorId": "fdcec5fc0acc497097b5595f555306625de122b3",
        "sponsorName": "Sanquin"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antibiotics and antiparasitics",
    "trialId": ""
  },
  {
    "brandName": "Ampligen",
    "chemicalName": "rintatolimod",
    "conditionOrDisease": "SARS Coronavirus 2 Infection,Malignant Neoplasm",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "1",
    "otherPartners": "",
    "phase": "1/2a",
    "preferredName": "rintatolimod",
    "productId": 442,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [
      {
        "city": "Buffalo",
        "country": "US",
        "lat": 42.8986822,
        "lng": -78.86464830000001,
        "locationId": "7cfb661a6da9171a906ca89f4b15f752ea117b53",
        "name": "665 Elm St, Buffalo, NY 14203, USA",
        "state": "NY"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a5d57560d2358d025ed56eb6ac56526d88680140",
        "sponsorName": "Aim Immunotech Inc"
      },
      {
        "sponsorId": "2e24540b50be00a931dccd241b0636b9266f04e9",
        "sponsorName": "GP Pharma SA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": "NCT04379518"
  },
  {
    "brandName": "NK1R,MSC",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "NK1R_MSC",
    "productId": 443,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c9db829f16ef51a61f3cd081ad98c89a77816915",
        "sponsorName": "Biocardia Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "CB-5064",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "ARDS",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 05 May 2020 00:00:00 GMT",
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CB5064",
    "productId": 444,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "afe0ce46a6b36052788fe265d4169a7e91f11c15",
        "sponsorName": "Cohbar Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Nonspecific anti-inflammatory and immunosuppressive drugs",
    "trialId": ""
  },
  {
    "brandName": "DW-2008",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["South Korea"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 42,
        "name": "phase_2",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Other",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DW2008",
    "productId": 445,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0ea71c946179e2be0e9be90836aebd96833546ef",
        "sponsorName": "Dongwha Pharmaceutical Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Antiviral drugs-not specified",
    "trialId": ""
  },
  {
    "brandName": "EDP-1815",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "EDP1815",
    "productId": 446,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f550d0dbaee63bc003995e8c7af74aca187e11a2",
        "sponsorName": "Evelo Biosciences Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Nucleic Acid Therapy",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nucleic_Acid_Therapy",
    "productId": 447,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "330a20d0af980a475ef093d65b4d4ea3e054756b",
        "sponsorName": "Aligos Therapeutics Inc"
      },
      {
        "sponsorId": "a23d124d39198914a13ff22112de76a68eaed76e",
        "sponsorName": "Luxna Biotech Co Ltd"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 448,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "acd14e0eb640e0edd21f95856232fcef09bac5ff",
        "sponsorName": "Amgen Inc"
      },
      {
        "sponsorId": "41e5fc673f8854b964c241d3e222a9d61b432222",
        "sponsorName": "Adaptive Biotechnologies Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Monoclonal antibodies",
    "trialId": ""
  },
  {
    "brandName": "Antiviral",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Therapeutic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Mon, 20 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Small molecule",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antiviral",
    "productId": 449,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "360810fb2f49838a5afb9da083af7b2c1effa9be",
        "sponsorName": "Anixa Bioscience Inc"
      },
      {
        "sponsorId": "a4ef2f5ab85094f28d88aa3073d73426d3009319",
        "sponsorName": "Ontochem GmbH"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Other antiviral drugs",
    "trialId": ""
  },
  {
    "brandName": "Recombinant vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Mexico"],
    "countryCodes": ["MEX"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "Laboratorios Liomont",
    "phase": "",
    "preferredName": "Recombinant_vaccine",
    "productId": 452,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ae65368e5dda7ac06191005363e4844d4740b0c1",
        "sponsorName": "Autonomous University of Mexico"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Mexico"],
    "countryCodes": ["MEX"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "National Council of Science and Technology",
    "phase": "",
    "preferredName": "Autonomous_University_of_Queretero-453",
    "productId": 453,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0bbca0d5754c5267ed051d9e9e225d44a2afcb2d",
        "sponsorName": "Autonomous University of Queretero"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "CpG 1018",
    "chemicalName": "",
    "conditionOrDisease": "COVID-19",
    "countries": ["United States", "China"],
    "countryCodes": [""],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 12,
        "name": "pre_clinical_studies",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": null,
        "milestoneId": 13,
        "name": "lead_selection",
        "status": "COMPLETED"
      },
      {
        "category": "manufacturing",
        "date": null,
        "milestoneId": 21,
        "name": "clinical_batch",
        "status": "COMPLETED"
      },
      {
        "category": "regulatory",
        "date": null,
        "milestoneId": 31,
        "name": "ind",
        "status": "COMPLETED"
      },
      {
        "category": "clinical_development",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 41,
        "name": "phase_1",
        "status": "COMPLETED"
      },
      {
        "category": "pre-clinical",
        "date": "Thu, 16 Apr 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Combination",
    "notes": "",
    "numSites": "1",
    "otherPartners": "Dynavax,Sinovac Biotech Ltd.",
    "phase": "Phase I",
    "preferredName": "CpG_1018",
    "productId": 454,
    "repurposed": "Repurposed-Approved",
    "siteLocations": [
      {
        "city": "Xuzhou",
        "country": "CN",
        "lat": 33.912597,
        "lng": 117.941563,
        "locationId": "47151f5272ba9c4d843a0c36b76b84bd48c9a026",
        "name": "Suining, Xuzhou, Jiangsu, China",
        "state": "Jiangsu"
      }
    ],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "8e7b2da49f08d6b67425d83fea0307211169ec91",
        "sponsorName": "Dynavax Technologies Corp"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": "NCT04352608"
  },
  {
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Japan"],
    "countryCodes": ["JPN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Nucleic acid based therapies/vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Daiichi Sankyo,University of Tokyo",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "productId": 455,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0bd3e0565493c03d25691fe59c64e75df50c6269",
        "sponsorName": "Daiichi Sankyo"
      },
      {
        "sponsorId": "ab1e8ad3d379bcd134e4e3f47f828591f21bca7b",
        "sponsorName": "University of Tokyo"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "Viral Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Germany"],
    "countryCodes": ["DEU"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "clinical_development",
        "date": null,
        "milestoneId": 41,
        "name": "phase_1",
        "status": "ESTIMATED"
      }
    ],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "German Center for Infection Research",
    "phase": "",
    "preferredName": "Viral_Vector_Vaccine",
    "productId": 456,
    "repurposed": "Repurposed-Not Approved",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "43c5ca205d979b4627d9786a10dbcc7a28efe620",
        "sponsorName": "German Center for Infection Research"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "brandName": "TerraCoV2",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "Oragenics Inc.",
    "phase": "",
    "preferredName": "TerraCoV2",
    "productId": 457,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "525e613a8f2932fe3f0c17345916ceb457584531",
        "sponsorName": "Noachis Terra Inc"
      },
      {
        "sponsorId": "37d795f226c583b0923370765712cfb305ea7951",
        "sponsorName": "Oragenics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "CORVax12",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "Subunit Vaccines",
    "notes": "",
    "numSites": "",
    "otherPartners": "OncoSec",
    "phase": "",
    "preferredName": "CORVax12",
    "productId": 458,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "870027d79725ce8aba9d63e3e3e414b41ab3e6a9",
        "sponsorName": "Oncosec Medical Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Combination",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["France"],
    "countryCodes": ["FRA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 05 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "OSE Immunotherapeutics",
    "phase": "",
    "preferredName": "Ose_Immunotherapeutics_SA-459",
    "productId": 459,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b0c93e38a17b3b588585e151d3fc7aad0ba591b1",
        "sponsorName": "Ose Immunotherapeutics SA"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["United States"],
    "countryCodes": ["USA"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Tue, 05 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Cell therapies",
    "notes": "",
    "numSites": "",
    "otherPartners": "California Institute for Regenerative Medicine",
    "phase": "",
    "preferredName": "Lineage_Cell_Therapeutics_Inc-460",
    "productId": 460,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "af5704392ebc92bfa0587cb489a242a1ecec053a",
        "sponsorName": "Lineage Cell Therapeutics Inc"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": ["Canada"],
    "countryCodes": ["CAN"],
    "currentStatus": "",
    "indication": "COVID-19",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [
      {
        "category": "pre-clinical",
        "date": "Thu, 07 May 2020 00:00:00 GMT",
        "milestoneId": 11,
        "name": "discovery",
        "status": "COMPLETED"
      }
    ],
    "moleculeType": "Protein-based (including monoclonal antibodies)",
    "notes": "",
    "numSites": "",
    "otherPartners": "ZYUS Life Sciences Inc.,VIDO-InterVac",
    "phase": "",
    "preferredName": "Zyus_Life_Sciences_Inc_VIDOIntervac-461",
    "productId": 461,
    "repurposed": "New",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f0c03914ca02d3e8f2291af133d7cfda224953cd",
        "sponsorName": "Zyus Life Sciences Inc"
      },
      {
        "sponsorId": "7b2a555245dac6b0ae7cb9dd0f33a50d08853697",
        "sponsorName": "VIDOIntervac"
      }
    ],
    "status": "Ongoing",
    "therapeuticApproach": "Vaccine",
    "trialId": ""
  },
  {
    "brandName": "COVID-19 Immunoglobulin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "COVID19_Immunoglobulin",
    "productId": 462,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "086ded7bc6410c1971ea41cc7b102bd61b78be5d",
        "sponsorName": "CSL Behring Australia"
      },
      {
        "sponsorId": "c51b564ec05a307bbc3b22a4b89f9c032a847dca",
        "sponsorName": "CSL Limited"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Opdivo",
    "chemicalName": "nivolumab",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nivolumab",
    "productId": 463,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6b014b07406a291e8e325b2a212ac65562a16644",
        "sponsorName": "University of Hong Kong"
      },
      {
        "sponsorId": "45cb448ccda5ba5bd7b24c304ad43117f0f1545f",
        "sponsorName": "BMS"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "AiRuiKa",
    "chemicalName": "camrelizumab",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "camrelizumab",
    "productId": 464,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0c5c1dfd859ef4ba55b56530a5b4f12cf700ccc4",
        "sponsorName": "Wuhan Jinyintan Hospital"
      },
      {
        "sponsorId": "67daca15db7dda94d46b570fc990f1a5b1d276a7",
        "sponsorName": "Jiangsu HengRui Medicine Co"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 465,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9b2652ee65b8f7ac2fbc009851b6ef7d2faac03a",
        "sponsorName": "Chelsea and Westminster Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 466,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "090447dc6c4ec30f0734d643a191fd594b173d68",
        "sponsorName": "Prellis Biologics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 467,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "84ed689e0ab14d5e34784cc4f76cde94a060206f",
        "sponsorName": "Ligand Pharmaceuticals"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 468,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "956cde5aa334fee5ea41b8ef8bfcd942e83008fc",
        "sponsorName": "Costa Rican Social Security Fund"
      },
      {
        "sponsorId": "b079ef3c1beae82abe8140f4ec81a68a9474e117",
        "sponsorName": "University of Cost Rica"
      },
      {
        "sponsorId": "23956132e25e7933f285e2c95f701acdc8fa75b3",
        "sponsorName": "Clodomiro Picado Institute"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "MEDI3506",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "MEDI3506",
    "productId": 469,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bb9ed07e215d6bebb274790c7ee0711a0da9f41e",
        "sponsorName": "AstraZeneca"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "BTK inhibitor",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BTK_inhibitor",
    "productId": 470,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bb9ed07e215d6bebb274790c7ee0711a0da9f41e",
        "sponsorName": "AstraZeneca"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Octagam",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Octagam",
    "productId": 471,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "01f8847bee12adc194325c04b865f80d3f338fed",
        "sponsorName": "Octapharma USA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Immunoglobulin from Immunized Sheep",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Immunoglobulin_from_Immunized_Sheep",
    "productId": 472,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "f9a892adb6624b2c054ff75c09fe66c94b05ec8a",
        "sponsorName": "Public Health England"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 473,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3cf57c67576a69c157365187bca4fa4cae4548a6",
        "sponsorName": "Ablexis"
      },
      {
        "sponsorId": "6d78600d48c5ae40de6b7121b4357fa753958e26",
        "sponsorName": "AlivaMab Discovery Services"
      },
      {
        "sponsorId": "a3fae7815b10a27a8b4c46a4e980cc12bef7bc77",
        "sponsorName": "Berkeley Lights Collaborative"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "monoclonal antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "monoclonal_antibodies",
    "productId": 474,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1753a313e0d479ef0ea4b9cb41d499dc5703aee5",
        "sponsorName": "Abcore"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Prezista",
    "chemicalName": "darunavir",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "darunavir",
    "productId": 475,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "79c2245b2e99e2ee02f6cc48aaefe048e67e29e0",
        "sponsorName": "Johnson  Johnson"
      },
      {
        "sponsorId": "667987d4de01dd23efc5563684db4e2117b5d910",
        "sponsorName": "Janssen"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Levovir",
    "chemicalName": "clevudine",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "clevudine",
    "productId": 476,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9560701a2c38713238ec1009dbb4dcf6fdf36153",
        "sponsorName": "Bukwang Pharm"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "BTL-tml",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "BTLtml",
    "productId": 477,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "726053ab8e4d96ab800e4589733fc5b6baaf03e3",
        "sponsorName": "Beech Tree Labs"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "emetine hydrochloride",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "emetine_hydrochloride",
    "productId": 478,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5ad93754d0bd669c3270518802ff29ac3e9c49f5",
        "sponsorName": "Acer Therapeutics Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "AT-527",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AT527",
    "productId": 479,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1af131cb41f699e8e340d1a93623b584af0336e5",
        "sponsorName": "Atea Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Astrotem-V",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AstrotemV",
    "productId": 480,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "684afe67ec273a6d3fa849859049d84db2437fbe",
        "sponsorName": "Naturecell"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DukeNUS_Medical_School-481",
    "productId": 481,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "341b155328dbb89ef8d5f50acdfff58dffee22a5",
        "sponsorName": "DukeNUS Medical School"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "Dexamethasone",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Dexamethasone",
    "productId": 482,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "38652628acf1b84b92cad2bea1a82015a920b0c3",
        "sponsorName": "University of Oxford"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Alvesco",
    "chemicalName": "ciclesonide",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ciclesonide",
    "productId": 483,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "531c7eed34b2778b17fc1ab00a5e3e9417e11f4e",
        "sponsorName": "Covis Pharma BV"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "PegiHep",
    "chemicalName": "Pegylated Interferon alpha-2b",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Pegylated_Interferon_alpha2b",
    "productId": 484,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Novaferon,Nova",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Novaferon_Nova",
    "productId": 485,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dfbc81449bec6db056d375ff6145db5fecbe6806",
        "sponsorName": "First Affiliated Hosptial of Zhejiang University Medical School"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Rebif",
    "chemicalName": "interferon beta-1a",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "interferon_beta1a",
    "productId": 486,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "23e976410b2cf3003eb62c734eb8e73702df9f66",
        "sponsorName": "Merck kGaA"
      },
      {
        "sponsorId": "501208e53cef559b699e97764991aad6e3fe9e17",
        "sponsorName": "French Institut National de la Sante et de la Recherche Medicale"
      },
      {
        "sponsorId": "0e1ea407af0902261db76719a57a5c127ea53bfe",
        "sponsorName": "INSERM"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Micardis",
    "chemicalName": "telmisartan",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "telmisartan",
    "productId": 487,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fddf7abcdfe84560834e2538e757cf92b17c723e",
        "sponsorName": "Boehringer Ingelheim"
      },
      {
        "sponsorId": "2754aaae83566135ed0f7567cbcbf97a4c92f738",
        "sponsorName": "University of Hawaii"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Heparin",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Heparin",
    "productId": 488,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c271659ad5abc7b45c3da45b2f6d7536dd667619",
        "sponsorName": "Union Hospital"
      },
      {
        "sponsorId": "f857eb83d5547b637ff03a9a03a62ecae804b9ef",
        "sponsorName": "Tongji Medical College"
      },
      {
        "sponsorId": "206ac05e9d2f53359faa2f484ba97fb9947ad488",
        "sponsorName": "Huazhong University of Science and Technology"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ST-001,nanoFenretinide",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ST001_nanoFenretinide",
    "productId": 489,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "300768e32f497d80e46fc738e6eb076afe1278b6",
        "sponsorName": "SciTech Development"
      },
      {
        "sponsorId": "f9ea624f8683db34fe27d8b66556e1c68a0bbff7",
        "sponsorName": "LLC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Ruconest",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Ruconest",
    "productId": 490,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "201d1167355ba363a989f5f3c28beafd43c63d43",
        "sponsorName": "Pharming"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "DIBI",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DIBI",
    "productId": 491,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "6a6bd2de0eb5947c17ac3a602d9acff5ad7670aa",
        "sponsorName": "Chelation Partners"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "GP-1681",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "GP1681",
    "productId": 492,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0be22b6b259f83f59ccbd5be89ac8e0889ac4303",
        "sponsorName": "Quotient Sciences"
      },
      {
        "sponsorId": "b70cb7686ccf395a7b83bebb5de6068269194a5a",
        "sponsorName": "CytoAgents Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "nebulized alkaline",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "nebulized_alkaline",
    "productId": 493,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96ddec31a0c1ab283619baa3878b527fb94d020f",
        "sponsorName": "pHbarrier"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Coronzot",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Coronzot",
    "productId": 494,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "bd527ac2a1926e920092457295a6316ab04959d2",
        "sponsorName": "Silkim Pharma"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Lysteda,Cyklokapron",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Lysteda_Cyklokapron",
    "productId": 495,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "554e9b0524bfdbca43acc75ad124f0ba00fa67b6",
        "sponsorName": "University of Alabama at Birmingham"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "senicapoc",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "senicapoc",
    "productId": 496,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "72e1254f1f77af47e0f6f7da408cde214f876377",
        "sponsorName": "Aarhus University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Luvox",
    "chemicalName": "fluvoxamine",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "fluvoxamine",
    "productId": 497,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "088525c7f9eadc1d83414786054e0737521e7139",
        "sponsorName": "Washington University School of Medicine in St Louis"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Gleevac",
    "chemicalName": "imatinib",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "imatinib",
    "productId": 498,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d64dcdacea903a1d726c93fb9c27abff2ac03d67",
        "sponsorName": "Exvastat Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "ABX464",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "ABX464",
    "productId": 499,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c6da54a03f32dd41b8400b76dcd51eb01ec5cb77",
        "sponsorName": "Abivax"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "sPIF",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "sPIF",
    "productId": 500,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a0388d32f7374fcd8165cab8a9c23eeb7f9c5b4a",
        "sponsorName": "BioIncept"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "DNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "DNA_Vaccine",
    "productId": 501,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a07da6c1efe123b7fa3c2ce439820c1646f72988",
        "sponsorName": "University of Waterloo"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated_Vaccine",
    "productId": 502,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "112dadb966996e2ab8f5db397f1a2361410582fc",
        "sponsorName": "Institute of Medical Biology"
      },
      {
        "sponsorId": "bf5e7b2bebc0928fcae433d07b46f1bb4fc5c3ba",
        "sponsorName": "Chinese Academy of Medical Sciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Inactivated + CpG 1018 Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated__CpG_1018_Vaccine",
    "productId": 503,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "93bef25f8dc322ecb56eae9b00dfed2b3169a709",
        "sponsorName": "Sinovac"
      },
      {
        "sponsorId": "8b4d210c885dc58c6711e526b8b4bd37c6acfd55",
        "sponsorName": "Dynavax"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated_Vaccine",
    "productId": 504,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      },
      {
        "sponsorId": "b82c2c21ac862400b11d6f29c7cae746450bbde7",
        "sponsorName": "BIKEN"
      },
      {
        "sponsorId": "780f15c43efde8ab3fb2054bfabbd4431f961fb1",
        "sponsorName": "NIBIOHN"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VLP-recombinant protein + Adjuvant Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VLPrecombinant_protein__Adjuvant_Vaccine",
    "productId": 505,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "51adf29b45adb2321acc929eef1a1764661b4261",
        "sponsorName": "Osaka University"
      },
      {
        "sponsorId": "b82c2c21ac862400b11d6f29c7cae746450bbde7",
        "sponsorName": "BIKEN"
      },
      {
        "sponsorId": "17cbf856bb10416eb209f893f15592c5b0c5cf20",
        "sponsorName": "National Institutes of Biomedical Innovation"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Inactivated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Inactivated_Vaccine",
    "productId": 506,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "491e7541c9106c54795c4fab54aeb1e6140c1faf",
        "sponsorName": "Research Institute for Biological Safety Problems"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Codon deoptimized live attenuated virus",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Codon_deoptimized_live_attenuated_virus",
    "productId": 507,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b5cb9e1deb926ecff4779f7d91e9cb95f8813c17",
        "sponsorName": "Indian Immunologicals Ltd"
      },
      {
        "sponsorId": "4c0a544a8c18a6d3d126ac58097808c42561d093",
        "sponsorName": "Griffith University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Non-replicating viral vector MVA expressing structural proteins",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nonreplicating_viral_vector_MVA_expressing_structural_proteins",
    "productId": 508,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "880c99550c8a42deeaff83ad0902af0b020c8848",
        "sponsorName": "Centro Nacional Biotecnologia"
      },
      {
        "sponsorId": "ff7e4fdfaae0a64a50db02f60295658c622d7b87",
        "sponsorName": "CNBCSIC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Non-replicating viral vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Nonreplicating_viral_vector_vaccine",
    "productId": 509,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "459eec13328a1d43f3fa5a6bd1f187b1c2e6ea3d",
        "sponsorName": "University of Manitoba"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Recombinant deactivated rabies virus containing S1",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recombinant_deactivated_rabies_virus_containing_S1",
    "productId": 510,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9d4dee599ac3bb32cc6f8f46985c93c9410e5262",
        "sponsorName": "Bharat Biotech"
      },
      {
        "sponsorId": "1b9164e80e6eebf015de1a8aa6d9744d383d94d4",
        "sponsorName": "Thomas Jefferson University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein subunit S Protein + adjuvant",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_subunit_S_Protein__adjuvant",
    "productId": 511,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "e070ac198c1403ee83ff4b95b61c5b221dd1fe67",
        "sponsorName": "National Institute of Infectious Disease"
      },
      {
        "sponsorId": "fcf29f6cad3232704b33e962ef5194fad3b6817b",
        "sponsorName": "Japan"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "PittCoVacc",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "PittCoVacc",
    "productId": 512,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0c65a74d63b7a88d66a6d28b2f99159bd2923517",
        "sponsorName": "University of Pittsburgh"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Peptide Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Peptide_Vaccine",
    "productId": 513,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Subunit_Vaccine",
    "productId": 514,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "productId": 515,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "716eefa2065d7dc4e322e6d5e2d9319014688bc3",
        "sponsorName": "LakePharma"
      },
      {
        "sponsorId": "72a5f6c42a6c39ea891ecb24d22128fd281d0e18",
        "sponsorName": "Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "productId": 516,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "12c3dd5f9333a0c4d0ae98732f48bf25cad78edd",
        "sponsorName": "University of Alberta"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "productId": 517,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "077fdd2e748f24405b69a367b3773ec90b94b59d",
        "sponsorName": "AnyGo Technology"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "productId": 518,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ba53ce7d125486beb154102a37b226621b7f1fc7",
        "sponsorName": "Yisheng Biopharma"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "productId": 519,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "d66666a3c071393a24620b24d358e69ba3509e16",
        "sponsorName": "Vabiotech"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Protein Subunit Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Protein_Subunit_Vaccine",
    "productId": 520,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "486a33cf556d4a11ca1a393e8f93ddeee90e3aa8",
        "sponsorName": "University of California"
      },
      {
        "sponsorId": "acb342916471ac6bed5f3a6a13ca8e3ecdc48429",
        "sponsorName": "San Diego"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "OMV-based Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "OMVbased_Vaccine",
    "productId": 521,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "442afaf6e99f2d9c98f45ff216cd938e8a81ddf1",
        "sponsorName": "Quadram Institute Biosciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Replicating Viral Vector,YF17D Vector",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Replicating_Viral_Vector_YF17D_Vector",
    "productId": 526,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "32ce15bbd44eb2c4a104acc7af8fe4766751c699",
        "sponsorName": "KU Leuven"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Measles Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Measles_Vector_Vaccine",
    "productId": 527,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7",
        "sponsorName": "Zydus Cadila"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Measles Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Measles_Vector_Vaccine",
    "productId": 528,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Recombinant Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recombinant_Vaccine",
    "productId": 529,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VSV Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VSV_Vector_Vaccine",
    "productId": 530,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "productId": 531,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ecfe160f6421e8373446c4cf127484c21d580da4",
        "sponsorName": "FBRI SRC VB VECTOR"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VSV-S Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VSVS_Vaccine",
    "productId": 532,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "64b8159213f0e0f1b682d64dcd70edf9ca69799b",
        "sponsorName": "University of Western Ontario"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Newcastle Disease Virus Vector Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Newcastle_Disease_Virus_Vector_Vaccine",
    "productId": 533,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "2fac1a221a15fc083eae5305d2594c769015b137",
        "sponsorName": "Intravacc"
      },
      {
        "sponsorId": "ce48076f605d7364d1dba7c47a51996d843222db",
        "sponsorName": "Wageningen Bioveterinary Research"
      },
      {
        "sponsorId": "b80905e2bb739693e1253446c2e0849e97ab16dd",
        "sponsorName": "Utrecht University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Avian paramyxovirus vector vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Avian_paramyxovirus_vector_vaccine",
    "productId": 534,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3f5ef18f6b48973f961a316e793e87f14b04ffff",
        "sponsorName": "Lancaster University"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "LNP-encapsulated mRNA cocktail encoding RBD",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "LNPencapsulated_mRNA_cocktail_encoding_RBD",
    "productId": 535,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "4567098e44fc907783878b149c6d70d1f14aec40",
        "sponsorName": "Fudan University"
      },
      {
        "sponsorId": "aa6799f660cd49b264d3e155560878bb15e8b804",
        "sponsorName": "Shanghai JiatTong University"
      },
      {
        "sponsorId": "f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0",
        "sponsorName": "RNACure Biopharma"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Replicating Defective SARS-CoV-2 derived RNAs Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Replicating_Defective_SARSCoV2_derived_RNAs_Vaccine",
    "productId": 536,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c1eb0322cb877870cc4fe7c42c87c0a02c5d0674",
        "sponsorName": "Centro Nacional biotecnologia"
      },
      {
        "sponsorId": "ff7e4fdfaae0a64a50db02f60295658c622d7b87",
        "sponsorName": "CNBCSIC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "productId": 537,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "96c9c4abf003991d12896ec5fc930b3875d2aa18",
        "sponsorName": "RNAImmune Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "productId": 538,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a16b70b82bdd9b5e61c50e750862a8851ee80507",
        "sponsorName": "GeneOne Life Science"
      },
      {
        "sponsorId": "0276ff1989d288ace3c36f410d4c8c1aa98a6910",
        "sponsorName": "Houston Methodist"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "productId": 539,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "9bc71603d5f1ceefbc96ff17289d5ada42219959",
        "sponsorName": "Greenligh Biosciences"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VLP Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VLP_Vaccine",
    "productId": 540,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dbc7ace17cd35ff8f85b54d21988dfa7824dcf8a",
        "sponsorName": "OSIVAX"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VLP Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VLP_Vaccine",
    "productId": 541,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "07a812ba1b31cfbef19b397a145bcc9d34fc20a1",
        "sponsorName": "ARTES Biotechnology"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "VLP,Whole Virus Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "VLP_Whole_Virus_Vaccine",
    "productId": 542,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "65766da43898183e2da98c6704a2abbfa7aa4632",
        "sponsorName": "Univeristy of Sao Paulo"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 543,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "478b6fcffcd9bf799b6789693a95c51d1d06af57",
        "sponsorName": "SK Biosciences"
      },
      {
        "sponsorId": "b1e925b723690d4fd21dcf9ec6c1f26f2eb70ca5",
        "sponsorName": "SK Group"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 544,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "1fed0b53fb22b1b1719e57613378cadb6bf64f66",
        "sponsorName": "Precision Vaccines Program"
      },
      {
        "sponsorId": "30710cd9a14eb8e8b8fa545333e304e084ebcfc4",
        "sponsorName": "Boston Childrens Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 545,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "c166c578447a7c9ab34935edb79ae58af5c26833",
        "sponsorName": "Kentucky BioProcessing"
      },
      {
        "sponsorId": "04f6cb5885013bae64d2b1cecf249bb94735046b",
        "sponsorName": "BAT"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 546,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "68fc3905a9dd7aa4f14be93f6f536bd303d16bab",
        "sponsorName": "University of Laval"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 547,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "aaa32a3979ac5c274f389b02e07a20f54af034c7",
        "sponsorName": "Universidad Catolica Instituto Milenio de Inmunologia e Inmunoterapia"
      },
      {
        "sponsorId": "3ecea3e5816f686ca7b07b073600326888093983",
        "sponsorName": "Consorcio Technologica en Biomedicina Clinico Molecular"
      },
      {
        "sponsorId": "cfa06ba512db41f4402457107b0efb25017d088e",
        "sponsorName": "IMMII"
      },
      {
        "sponsorId": "cbfa70574d8abd0d988aca0261d66abecf7cdebb",
        "sponsorName": "BMRC"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Vaccine",
    "productId": 548,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "edc8416948cc1ae11508ef4ae0b416a22c12ad4e",
        "sponsorName": "Emergex Vaccines Holding Limited"
      },
      {
        "sponsorId": "592426722c1b68f6ce3b0cb2833cd378cea35d20",
        "sponsorName": "George Mason Universitys National Center for Biodefense and Infectious Diseases"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "AVI-205",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "AVI205",
    "productId": 549,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "87bbf3a331efd56467b205749e5d6c3ea94ff4ad",
        "sponsorName": "AbVision"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Recombinant LVS Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Recombinant_LVS_Vaccine",
    "productId": 550,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "68a801de11b20a5784e2f9993135e416ea6d5ccc",
        "sponsorName": "University of California Los Angeles"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "mRNA Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "mRNA_Vaccine",
    "productId": 551,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b41a4d43ef7f7aa0b03c1fa4cb9acc260b974c38",
        "sponsorName": "eTheRNA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Attenuated Vaccine",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Vaccine - Prophylactic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Attenuated_Vaccine",
    "productId": 552,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a428a9d798bc8d58f26fe00c022c9f48b3f79576",
        "sponsorName": "Fundacao Oswaldo Cruz"
      },
      {
        "sponsorId": "e23ad6b02eceefb9094a74410045931a10079a06",
        "sponsorName": "Instituto Butantan"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Organicell Flow",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Organicell_Flow",
    "productId": 553,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fd115f17ad17409455bb40c8d7b56ec40407be62",
        "sponsorName": "Organicell Regenerative Medicine"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "KB-109",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "KB109",
    "productId": 554,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "b7a8a2d712ee76890113aebcca4616bf1019b420",
        "sponsorName": "Kaleido Biosciences Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Estradiol patch",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Estradiol_patch",
    "productId": 555,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "a7721518ad3f33d0aa3b8af76ef0c1880324607a",
        "sponsorName": "Stony Brook University Hospital"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Anticovir",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Anticovir",
    "productId": 556,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "80e96db9c9f78a58f5b44d2793c88c981132970f",
        "sponsorName": "Betterlife Pharma Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Apograft-treated stem cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Apografttreated_stem_cells",
    "productId": 557,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "3677197cebff0cf7947d2809124f96acf1cf3201",
        "sponsorName": "Cellect Biotechnology Ltd"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Mesenchymal Stem Cells",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Mesenchymal_Stem_Cells",
    "productId": 558,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "ea3716c6b0205d251944d5e3a61cc9f1ba3744d4",
        "sponsorName": "Citius Pharmaceuticals Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "CAL-02",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "CAL02",
    "productId": 559,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "01da66d9faf1279ac5cdf58ec85f96945d297558",
        "sponsorName": "Combioxin SA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "eTherapeutics_plc-560",
    "productId": 560,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fa4ddbe589e7b8b772f35f4f16d787866b9f4ae9",
        "sponsorName": "eTherapeutics plc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "KAND-567",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "KAND567",
    "productId": 561,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "fe4146d58f781a4971c5ec8a946b4fe02036a3cb",
        "sponsorName": "Kancera AB"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Capton product",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Capton_product",
    "productId": 562,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "5b62e5f42bf6b8790b1f5d3d525aa8d615ab1ac0",
        "sponsorName": "Mercaptor Discoveries Inc"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "TC-C 19",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "TCC_19",
    "productId": 563,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "daeec1530e0e8919a34fb5c99ed5ddc5cd2e8f43",
        "sponsorName": "Vsy Biotechnology GmbH"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibody",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibody",
    "productId": 564,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "0174fd8a066ed49f55c03cae0c00a6e53d1f1356",
        "sponsorName": "Xavier Saelens"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  },
  {
    "brandName": "Antibodies",
    "chemicalName": "",
    "conditionOrDisease": "",
    "countries": [""],
    "countryCodes": ["GBR"],
    "currentStatus": "",
    "indication": "",
    "interventionType": "Therapeutic",
    "milestones": [],
    "moleculeType": "",
    "notes": "",
    "numSites": "",
    "otherPartners": "",
    "phase": "",
    "preferredName": "Antibodies",
    "productId": 565,
    "repurposed": "",
    "siteLocations": [],
    "sources": [""],
    "sponsors": [
      {
        "sponsorId": "dfe8fccd9d4a4ca4e46009e309f1281be6f25f78",
        "sponsorName": "Proteogenix SA"
      }
    ],
    "status": "",
    "therapeuticApproach": "",
    "trialId": ""
  }
]
